In Vivo and in Vitro Stimulation of Murine Splenocytes With Brevetoxin-2 Immunogenic Conjugates for the Preparation of Monoclonal Antibodies Against Ciguatoxin-Related Compounds. by Guzman perez, Sonia Edith
Louisiana State University
LSU Digital Commons
LSU Historical Dissertations and Theses Graduate School
1999
In Vivo and in Vitro Stimulation of Murine
Splenocytes With Brevetoxin-2 Immunogenic
Conjugates for the Preparation of Monoclonal
Antibodies Against Ciguatoxin-Related
Compounds.
Sonia Edith Guzman perez
Louisiana State University and Agricultural & Mechanical College
Follow this and additional works at: https://digitalcommons.lsu.edu/gradschool_disstheses
This Dissertation is brought to you for free and open access by the Graduate School at LSU Digital Commons. It has been accepted for inclusion in
LSU Historical Dissertations and Theses by an authorized administrator of LSU Digital Commons. For more information, please contact
gradetd@lsu.edu.
Recommended Citation
Guzman perez, Sonia Edith, "In Vivo and in Vitro Stimulation of Murine Splenocytes With Brevetoxin-2 Immunogenic Conjugates for




This manuscript has been reproduced from the microfilm master. UMI 
films the text directly from the original or copy submitted. Thus, some 
thesis and dissertation copies are in typewriter face, while others may be 
from any type of computer printer.
The quality of this reproduction is dependent upon the quality of the 
copy submitted. Broken or indistinct print, colored or poor quality 
illustrations and photographs, print bleedthrough, substandard margins, 
and improper alignment can adversely affect reproduction.
In the unlikely event that the author did not send UMI a complete 
manuscript and there are missing pages, these will be noted. Also, if 
unauthorized copyright material had to be removed, a note will indicate 
the deletion.
Oversize materials (e.g., maps, drawings, charts) are reproduced by 
sectioning the original, beginning at the upper left-hand comer and 
continuing from left to right in equal sections with small overlaps. Each 
original is also photographed in one exposure and is included in reduced 
form at the back o f the book.
Photographs included in the original manuscript have been reproduced 
xerographically in this copy. Higher quality 6” x 9” black and white 
photographic prints are available for any photographs or illustrations 
appearing in this copy for an additional charge. Contact UMI directly to 
order.
UMI
A Bell & Howell Information Company 
300 North Zeeb Road, Ann Aitoor MI 48106-1346 USA 
313/761-4700 800/521-0600
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
IN VIVO AND IN VITRO STIMULATION OF MURINE SPLENOCYTES WITH 
BREVETOXIN-2 IMMUNOGENIC CONJUGATES FOR THE PREPARATION OF 
MONOCLONAL ANTIBODIES AGAINST CIGUATOXIN-RELATED
COMPOUNDS
A Dissertation
Submitted to the Graduate Faculty of the 
Louisiana State University and 
Agricultural and Mechanical College 
in partial fulfillment of the 
requirements for the degree of 
Doctor of Philosophy
in
The Department of Food Science
by
Sonia Edith Guzman P6rez 
B.S., Universidad La Salle, 1995 
May 1999
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
UMI Number: 9925532
UMI Microform 9925532 
Copyright 1999, by UMI Company. All rights reserved.
This microform edition is protected against unauthorized 
copying under Title 17, United States Code.
UMI
300 North Zeeb Road 
Ann Arbor, MI 48103
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
DEDICATION
To Bernardo Ordonez, whose patience, love, and encouragement helped me to keep 
in mind that despite the many problems encountered during this study, this was my 
dream and I would be able to make it real.
To my littie brother Panchito, who has taught me the meaning of fraternal love. I 
have always kept him in my mind and heart Just the thought of seeing him again kept 
me going.
To my Mom and Dad who have supported my decisions ever since I was a little 
kid, and to Agustm Guzman Maciel for making me a proud aunt.
To Dr. Robert Truax, not only for being the person who closely guided this 
research, but also because he became a role model and a friend.
ii
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
ACKNOWLEDGEMENTS
I wish to thank Dr. Douglas L. Park, major professor, for his help and trust 
throughout the development of this Dissertation, and Mr. and Mrs. Goldsmith of 
HawaiiChemtect International for their financial support Special gratitude is due to Dr. 
Wanda Lyon, Dr. Vince Wilson, Dr. James Miller, and Dr. Leslie Plhak for their 
continuous encouragement
I want to specially acknowledge the unconditional help of Dr. Robert Truax from 
The School of Veterinary Medicine, Department of Veterinary Microbiology and 
Parasitology. His continuous advice and patience were essential in the progress of this 
Dissertation. He was a guardian angel willing to answer any question at any time. I will 
never forget his help.
Special thanks to Dr. Kathy O'Reilly for her endless discussions on how to 
overcome the many problems encountered throughout my research. She shared her 
experience and knowledge without asking anything in return.
Special thanks to Laurie Henderson, Chris Chustz, Carol Howze, and George de los 
Santos for their help in taking care of the mice.
iii




LIST OF TABLES....................................................................................................... vi
LIST OF FIGURES..................................................................................................... ix
ABSTRACT.............................................................................................................. xxi
INTRODUCTION.........................................................................................................1
REVIEW OF LITERATURE........................................................................................ 3
A) CIGUATERA FISH POISONING........................................................................3
1. Occurrence........................................................................................................ 3
2. Source of Toxins................................................................................................5
3. Properties of Toxins.......................................................................................... 7
4. Analytical Methods.......................................................................................... 17
5. Symptomatology..............................................................................................24




B) NEUROTOXIC SHELLFISH POISONING........................................................30
1. Occurrence.......................................................................................................30
2. Source of Toxins..............................................................................................31
3. Properties of Toxins........................................................................................ 31
4. Analytical Methods.......................................................................................... 34
5. Symptomatology..............................................................................................36




C) PREPARATION OF MONOCLONAL ANTIBODIES......................................42
1. Antigens and Immunogens.............................................................................. 43
2. Immunization...................................................................................................45
3. Fusion............................................................................................................. 48
4. Screening of hybridoma supernatants............................................................... 52
5. Cloning............................................................................................................52
6. Antibody Characterization............................................................................... 54
7. Antibody purification...................................................................................... 54
D) IN VITRO IMMUNIZATION............................................................................55
E) THIS STUDY....................  58
iv
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
MATERIALS AND METHODS................................................................................ 61
A) MATERIALS.....................................................................................................61
B) METHODS.........................................................................................................63
1. Preparation of Monoclonal Antibodies............................................................. 63
2. Competitive ELISA......................................................................................... 71
3. Isotyping ELISA..............................................................................................73





2. Fusion 2 ...........................................................................................................93
3. Fusion 3 .......................................................................................................... 98
B) KLH-PbTx-2..................................................................................................... 109
1. Fusion 4 .........................................................................................................109
2. Fusion 5 .........................................................................................................119
3. Fusion 6 .........................................................................................................130
4. Fusion 7 .........................................................................................................140
C) BSA-PbTx-2.....................................................................................................151
1. Fusion 8 .........................................................................................................151
2. Fusion 9 .........................................................................................................160
3. Fusion 10.......................................................................................................170
4. Fusion 11....................................................................................................... 179
DISCUSSION OF RESULTS....................................................................................189
A) PREPARATION OF MONOCLONAL ANTIBODIES.................................... 189
B) IN VITRO STIMULATION.............................................................................. 206




APPENDIX A: FORMULATIONS.......................................................................... 244
APPENDIX B: ELISA PROCEDURES....................................................................248
APPENDIX C: RAW DATA.................................................................................... 250
APPENDIX D: PERMISSION REQUEST FORMS..................................................286
VITA......................................................................................................................... 291
v
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
LIST OF TABLES
Table 1. Female BALB/C mice used for immunization...............................................78
Table 2. Immunization schedule for mouse 1 using LPH-Brevetoxin-2 (PbTx-2)
for preparation of anti-PbTx-2 antibodies.....................................................79
Table 3. Wells derived from fusion 1 (mouse 1 immunized with LPH-Brevetoxin- 
2) selected for cloning. The ELISA for screening was performed using 
50 pL volumes, goat anti-mouse IgG (H&L)-HRPO at 1:1000 and ABTS 
for color development...................................................................................85
Table 4. Cloning wells derived from fusion 1 (mouse 1 immunized with LPH- 
Brevetoxin-2). The ELISA for screening was performed using 50 pL 
volumes, goat anti-mouse IgG (H&L)-HRPO at 1:1000 and ABTS for 
color development Isotyping was performed using a commercial kit 86
Table 5. Immunization schedule for mouse 2 using LPH-Brevetoxin-2 (PbTx-2)
for preparation of anti-PbTx-2 antibodies.....................................................93
Table 6. Immunization schedule for mice 3 and 4 using LPH-Brevetoxin-2 (PbTx-
2) for preparation of anti-PbTx-2 antibodies.................................................99
Table 7. Wells derived from fusion 3 (mice 3 and 4 immunized with LPH- 
Brevetoxin-2) selected for cloning. The ELISA for screening was 
performed using 50 pL volumes, goat anti-mouse IgG (H&L)-HRPO at 
1:1000 and ABTS for color development................................................... 104
Table 8. Cloning wells derived from fusion 3 (mice 3 and 4 immunized with 
LPH-Brevetoxin-2). The ELISA for screening was performed using 50 
pL volumes, goat anti-mouse IgG (H&L)-HRPO at 1:1000 and ABTS 
for color development. Isotyping was performed using a commercial kit. ..105
Table 9. Immunization schedule for mouse 7 using KLH-Brevetoxin-2 (PbTx-2)
for preparation of anti-PbTx-2 antibodies................................................... 110
Table 10.Wells derived from fusion 4 (mouse 7 immunized with KLH- 
Brevetoxin-2) selected for cloning. The ELISA for screening was 
performed using 50 pL volumes, goat anti-mouse IgG (H&L)-HRPO at 
1:1000 and ABTS for color development....................................................114
Table 11. Cloning wells derived from fusion 4 (mouse 7 immunized with KLH- 
Brevetoxin-2). The ELISA for screening was performed using 50 pL
vi
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
volumes, goat anti-mouse IgG (H&L)-HRPO at 1:1000 and ABTS for 
color development. Isotyping was performed using a commercial kit......... 115
Table 12. Immunization schedule for mouse 8 using KLH-Brevetoxin-2 (PbTx-2)
for preparation of anti-PbTx-2 antibodies................................................... 119
Table 13. Wells derived from fusion 5 (mouse 8 immunized with KLH-Brevetoxin- 
2) selected for cloning. The ELISA for screening was performed using 
50 pL volumes, goat anti-mouse IgG (H&L)-HRPO at 1:1000 and ABTS 
for color development................................................................................ 124
Table 14. Cloning wells derived from fusion 5 (mouse 8 immunized with KLH- 
Brevetoxin-2). The ELISA for screening was performed using 50 pL 
volumes, goat anti-mouse IgG (H&L)-HRPO at 1:1000 and ABTS for 
color development. Isotyping was performed using a commercial kit........ 125
Table 15. Immunization schedule for mouse 10 using KLH-Brevetoxin-2 (PbTx-2)
for preparation of anti-PbTx-2 antibodies................................................... 130
Table 16.Wells derived from fusion 6 (mouse 10 immunized with KLH- 
Brevetoxin-2) selected for cloning. The ELISA for screening was 
performed using 100 pL volumes, goat anti-mouse IgG (H&L)-HRPO at 
1:1000 and TMB for color development.....................................................136
Table 17. Cloning wells derived from fusion 6 (mouse 10 immunized with KLH- 
Brevetoxin-2). The ELISA for screening was performed using 100 pL 
volumes, goat anti-mouse IgG (H&L)-HRPO at 1:1000 and TMB for 
color development. Isotyping was performed using a commercial kit......... 136
Table 18. Immunization schedule for mouse 11 using KLH-Brevetoxin-2 (PbTx-2)
for preparation of anti-PbTx-2 antibodies................................................... 141
Table 19.Wells derived from fusion 7 (mouse 11 immunized with KLH- 
Brevetoxin-2) selected for cloning. The ELISA for screening was 
performed using 100 pL volumes, goat anti-mouse IgG (H&L)-HRPO at 
1.1000 and TMB for color development.....................................................145
Table 20. Cloning wells derived from fusion 7 (mouse 11 immunized with KLH- 
Brevetoxin-2). The ELISA for screening was performed using 100 pL 
volumes, goat anti-mouse IgG (H&L)-HRPO at 1:1000 and TMB for 
color development. Isotyping was performed using a commercial kit......... 146
Table 21. Immunization schedule for mouse 12 using BSA-Brevetoxin-2 (PbTx-2)
for preparation of anti-PbTx-2 antibodies................................................... 152
vii
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Table 22.Wells derived from fusion 8 (mouse 12 immunized with BSA- 
Brevetoxin-2) selected for further testing. The ELISA for screening was 
performed using 100 pL volumes, goat anti-mouse IgG (H&L)-HRPO at 
1:1000 and TMB for color development Isotyping was performed using 
a commercial k i t ...................................................................................... 156
Table 23. Immunization schedule for mouse 13 using BSA-Brevetoxin-2 (PbTx-2)
for preparation of anti-PbTx-2 antibodies...................................................161
Table 24.Wells derived from fusion 9 (mouse 13 immunized with BSA- 
Brevetoxin-2) selected for further testing. The ELISA for screening was 
performed using 100 pL volumes, goat anti-mouse IgG (H&L)-HRPO at 
1:1000 and TMB for color development.....................................................166
Table 25. Immunization schedule for mouse 14 using BSA-Brevetoxin-2 (PbTx-2)
for preparation of anti-PbTx-2 antibodies...................................................170
Table 26. Wells derived from fusion 10 (mouse 14 immunized and stimulated with 
BSA-Brevetoxin-2) selected for further testing. The ELISA for screening 
was performed using 100 pL volumes, goat anti-mouse IgG (H&L)- 
HRPO at 1:1000 and TMB for color development. Isotyping was 
performed using a commercial kit..............................................................175
Table 27. Immunization schedule for mouse 15 using BSA-Brevetoxin-2 (PbTx-2)
for preparation of anti-PbTx-2 antibodies...................................................179
Table 28.Wells derived from fusion 11 (mouse 15 immunized with BSA- 
Brevetoxin-2 and stimulated with brevetoxin-2) selected for further 
testing. The ELISA for screening was performed using 100 pL volumes, 
goat anti-mouse IgG (H&L)-HRPO at 1:1000 and TMB for color 
development. Isotyping was performed using a commercial kit................. 184
Table 29. Summary of fusions performed in an attempt to produce monoclonal 
antibodies against ciguatoxin-related compounds using protein- 
conjugated brevetoxin-2 (PbTx-2) as immunogen......................................212
viii
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
LIST OF FIGURES
Figure 1. Worldwide areas with the highest occurrence of ciguatera fish poisoning 4
Figure 2. Proposed transmission path of ciguatera toxins............................................. 6
Figure 3. Structure of Pacific ciguatoxins (P-CTXs)......................................................8
Figure 4. Structure of gambiertoxin-4A and -4B.......................................................... 10
Figure 5. Biotransformation of gambiertoxins and ciguatoxins................................... 11
Figure 6. Structure of gambierol.................................................................................. 12
Figure 7. Structure of ciguatoxin-3C............................................................................13
Figure 8. Structure of okadaic acid..............................................................................16
Figure 9. Structure of brevetoxins.............................................................................. 32
Figure 10. Functional map of the a  subunit of the voltage-gated sodium channel........ 39
Figure 11. Three-dimensional structure of the voltage-gated sodium channel...............39
Figure 12.Hypothetical model of the binding of brevetoxins to site 5 of the
voltage-gated sodium channel...................................................................... 40
Figure 13.Structure of brevetoxin-2 and Pacific ciguatoxin-1......................................59
Figure 14.Antibody production response of mouse 1 after each immunization with 
LPH-Brevetoxin-2 (PbTx-2). Plates were coated with BSA-PbTx-2 at 5 
pg/mL. Each serum was diluted 1:1000. Goat anti-mouse IgG (H&L)- 
HRPO was diluted 1:5000. TMB was used for color development. 
Plotted points are the means of triplicate determinations. Variation from 
the mean was typically 5% or less................................................................ 80
Figure 15.Titer of serum collected the day of the fusion of mouse 1 immunized with 
LPH-Brevetoxin-2 (PbTx-2). Plates were coated with BSA-PbTx-2, 
BSA, and LPH at 5 (ig/mL. Goat anti-mouse IgG (y)-HRPO was diluted 
1:5000. TMB was used for color development. Plotted points are the 
means of triplicate determinations. Variation from the mean was 
typically 5% or less...................................................................................... 81
ix
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Figure 16.Computer-generated best fit competition curve for serum collected the 
day of the fusion of mouse 1 (immunized with LPH-Brevetoxin-2 [PbTx- 
2]). Plates were coated with BSA-PbTx-2 at 5 pg/mL. Goat anti-mouse 
IgG (y)-HRPO was diluted 1:5000. TMB was used for color 
development. Plotted points are the means of duplicate determinations. 
Variation from the mean was typically 5% or less........................................82
Figure 17.Antigen-specific and capture isotyping for serum collected the day of the 
fusion of mouse 1 (immunized with LPH-Brevetoxin-2 [PbTx-2]). Serum 
was diluted 1:1000 for testing.......................................................................83
Figure 18.Ammonium sulfate precipitates of cloned hybridoma supernatants 
obtained from fusion 1 (mouse 1 immunized with LPH-Brevetoxin-2). 
Precipitates were diluted 1:100 and 1:1000 for testing. Goat anti-mouse 
IgG (H&L)-HRPO was diluted 1:1000. TMB was used for color 
development.................................................................................................87
Figure 19.Response of serum collected the day of the fusion of mouse 1 
(immunized with LPH-Brevetoxin-2 [PbTx-2]) with different coating 
antigens at 5 pg/mL. Serum was diluted 1:1000 for testing. Goat anti­
mouse IgG (H&L)-HRPO was diluted 1:5000. TMB was used for color 
development................................................................................................. 89
Figure 20.Competition assay using tissue culture supernatants from fusion 1 
(mouse 1 immunized with LPH-Brevetoxin-2 [PbTx-2]) and PbTx-2 at 
20 pg/mL. Plates were coated with BSA-PbTx-2 at 5 pg/mL. Goat anti­
mouse IgG (H&L)-HRPO was diluted 1:5000. TMB was used for color 
development.................................................................................................90
Figure 21.Brevetoxin-2 (PbTx-2) standard curve using two incubation periods and 
ouabain/veratridine (O/V) dependence. Plotted points are the means of 
triplicate determinations. Variation from the mean was typically 5% or 
less............................................................................................................... 91
Figure 22.Antibody production response of mouse 2 after each immunization with 
LPH-Brevetoxin-2 (PbTx-2). Plates were coated with BSA-PbTx-2 at 5 
pg/mL. Each serum was diluted 1:1000. Goat anti-mouse IgG (H&L)- 
HRPO was diluted 1:5000. TMB was used for color development. 
Plotted points are the means of triplicate determinations. Variation from 
the mean was typically 5% or less................................................................ 94
Figure 23.Titer of serum collected the day of the fusion of mouse 2 immunized with 
LPH-Brevetoxin-2 (PbTx-2). Plates were coated with BSA-PbTx-2, 
BSA, and LPH at 5 pg/mL. Goat anti-mouse IgG (y)-HRPO was diluted
x
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
1:5000. TMB was used for color development Plotted points are the 
means of triplicate determinations. Variation from the mean was 
typically 5% or less......................................................................................94
Figure 24.Computer-generated best fit competition curve for serum collected the 
day of the fusion of mouse 2 (immunized with LPH-Brevetoxin-2 [PbTx- 
2]). Plates were coated with BSA-PbTx-2 at 5 pg/mL. Goat anti-mouse 
IgG (y)-HRPO was diluted 1:5000. TMB was used for color 
development. Plotted points are the means of duplicate determinations. 
Variation from the mean was typically 5% or less........................................96
Figure 25 .Antigen-specific and capture isotyping for serum collected the day of the 
fusion of mouse 2 (immunized with LPH-Brevetoxin-2 [PbTx-2]). 
Serum was diluted 1:1000 for testing...........................................................96
Figure 26.Response of serum collected the day of the fusion of mouse 2 
(immunized with LPH-Brevetoxin-2 [PbTx-2]) with different coating 
antigens at 5 pg/mL. Serum was diluted 1:1000 for testing. Goat anti­
mouse IgG (H&L)-HRPO was diluted 1:5000. TMB was used for color
development.................................................................................................98
Figure 27. Antibody production response of mice 3 and 4 after each immunization 
with LPH-Brevetoxin-2 (PbTx-2). Plates were coated with BSA-PbTx-2 
at 5 pg/mL. Each serum was diluted 1:1000. Goat anti-mouse IgG 
(H&L)-HRPO was diluted 1:5000............................................................... 99
Figure 28.Titer of serum collected the day of the fusion of mouse 3 immunized with 
LPH-Brevetoxin-2 (PbTx-2). Plates were coated with BSA-PbTx-2, 
BSA, and LPH at 5 pg/mL. Goat anti-mouse IgG (y)-HRPO was diluted 
1:5000. TMB was used for color development. Plotted points are the 
means of triplicate determinations. Variation from the mean was 
typically 5% or less.................................................................................... 100
Figure 29.Titer of serum collected the day of the fusion of mouse 4 immunized with 
LPH-Brevetoxin-2 (PbTx-2). Plates were coated with BSA-PbTx-2, 
BSA, and LPH at 5 pg/mL. Goat anti-mouse IgG (y)-HRPO was diluted 
1:5000. TMB was used for color development. Plotted points are the 
means of triplicate determinations. Variation from the mean was 
typically 5% or less.................................................................................... 101
Figure 30.Computer-generated best fit competition curves for sera collected the 
day of the fusion of mice 3 and 4 (immunized with LPH-Brevetoxin-2 
[PbTx-2]). Plates were coated with BSA-PbTx-2 at 5 pg/mL. Goat anti­
mouse IgG (y)-HRPO was diluted 1:5000. TMB was used for color
xi
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
development. Plotted points are the means of duplicate determinations. 
Variation from the mean was typically 5% or less...................................... 102
Figure 31 .Antigen-specific and capture isotyping for serum collected the day of the 
fusion of mouse 3 (immunized with LPH-Brevetoxin-2 [PbTx-2]). Serum 
was diluted 1:1000 for testing.................................................................... 103
Figure 32.Antigen-specific and capture isotyping for serum collected the day of the 
fusion of mouse 4 (immunized with LPH-Brevetoxin-2 [PbTx-2]). Serum 
was diluted 1:1000 for testing.................................................................... 103
Figure 33.Ammonium sulfate precipitates of cloned hybridoma supernatants 
obtained from fusion 3 (mice 3 and 4 immunized with LPH-Brevetoxin- 
2). Precipitates were diluted 1:100 and 1:1000 for testing. Goat anti­
mouse IgG (H&L)-HRPO was diluted 1:1000. TMB was used for color 
development.............................................................................................. 106
Figure 34.Response of sera collected the day of the fusion of mice 3 and 4 
(immunized with LPH-Brevetoxin-2 [PbTx-2]) with different coating 
antigens at 5 pg/mL. Serum was diluted 1:1000 for testing. Goat anti­
mouse IgG (H&L)-HRPO was diluted 1:5000. TMB was used for color 
development.............................................................................................. 107
Figure 35.Competition assay using tissue culture supernatants from fusion 3 (mice 
3 and 4 immunized with LPH-Brevetoxin-2 [PbTx-2]) and PbTx-2 at 20 
pg/mL. Plates were coated with BSA-PbTx-2 at 5 pg/mL. Goat anti­
mouse IgG (H&L)-HRPO was diluted 1:5000. TMB was used for color 
development.............................................................................................. 108
Figure 36.Antibody production response of mouse 7 after each immunization with 
KLH-Brevetoxin-2 (PbTx-2). Plates were coated with BSA-PbTx-2 at 5 
pg/mL. Each serum was diluted 1:1000. Goat anti-mouse IgG (H&L)- 
HRPO was diluted 1:5000. TMB was used for color development. 
Plotted points are the means of triplicate determinations. Variation from 
the mean was typically 5% or less..............................................................110
Figure 37.Titer of serum collected the day of the fusion of mouse 7 immunized with 
KLH-Brevetoxin-2 (PbTx-2). Plates were coated with BSA-PbTx-2, 
BSA, and KLH at 5 pg/mL. Goat anti-mouse IgG (y)-HRPO was diluted 
1:5000. TMB was used for color development. Plotted points are the 
means of triplicate determinations. Variation from the mean was 
typically 5% or less....................................................................................111
xii
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Figure 38.Computer-generated best fit competition curve for serum collected the 
day of the fusion of mouse 7 (immunized with KLH-Brevetoxin-2 
[PbTx-2]). Plates were coated with BSA-PbTx-2 at 5 pg/mL. Goat anti­
mouse IgG (y)-HRPO was diluted 1:5000. TMB was used for color 
development. Plotted points are the means of duplicate determinations. 
Variation from the mean was typically 5% or less.......................................112
Figure 39.Antigen-specific and capture isotyping for serum collected the day of the 
fusion of mouse 7 (immunized with KLH-Brevetoxin-2 [PbTx-2]). 
Serum was diluted 1:1000 for testing......................................................... 113
Figure 40.Ammonium sulfate precipitates of cloned hybridoma supernatants 
obtained from fusion 4 (mouse 7 immunized with KLH-Brevetoxin-2). 
Precipitates were diluted 1:100 and 1:1000 for testing. Goat anti-mouse 
IgG (H&L)-HRPO was diluted 1:1000. TMB was used for color 
development................................................................................................116
Figure 41.Response of serum collected the day of the fusion of mouse 7 
(immunized with KLH-Brevetoxin-2 [PbTx-2]) with different coating 
antigens at 5 pg/mL. Serum was diluted 1:1000 for testing. Goat anti­
mouse IgG (H&L)-HRPO was diluted 1:5000. TMB was used for color 
development................................................................................................117
Figure 42.Competition assay using tissue culture supernatants from fusion 4 
(mouse 7 immunized with KLH-Brevetoxin-2 [PbTx-2]) and PbTx-2 at 
20 pg/mL. Plates were coated with BSA-PbTx-2 at 5 pg/mL. Goat anti­
mouse IgG (H&L)-HRPO was diluted 1:5000. TMB was used for color 
development............................................................................................... 118
Figure 43 .Antibody production response of mouse 8 after each immunization with 
KLH-Brevetoxin-2 (PbTx-2). Plates were coated with BSA-PbTx-2 at 5 
pg/mL. Each serum was diluted 1:1000. Goat anti-mouse IgG (H&L)- 
HRPO was diluted 1:5000. TMB was used for color development. 
Plotted points are the means of triplicate determinations. Variation from 
the mean was typically 5% or less.............................................................. 120
Figure 44.Titer of serum collected the day of the fusion of mouse 8 immunized with 
KLH-Brevetoxin-2 (PbTx-2). Plates were coated with BSA-PbTx-2, 
BSA, and KLH at 5 pg/mL. Goat anti-mouse IgG (y)-HRPO was diluted 
1:1000. TMB was used for color development. Plotted points are the 
means of triplicate determinations. Variation from the mean was 
typically 5% or less.....................................................................................121
X1U
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Figure 45. C omputer-generated best fit competition curve for serum collected the 
day of the fusion of mouse 8 (immunized with KLH-Brevetoxin-2 
[PbTx-2]). Plates were coated with BSA-PbTx-2 at 5 pg/mL. Goat anti­
mouse IgG (y)-HRPO was diluted 1:5000. TMB was used for color 
development. Plotted points are the means of duplicate determinations. 
Variation from the mean was typically 5% or less.......................................122
Figure 46 Antigen-specific and capture isotyping for serum collected the day of the 
fusion of mouse 8 (immunized with KLH-Brevetoxin-2 [PbTx-2]). 
Serum was diluted 1:1000 for testing..........................................................123
Figure 47.Ammonium sulfate precipitates of cloned hybridoma supernatants 
obtained from fusion 5 (mouse 8 immunized with KLH-Brevetoxin-2). 
Precipitates were diluted 1:100 and 1:1000 for testing. Goat anti-mouse 
IgG (H&L)-HRPO was diluted 1:1000. TMB was used for color 
development...............................................................................................127
Figure 48.Response of serum collected the day of the fusion of mouse 8 
(immunized with KLH-Brevetoxin-2 (PbTx-2) with different coating 
antigens at 5 pg/mL. Serum was diluted 1:1000 for testing. Goat anti­
mouse IgG (H&L)-HRPO was diluted 1:5000. TMB was used for color 
development............................................................................................... 128
Figure 49.Competition assay using tissue culture supernatants from fusion 5 
(mouse 8 immunized with KLH-Brevetoxin-2 [PbTx-2]) and PbTx-2 at 
20 pg/mL. Plates were coated with BSA-PbTx-2 at 5 pg/mL. Goat anti­
mouse IgG (H&L)-HRPO was diluted 1:5000. TMB was used for color 
development............................................................................................... 129
Figure 50.Antibody production response of mouse 10 after each immunization 
with KLH-Brevetoxin-2 (PbTx-2). Plates were coated with BSA-PbTx-2 
at 5 pg/mL. Each serum was diluted 1:1000. Goat anti-mouse IgG 
(H&L)-HRPO was diluted 1:5000. TMB was used for color 
development. Plotted points are the means of triplicate determinations. 
Variation from the mean was typically 5% or less.......................................131
Figure 51.Titer of serum collected the day of the fusion of mouse 10 immunized 
with KLH-Brevetoxin-2 (PbTx-2). Plates were coated with BSA-PbTx-2, 
BSA, and KLH at 5 pg/mL. Goat anti-mouse IgG (y)-HRPO was diluted 
1:1000. TMB was used for color development. Plotted points are the 
means of triplicate determinations. Variation from the mean was 
typically 5% or less.....................................................................................132
xiv
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Figure 52.Computer-generated best fit competition curve for serum collected the 
day of the fusion of mouse 10 (immunized with KLH-Brevetoxin-2 
[PbTx-2]). Plates were coated with BSA-PbTx-2 at 5 pg/mL. Goat anti­
mouse IgG (y)-HRPO was diluted 1:5000. TMB was used for color
development. Plotted points are the means of duplicate determinations. 
Variation from the mean was typically 5% or less...................................... 133
Figure 53.Antigen-specific and capture isotyping for serum collected the day of the 
fusion of mouse 10 (immunized with KLH-Brevetoxin-2 [PbTx-2]). 
Serum was diluted 1:1000 for testing......................................................... 134
Figure 54.Ammonium sulfate precipitates of cloned hybridoma supernatants 
obtained from fusion 6 (mouse 10 immunized with KLH-Brevetoxin-2). 
Precipitates were diluted 1:100 and 1:1000 for testing. Goat anti-mouse 
IgG (H&L)-HRPO was diluted 1:1000. TMB was used for color 
development...............................................................................................138
Figure 55.Response of serum collected the day of the fusion of mouse 10 
(immunized with KLH-Brevetoxin-2 [PbTx-2]) with different coating 
proteins at 5 pg/mL. Serum was diluted 1:1000 for testing. Goat anti­
mouse IgG (H&L)-HRPO was diluted 1:5000. TMB was used for color 
development.............................................................................................. 139
Figure 56.Competition assay using tissue culture supernatants from fusion 6 
(mouse 10 immunized with KLH-Brevetoxin-2 [PbTx-2]) and PbTx-2 at 
20 pg/mL. Plates were coated with BSA-PbTx-2 at 5 pg/mL. Goat anti­
mouse IgG (H&L)-HRPO was diluted 1:5000. TMB was used for color 
development.............................................................................................. 139
Figure 57.Antibody production response of mouse 11 after each immunization with 
KLH-Brevetoxin-2 (PbTx-2). Plates were coated with BSA-PbTx-2 at 5 
pg/mL. Each serum was diluted 1:1000. Goat anti-mouse IgG (H&L)- 
HRPO was diluted 1:5000. TMB was used for color development. 
Plotted points are the means of triplicate determinations. Variation from 
the mean was typically 5% or less.............................................................. 141
Figure 58.Titer of serum collected the day of the fusion of mouse 11 immunized 
with KLH-Brevetoxin-2 (PbTx-2). Plates were coated with BSA-PbTx-2 
at 5 pg/mL. Goat anti-mouse IgG (y)-HRPO was diluted 1:1000. TMB 
was used for color development. Plotted points are the means of triplicate 
determinations. Variation from the mean was typically 5% or less.............142
Figure 59.Computer-generated best fit competition curve for serum collected the 
day of the fusion of mouse 11 (immunized with KLH-Brevetoxin-2
xv
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
[PbTx-2]). Plates were coated with BSA-PbTx-2 at 5 (ig/mL. Goat anti­
mouse IgG (y)-HRPO was diluted 1:5000. TMB was used for color 
development. Plotted points are the means of duplicate determinations. 
Variation from the mean was typically 5% or less...................................... 143
Figure 60.Antigen-specific and capture isotyping for serum collected the day of the 
fusion of mouse 11 (immunized with KLH-Brevetoxin-2 [PbTx-2]). 
Serum was diluted 1:1000 for testing..........................................................144
Figure 61.Ammonium sulfate precipitates of cloned hybridoma supernatants 
obtained from fusion 7 (mouse 11 immunized with KLH-Brevetoxin-2). 
Precipitates were diluted 1:100 and 1:1000 for testing. Goat anti-mouse 
IgG (H&L)-HRPO was diluted 1:1000. TMB was used for color 
development...............................................................................................148
Figure 62.Response of serum collected the day of the fusion of mouse 11 
(immunized with KLH-Brevetoxin-2 [PbTx-2]) with different coating 
antigens at 5 jig/mL. Serum was diluted 1:1000 for testing. Goat anti­
mouse IgG (H&L)-HRPO was diluted 1:5000. TMB was used for color 
development...............................................................................................149
Figure 63.Competition assay using tissue culture supernatants from fusion 7 
(mouse 11 immunized with KLH-Brevetoxin-2 [PbTx-2]) and PbTx-2 at 
20 pg/mL. Plates were coated with BSA-PbTx-2 at 5 (ig/mL. Goat anti­
mouse IgG (H&L)-HRPO was diluted 1:5000. TMB was used for color 
development...............................................................................................150
Figure 64.Antibody production response of mouse 12 after each immunization with 
BSA-Brevetoxin-2 (PbTx-2). Plates were coated with OVA-PbTx-2 at 5 
(ig/mL. Each serum was diluted 1:1000. Goat anti-mouse IgG (H&L)- 
HRPO was diluted 1:5000. TMB was used for color development. 
Plotted points are the means of triplicate determinations. Variation from 
the mean was typically 5% or less...............................................................152
Figure 65 .Titer of serum collected the day of the fusion of mouse 12 immunized 
with BSA-Brevetoxin-2 (PbTx-2). Plates were coated with OVA-PbTx- 
2, OVA, and BSA at 5 pg/mL. Goat anti-mouse IgG (y)-HRPO was 
diluted 1:5000. TMB was used for color development. Plotted points are 
the means of triplicate determinations. Variation from the mean was 
typically 5% or less.................................................................................... 153
Figure 66.Computer-generated best fit competition curve for serum collected the 
day of the fusion of mouse 12 (immunized with BSA-Brevetoxin-2 
[PbTx-2]). Plates were coated with OVA-PbTx-2 at 5 (ig/mL. Goat anti-
xvi
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
mouse IgG (y)-HRPO was diluted 1:5000. TMB was used for color
development. Plotted points are the means of duplicate determinations. 
Variation from the mean was typically 5% or less...................................... 154
Figure 67 Antigen-specific and capture isotyping for serum collected the day of the 
fusion of mouse 12 (immunized with BSA-Brevetoxin-2 [PbTx-2]). 
Serum was diluted 1:1000 for testing..........................................................155
Figure 68.Tissue culture supernatants obtained from fusion 8 (mouse 12 immunized 
with BSA-Brevetoxin-2). Goat anti-mouse IgG (H&L)-HRPO was 
diluted 1:1000. TMB was used for color development................................157
Figure 69.Response of serum collected the day of the fusion of mouse 12 
(immunized with BSA-Brevetoxin-2 [PbTx-2]) with different coating 
proteins at 5 pg/mL. Serum was diluted 1:1000 for testing. Goat anti­
mouse IgG (H&L)-HRPO was diluted 1:5000. TMB was used for color 
development..............................................................................................159
Figure 70.Competition assay using tissue culture supernatants from fusion 8 
(mouse 12 immunized with BSA-Brevetoxin-2 [PbTx-2]) and PbTx-2 at 
20 pg/mL. Plates were coated with OVA-PbTx-2 at 5 pg/mL. Goat anti­
mouse IgG (H&L)-HRPO was diluted 1:5000. TMB was used for color
development............................................................................................... 159
Figure 71.Antibody production response of mouse 13 after each immunization with 
BSA-Brevetoxin-2 (PbTx-2). Plates were coated with OVA-PbTx-2 at 5 
pg/mL. Each serum was diluted 1:1000. Goat anti-mouse IgG (H&L)- 
HRPO was diluted 1:5000. TMB was used for color development............. 161
Figure 72.Titer of serum collected the day of the fusion of mouse 13 immunized 
with BSA-Brevetoxin-2 (PbTx-2). Plates were coated with OVA-PbTx- 
2, OVA, and BSA at 5 pg/mL. Goat anti-mouse IgG (y)-HRPO was 
diluted 1:5000. TMB was used for color development. Plotted points are 
the means of triplicate determinations. Variation from the mean was 
typically 5% or less.....................................................................................162
Figure 73 .Computer-generated best fit competition curve for serum collected the 
day of the fusion of mouse 13 (immunized with BSA-Brevetoxin-2 
[PbTx-2]). Plates were coated with OVA-PbTx-2 at 5 pg/mL. Goat anti­
mouse IgG (y)-HRPO was diluted 1:5000. TMB was used for color 
development. Plotted points are the means of duplicate determinations. 
Variation from the mean was typically 5% or less...................................... 164
xvii
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Figure 74.Antigen-specific and capture isotyping serum collected the day of the 
fusion o f mouse 13 (immunized with BSA-Brevetoxin-2 [PbTx-2]). 
Serum was diluted 1:1000 for testing..........................................................164
Figure 75.Tissue culture supernatants obtained from fusion 9 (mouse 13 immunized 
with BSA-Brevetoxin-2). Goat anti-mouse IgG (H&L)-HRPO was 
diluted 1:1000. TMB was used for color development................................167
Figure 76.Response of serum collected the day of the fusion of mouse 13 
(immunized with BSA-Brevetoxin-2 [PbTx-2]) with different coating 
proteins at 5 pg/mL. Serum was diluted 1:1000 for testing. Goat anti­
mouse IgG (H&L)-HRPO was diluted 1:5000. TMB was used for color 
development...............................................................................................168
Figure 77.Competition assay using tissue culture supernatants from fusion 9 
(mouse 13 immunized with BSA-Brevetoxin-2 [PbTx-2]) and PbTx-2 at 
20 pg/mL. Plates were coated with OVA-PbTx-2 at 5 pg/mL. Goat anti­
mouse IgG (H&L)-HRPO was diluted 1:5000. TMB was used for color 
development...............................................................................................169
Figure 78.Antibody production response of mouse 14 after each immunization with 
BSA-Brevetoxin-2 (PbTx-2) and before the in vitro stimulation. Plates 
were coated with OVA-PbTx-2 at 5 pg/mL. Each serum was diluted 
1:1000. Goat anti-mouse IgG (H&L)-HRPO was diluted 1:5000. TMB 
was used for color development. Plotted points are the means of triplicate 
determinations. Variation from the mean was typically 5% or less............ 171
Figure 79.Titer of serum collected before the in vitro stimulation of mouse 14 
immunized with BSA-Brevetoxin-2 (PbTx-2). Plates were coated with 
OVA-PbTx-2, OVA, and BSA at 5 pg/mL. Goat anti-mouse IgG (y)- 
HRPO was diluted 1:5000. TMB was used for color development. 
Plotted points are the means of triplicate determinations. Variation from 
the mean was typically 5% or less...............................................................172
Figure 80.Computer-generated best fit competition curve for serum collected before 
the in vitro stimulation of mouse 14 (immunized and stimulated with 
BSA-Brevetoxin-2 [PbTx-2]). Plates were coated with OVA-PbTx-2 at 5 
pg/mL. Goat anti-mouse IgG (y)-HRPO was diluted 1:5000. TMB was 
used for color development. Plotted points are the means of duplicate 
determinations. Variation from the mean was typically 5% or less............. 173
Figure 81.Antigen-specific and capture isotyping for serum collected before the in 
vitro stimulation of mouse 14 (immunized and stimulated with BSA- 
Brevetoxin-2 [PbTx-2]). Serum was diluted 1:1000 for testing...................174
xviii
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Figure 82.Tissue culture supernatants obtained from fusion 10 (mouse 14 
immunised and stimulated with BSA-PbTx-2). Goat anti-mouse IgG 
(H&L)-HRPO was diluted 1:1000. TMB was used for color 
development...............................................................................................176
Figure 83.Response of serum collected before the in vitro stimulation of mouse 14 
(immunized and stimulated with BSA-Brevetoxin-2 [PbTx-2]) with 
different coating antigens at 5 pg/mL. Serum was diluted 1:1000 for 
testing. Goat anti-mouse IgG (H&L)-HRPO was diluted 1:5000. TMB 
was used for color development................................................................. 177
Figure 84.Competition assay using tissue culture supernatants from fusion 10 
(mouse 14 immunized and stimulated with BSA-Brevetoxin-2 [PbTx-2]) 
and PbTx-2 at 20 pg/mL. Plates were coated with OVA-PbTx-2 at 5 
pg/mL. Goat anti-mouse IgG (H&L)-HRPO was diluted 1:5000. TMB 
was used for color development................................................................. 178
Figure 85.Antibody production response of mouse 15 after each immunization with 
BSA-Brevetoxin-2 (PbTx-2) and before the in vitro stimulation. Plates 
were coated with OVA-PbTx-2 at 5 pg/mL. Each serum was diluted 
1:1000. Goat anti-mouse IgG (H&L)-HRPO was diluted 1:5000. TMB 
was used for color development. Plotted point are the means of triplicate 
determinations. Variation from the mean was typically 5% or less........... 180
Figure 86.Titer of serum collected before the in vitro stimulation of mouse 15 
immunized with BSA-Brevetoxin-2 (PbTx-2). Plates were coated with 
OVA-PbTx-2, OVA, and BSA at 5 pg/mL. Goat anti-mouse IgG (y)- 
HRPO was diluted 1:5000. TMB was used for color development. 
Plotted points are the means of triplicate determinations. Variation from 
the mean was typically 5% or less.............................................................. 181
Figure 87.Computer-generated best fit competition curve for serum collected before 
the in vitro stimulation of mouse 15 (immunized with BSA-Brevetoxin-2 
[PbTx-2] and stimulated with PbTx-2). Plates were coated with OVA- 
PbTx-2 at 5 pg/mL. Goat anti-mouse IgG (y)-HRPO was diluted 1:5000. 
TMB was used for color development. Plotted points are the means of 
duplicate determinations. Variation from the mean was typically 5% or 
less............................................................................................................ 182
Figure 88.Antigen-specific and capture isotyping for serum collected before the in 
vitro stimulation of mouse 15 (immunized with BSA-Brevetoxin [PbTx- 
2] and stimulated with PbTx-2). Serum was diluted 1:1000 for testing 183
xix
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Figure 89 .Tissue culture supernatants obtained from fusion 11 (mouse 15 
immunized with BSA-Brevetoxin-2 [PbTx-2] and stimulated with PbTx- 
2). Goat anti-mouse IgG (H&L)-HRPO was diluted 1:1000. TMB was 
used for color development.........................................................................185
Figure 90.Response of serum collected before the in vitro stimulation of mouse 15 
(immunized with BSA-Brevetoxin-2 [PbTx-2] and stimulated with 
PbTx-2) with different coating antigens at 5 pg/mL. Serum was diluted 
1:1000 for testing. Goat anti-mouse IgG (H&L)-HRPO was diluted 
1:5000. TMB was used for color development............................................186
Figure 91.Competition assay using tissue culture supernatants from fusion 11 
(mouse 15 immunized with BSA-Brevetoxin-2 [PbTx-2] and stimulated 
with PbTx-2) and PbTx-2 at 20 pg/mL. Plates were coated with OVA- 
PbTx-2 at 5 pg/mL. Goat anti-mouse IgG (H&L)-HRPO was diluted 
1:5000. TMB was used for color development............................................187
Figure 92.Summary of immunization responses over time for mice immunized with
different protein-brevetoxin-2 (PbTx-2) conjugates....................................215
Figure 93.Summary of serum titers for mice immunized with different protein-
brevetoxin-2 (PbTx-2) conjugates.............................................................. 216
Figure 94.Summary of competition curves for mice immunized with different
protein-brevetoxin-2 (PbTx-2) conjugates.................................................. 217
xx
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
ABSTRACT
The proliferation of toxic algae is a natural phenomenon known as a harmful algal 
bloom. Ciguatera fish poisoning and neurotoxic fish poisoning are syndromes associated 
with this phenomenon. Current methods for the detection of their toxins (ciguatoxins 
and brevetoxins) are expensive, time-consuming, require trained personnel and special 
laboratory equipment In the case of ciguatoxins, the lack of standard material worsens 
the problem.
Specific objectives of this study included the use of brevetoxin-2 (PbTx-2) for the 
preparation of antibodies which could cross-react with ciguatoxins, the use of different 
PbTx-2 immunogenic conjugates, the use of in vivo versus in vitro stimulation of 
murine splenocytes, and the use of alternative screening assays to detect anti-PbTx-2 
antibodies.
Three different immunogenic conjugates were prepared for immunization (BSA- 
PbTx-2, KLH-PbTx-2, and LPH-PbTx-2) and given to three groups of mice. After 
several injections, murine anti-PbTx-2 IgG antibodies were detected in the serum of the 
mice using experiments such as measurement of titer, competition assays, and isotyping 
experiments. However, after fusion of the spleens of 12 mice, no monoclonal antibodies 
were obtained which could be used for detection of ciguatoxin-related compounds. 
Difficulties associated in producing antibodies against brevetoxin-2 are its size and 
hydrophobicity. Moreover, intrinsic problems in the production of monoclonal 
antibodies include the overgrowth of antibody-producing hybridomas by non-producer 
cells or fibroblasts in the same well and loss of chromosomes involved in the synthesis 
of heavy and/or light chains.
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The use of in vitro stimulation of murine spienocytes with the BSA-PbTx-2 
conjugate failed to yield monoclonal anti-PbTx-2 antibodies. However, this method 
should be further explored using different doses of stimulation and carrier-specific T 
cell lines to increase the probability of obtaining antibodies of the desired specificity.
To assure that anti-PbTx-2 antibodies had not been missed in the tissue culture 
supernatants, a highly sensitive modified cytotoxicity assay was used. However, this 
assay failed to detect antibodies capable of neutralizing the PbTx-2 activity on Neuro-2a 
cells. This may have been due to the lack of anti-PbTx-2 antibodies in the supernatants 
or to their low affinity which was insufficient to compete with the sodium channels on 
Neuro-2a cells for free PbTx-2.
xxii
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INTRODUCTION
Harmful algal blooms are natural phenomena which have occurred for hundreds of 
years. They are characterized by the proliferation and irregular prevalence of particular 
species of toxic algae. Over the last several decades, the United States has experienced 
an increasing and dangerous direction in the incidence of problems associated with 
harmful and toxic algae. At present, virtually every coastal state is threatened, in many 
cases over large geographic areas and by more than one harmful microalgal species. 
This increase could be the result of increased awareness, increased utilization of coastal 
waters for aquaculture, stimulation of blooms by cultural eutrophication and/or unusual 
climatological conditions, and transport of dinoflagellate resting cysts either in ships’ 
ballast water or associated with translocation of shellfish stocks from one area to 
another (HallegraefF, 1995). Impact of these phenomena include mass mortalities of 
wild and farmed fish and shellfish, human illness and death from contaminated shellfish 
or fish, death of marine mammals, seabirds, and other animals, and, alteration of marine 
habitats or trophic structure through shading, overgrowth, or adverse effects on life 
history stages of fish and other marine organisms. One major category of public health 
impact of harmful algal blooms occurs when toxic phytoplankton are filtered from the 
water by shellfish such as clams, mussels, oysters, or scallops, which then accumulate 
the algal toxins to levels that are potentially lethal to humans or other consumers.
Current methods for the detection of ciguatoxins (CTXs) and brevetoxins (PbTxs) 
are either non-specific and lack the necessary level of sensitivity or costly, time- 
consuming, require qualified researchers/technicians and specific laboratory equipment 
In the case of CTXs, the problem is more complex from the lack of standard material.
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This project proposed the use of the CTX-related toxin, PbTx-2, to produce cross­
reacting monoclonal antibodies for both CTXs and PbTxs to be used in 
immunochemical-based detection methods. The specific project’s objectives were the 
following: (1) to produce monoclonal antibodies to PbTxs and CTXs based on PbTx-2 
immunogenic conjugates, (2) to test the effect of different protein-PbTx-2 conjugates in 
the success of obtaining antibodies of the desired specificity, (3) to use in vivo and in 
vitro stimulation of murine splenocytes with the immunogenic conjugates, and (4) to 
test alternative screening assays for the detection of anti-PbTx-2 antibodies.
2
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REVIEW OF LITERATURE 
A) CIGUATERA FISH POISONING
The term ciguatera fish poisoning (CFP) was originated in the Caribbean area to 
designate an intoxication induced by the ingestion of the marine snail Turbo pica (called 
cigua by the Cuban natives), involved with food poisoning outbreaks during the Spanish 
conquest (Gudger, 1930). Now the word is used to designate the illness caused by 
ingestion of fish, primarily reef fish from the tropical and subtropical areas of the 
Caribbean and the Pacific, which have accumulated the toxins via their diet.
1. Occurrence
CFP is considered a world health problem, being the most common non-bacterial 
food poisoning disease associated with the consumption of fish in the United States and 
its territories (Ahmed, 1991). An accurate assessment of the incidence of CFP is not 
available; however, it has been estimated that around 50,000 cases occur each year 
(Ragelis, 1984). The incidence of CFP varies within regions, with the highest incidence 
in the Pacific Islands (43%) (Rodgers and Muench, 1986), Tuvalu (10%) (Dalzell, 
1994), Puerto Rico (7%) (Holt et al., 1984), and Micronesia (5%) (Peam and Lewis, 
1994). Other areas where there is a lower incidence include Hawaii (0.1%), Queensland 
(0.03%) (Gillespie et al., 1986), and French Polynesia (0.01%). In the United States, 
nearly half of the reported foodbome disease outbreaks of chemical origin are due to 
marine toxins, with ciguatoxin (CTX) causing at least one third of these outbreaks. In 
Miami, an average annual incidence of at least 5 cases/10,000 persons {i.e., 900 
cases/year) was estimated by voluntary reports to the Public Health Department and 
based on clinical diagnosis (Lawrence et a l, 1980).
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The illness is now widespread in the tropical Caribbean, subtropical Atlantic, and 
the Pacific regions (Bagnis, 1970; Bagnis et al., 1979a; Randall, 1980; Royal, 1982; 
Lewis, 1986; Maharaj et al., 1986). The past outbreaks were restricted to endemic areas; 
however, interregional transport of fish as well as return of tourists from endemic areas 
can lead to outbreaks in nontropical parts of the world (Juranovic and Park, 1991). The 
areas with the highest occurrence of CFP are shown in Figure 1.
Figure 1. Worldwide areas with the highest occurrence of ciguatera fish poisoning.
Ciguatoxic fish have been found at every season of the year. However, there is 
some evidence that certain species, such as the great barracuda, are more toxic during 
the reproductive season than at other times (Hessel et al., 1960). Herbivorous fish and 
coral feeders become toxic first, and the larger carnivores and omnivores then prey on 
these fish (Banner, 1976; Bagnis, 1981). Carnivores tend to be more toxic than 
herbivores because the toxins tend to accumulate in the tissues of the various fish as 
they move up the ocean food chain (Bagnis et al., 1979a). More than 400 species of fish 
have been reported to be associated with CFP outbreaks (Halstead, 1967), but the 
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Not all parts of the fish in a specific population contain equal levels o f toxins. Based 
on studies in the moray eel, it was found that the liver can have appreciable larger 
amounts of toxins while the flesh has no detectable levels (Yasumoto and Scheuer, 
1969). CTXs have been detected in the intestinal contents, liver, skin, mucus, gonads, 
and the flesh (Helftich et al., 1968; Yasumoto and Scheuer, 1969; Yasumoto et al., 
1971, 1977c; Bagnis et al., 1974; Chungue et al., 1977; Hofiman et al., 1983; Gamboa, 
1993).
An estimate of the elimination (depuration and metabolism to less potent forms) of 
CTXs from a population of moray eels in the central Pacific indicated a half-life of 264 
days (Lewis et al., 1992). Since toxins with a type A backbone are more polar than their 
type B isomers (see section 3 for structural descriptions of these toxins), it is expected 
that the former will depurate faster (Lewis and Holmes, 1993).
2. Source ofToxins
The major source of the toxins is a group of benthic and epiphytic dinoflagellates. 
Yasumoto and co-workers (1977b) found considerable toxicity in a sample of algae and 
detritus, and a large number of dinoflagellates in the toxic samples. The organism was 
first identified as Diplopsalis sp. by Adachi (Yasumoto et al., 1977a), but later placed in 
a new genus and named Gambierdiscus toxicus (G. toxicus) because of the place where 
the samples were collected (Gambier Islands in French Polynesia) (Adachi and Fukuyo,
1979).
More than 20 species of benthic dinoflagellates have been implicated in the 
production of CFP toxins. Some of the implicated genera are G. toxicus, Prorocentrum 
(P. lima, P. concavum, P. emarginatum, P. mexicanum), Amphidinium carterae,
5
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Ostreopsis (O. ovata, O. siamensis, O. lenticula, O. heptagona), Thecadinium sp., and 
Coolia monotis (Chungue et cd., 1979; Bergman and Alam, 1981; Besada et al, 1982; 
Carlson et al, 1982; Baden, 1983; Steidinger, 1983; Tindall et al., 1984; Norris et al., 
1985; Escalona De Mota et al., 1986; Bomber et al., 1988; Holmes et al., 1988). 
However, it is uncertain that ciguateric fish contain sufficiently high levels of toxins 
from all these species to cause human illness (Lewis and Holmes, 1993). Evidence to 
date suggests that, of the benthic dinoflagellates, only G. toxicus produces toxins 
responsible for the human syndrome known as CFP (Holmes and Lewis, 1994b).
The proposed transmission path of CFP toxins from toxigenic marine 
dinoflagellates through herbivorous and carnivorous fish to man can be seen in Figure
2. It has been hypothesized that molluscs and fish which feed on invertebrates such as 
shrimps may also be involved with CFP (Lewis et al., 1994b).
Carnivore
Herbivore






Figure 2.Proposed transmission path of ciguatera toxins.
G. toxicus is often attached to macroalgae (Bagnis et al., 1979b), such as Turbinaria 
omata, Amphiroa sp., and Jania sp. Under laboratory conditions, G. toxicus produces
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far more water soluble toxin, maitotoxin, than in nature (Yasumoto et al., 1977b). The 
low production of CTXs by cultured G. toxicus may be due to an unknown missing 
factor. This can be an appropriate stress or a chemical substance produced by another 
microorganism (Doorenbos, 1984).
3. Properties of Toxins
Several toxins have been implicated in CFP including CTXs, gambiertoxins 
(GTXs), gambierol, ciguatoxin-3C (CTX-3C), gambieric acids, maitotoxins (MTXs), 
scaritoxin, palytoxin, and okadaic acid (OA) (Yasumoto and Scheuer, 1969; Bagnis et 
al., 1974; Chungue et al., 1977; Tachibana, 1980; Tindall et al., 1984; Yasumoto and 
Murata, 1988a; Yasumoto and Murata, 1988b; Juranovic and Park, 1991; Legrand, 
1991; Gamboa et al., 1992; Legrand et al., 1992; Satake et al., 1993a, 1993b).
Pacific CTX-1 (P-CTX-1) is considered the major toxin involved in CFP, and this 
is the name given to the toxin isolated from Pacific moray eel by Scheuer's group 
(1967). The structure of P-CTX-1 was elucidated in 1989 (Murata et al., 1989, 1990). It 
is a highly oxygenated, white solid lipid, with a molecular weight o f 1111.7 ± 0.3 Da, 
determined by spectrometry (Nukina et al., 1984; Murata et al., 1990; Lewis et al., 
1991; Lewis and Sellin, 1992). Its L D 5 0  to mice (ip) was found to be 0.45 pg/Kg 
(Tachibana, 1980); but later, Lewis et al. (1991) proposed a toxicity of 0.25 pg/Kg from 
an extract o f moray eel. Figure 3 shows the structure of P-CTX-1 and its congeners.
Toxicity of P-CTX-1 can be maintained in methanol solution at room temperature 
for at least 6  months. It is stable in water, pyridine, acetic acid, and 1 N NaOH at 100°C 
for at least 1 0  min; it is also stable to exposure to sunlight in methanol solution for at 
least 1 hr, and to metallic solutions for at least 36 hrs. The toxicity is lost with 1 N HC1
7
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Figure 3.Structure of Pacific ciguatoxins (P-CTXs).
Lewis et al. (1991) isolated two less-polar CTXs from Pacific moray eel (P-CTX-2 
and P-CTX-3) which were less potent to mice (LD50 2.3 and 0.9 pg/Kg, ip, respectively, 
versus 0.25 pg/Kg for P-CTX-1). With the aid of *H NMR and mass spectrometry, it 
was found that P-CTX-2 (52-epi-P-CTX-3) and P-CTX-3 were less oxidized forms than 
P-CTX-1 (Lewis and Sellin, 1992), and that they were diastereoisomers (MW 1094 Da) 
(Lewis, 1992; Lewis et al., 1993b). They differ from P-CTX-1 by 16 mass units, lacking 
the secondary hydroxyl group on C-54 (Lewis et al., 1991).
Recently, the AB fragment (Sato and Hirama, 1992) and the JKLM rings of P- 
CTX-1 (Figure 3) have been synthesized (Sasaki et al., 1994). The latter may be useful
8
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as a hapten for the production of anti-CTX antibodies (Sasaki et al., 1994). This effort is 
currently underway by Pauillac and co-workers (1997), who report the conjugation of 
the JKLM fragment with bovine serum albumin in an effort to produce monoclonal 
antibodies which can cross-react with P-CTX-1. However, no further information has 
been presented regarding the success/failure of this attempt.
Several CTX congeners have been identified in wild and cultured G. toxicus from 
Gambier Islands and Rangiroa Atoll in French Polynesia and in Australia (Holmes et 
al., 1991; Legrand et a l, 1992; Nagai et al., 1992; Satake et al., 1993a, 1993b), 
although none identical to that found in moray eel (P-CTX-1). Nine gambiertoxins 
(GTXs) have been isolated from wild G. toxicus from French Polynesia (Legrand et al.,
1992); however, just the structure of GTX-4B (1061.587 Da) (Murata et al., 1990) and 
its stereoisomer, GTX-4A (52-epi-GTX-4B), are known (Figure 4). GTX-4A and -4B 
have a trans-butadiene moiety at one terminus of the molecule and lack a hydroxyl 
group at C-54 at the other end (Murata et al., 1990; Satake et al., 1997). GTX-4A is the 
major GTX produced by G. toxicus in culture (Yasumoto et al, 1993b). GTX-4C shows 
the highest mouse lethality and is less polar than GTX-4A and GTX-4B (Legrand et a l,
1992). GTX-4B appears to be the most important GTX since its oxidation product, P- 
CTX-1, accounts for more than 90% of the toxicity of CTXs (Lewis et a l, 1991). GTX- 
4B has an ip toxicity of approximately less than 10 times that of P-CTX-1 ( L D 5 0  in 
mouse 4 pg/Kg) (Murata et al., 1990; Lewis et al., 1991; Legrand et a l, 1992). The 
production of GTXs in culture depends on the dinoflagellate strain, and the major toxin 
produced is MTX. The size of the G. toxicus population does not reflect its capacity to 
produce GTXs (Holmes et al., 1994). It appears that the conditions that favor the growth
9
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of G. toxicus are not the ideal for the production of the toxins (Holmes and Lewis, 
1994b). The environmental parameters which control the size of G. toxicus, and the 
proportion of the cells which produce GTXs need to be determined before the potential 





Figure 4.Structure of gambiertoxin-4A and -4B.
It has been proposed that P-CTX-1 and P-CTX-3 may be formed from the 
oxidative biotransformation of GTX-4B produced by G. toxicus (Murata et al, 1990; 
Lewis et al., 1991). P-CTX-1 and P-CTX-3 share a "type B" backbone. P-CTX-2 (52- 
epi-P-CTX-3) ("type A" backbone) may be formed from the biotransformation of GTX- 
4A produced by G. toxicus. Both CTXs and GTXs share a spiroacetal associated with 
carbon 52 that can undergo spiroisomerization when exposed to acidic media, either 
during their passage through the food chain {e.g., the acid stomach of certain fish) or
10
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during purification processes (e.g., acidic solvents such as chloroform) (Deslongchamps 
et al., 1981; Perron and Albizati, 1989). At present, the specific place where the acid- 
catalyzed spiroisomerization occurs in the food chain remains to be determined (Lewis 
and Holmes, 1993), but likely occurs in the liver of fish (Lewis et al., 1991).
Thermodynamically, the "type B" conformation is the favored configuration for 
both GTXs and CTXs (Lewis and Holmes, 1993). CTXs with the "type A" backbone are 
more polar than their "type B" isomers (Lewis and Holmes, 1993). A biotransformation 
of GTXs and CTXs has been proposed by Lewis and Holmes (1993) (Figure 5).
+ 20H +1GH ?
GDC-4A  P-CIX-2 RCIX-4 ----- ►
k k k
T + 2CH + +1CH' ?
GIX-4B ----•'P-C IX -3-------►P-CIX-1 ----- -
Reprinted from Comparative Biochemistry
and Physiology, 106C, Lewis and Holmes,
Copyright (1993), with permission from
Elsevier Science.
Figure 5.Biotransformation of gambiertoxins and ciguatoxins.
The horizontal lines represent biotransformation of the toxins and the vertical 
arrows, the acid-catalyzed spiroisomerization. P-CTX-4 (52 epi-P-CTX-1) is a putative 
toxin. For P-CTX-4 and P-CTX-1, there are no known further biotransformations to 
more polar and/or less potent forms (Lewis and Holmes, 1993). The structural closeness 
between GTX-4B and P-CTX-1 indicates that the dinoflagellate toxin is oxidized at two 
terminals of the molecule while moving up to higher trophic levels. The result strongly 
supports that G. toxicus is the origin of CTXs (Yasumoto et al., 1993a).
11
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From 1100 L of G. toxicus strain RGI-1 isolated from the Rangiroa Atoll, French 
Polynesia, Satake and co-workers (1993a, 1993b) isolated two toxic fractions, RGT-1 
(1.2 mg) and RGT-2 (0.7 mg). RGT-1 was named gambierol (Figure 6); though not 
identical, its structure resembles that of P-CTX-1 in having many ether units aligned in 
a laddershape. This toxin also exhibited similar symptoms in mice (diarrhea, dyspnea, 
and convulsions before death) and chromatographic properties of P-CTX-1 (Satake et 
al., 1993a). This also raises the possibility that gambierol can be implicated in CFP 
(Yasumoto and Murata, 1993). Its molecular weight was reported to be 779.43 Da and 







Figure 6.Structure of gambierol.
RGT-2 resembled structurally GTX-4B isolated from wild G. toxicus, as shown by 
*H NMR spectra analysis (Satake et al., 1993b). This toxin was named CTX-3C 
(1,2,3,4-nor-E-homo-GTX-4B) (Figure 7). It lacks the butadiene side chain 
characteristic of GTXs. Rings D, F, and G agreed well with those of P-CTX-1. The 
eight-membered ring E appeared to take the same conformation as in brevetoxin-2. The 
structural resemblance of CTX-3C and GTX-4B, and of moray eel derived P-CTX-1
12
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confirms that G. toxicus is a major source of toxins implicated in CFP. Its L D 5 0  to mice 
(ip) was reported to be 1.3 pg/Kg, with a molecular weight of 1023.568 Da (Satake et 
aL, 1993b). CTX-3C has been recently detected in herbivorous fish from a Tuamotu 





Figure 7.Structure of ciguatoxin-3C.
Several CTXs have been characterized from horse-eye jack (Caranx latus) caught 
in the French West Indies in the Caribbean. Each of these toxins was found to differ 
from the Pacific family of CTXs. Toxins isolated include Caribbean CTX-1 (C-CTX-1) 
(LD50 3.6 pg/Kg, ip, mouse; MW 1141.7 Da), C-CTX-2 (LD50 1 pg/Kg, ip, mouse; MW 
1141.7 Da), a minor toxin, and a hydrophobic fast-acting toxin. The first two are 
diastereoisomers that differ from P-CTXs. Intraperitoneal injection of each toxin into 
mice induced signs typical of site 5 channel activator toxins such as P-CTXs and 
brevetoxins (Vemoux and Lewis, 1997). Using mouse potency as a guide to human 
poisoning potential, > 1 ppb C-CTX-1 would need to accumulate in fish, compared with 
>0.1 ppb P-CTX-1 (Lewis, 1992). C-CTX-1 is less polar than P-CTX-1 and may have 
a greater propensity to accumulate in fish through greater assimilation and lower
13
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depuration rates (Lewis and Holmes, 1993). The presence of this new family of C-CTXs 
has important implications for the detection of ciguateric fish. Antibody detection based 
on P-CTX-1 or its fragments may not be suitable for detecting C-CTXs (Vemoux and 
Lewis, 1997), although that would depend on the epitope(s) on the toxin(s) recognized 
by the antibody(ies).
Marquais and co-workers (1997) isolated and purified two principal toxins from 
Caribbean Carcmx latus flesh. Both toxins had the same MW (1142 Da), suggesting that 
they are diastereoisomers. They may be closely related to P-CTXs (MW 1112 Da).
MTX likely plays a role in altering CFP symptoms, particularly in the poisoning 
caused by herbivorous fish. It was first isolated from surgeon fish and is a major toxic 
component elaborated by G. toxicus (Tindall et al, 1984; Yasumoto et al., 1979), but 
there is litde probability that it can be accumulated in fish flesh (Holmes et al., 1990; 
Holmes and Lewis, 1994a). MTX has an extremely potent bioactivity (LD50 50 ng/Kg, 
mouse, ip) (Murata et al., 1993). However, the relatively low oral potency of MTX is 
likely to limit its role in human intoxication (Kelly et al., 1986). On basis of 
spectroscopic analysis, a total structure for MTX has been proposed. It is a disulphated 
ester that can be desulphated to form a less toxic compound (Murata et al., 1993). It has 
a composition Ci64H2 5 6 0 6 sS2Na2 with a MW of 3422 Da for the disodium salt and 3299 
Da for the monosodium salt (Yokoyama et al., 1988; Murata et al., 1993). It is 
considered a non-peptidic material which is soluble in water, methanol, and 
dimethylsulfoxide, but practically insoluble in chloroform, acetone, and acetonitrile. Its 
toxicity is not affected by 1 M NH4OH, but is lost after heating in 1 M HC1 and 1 M 
NaOH (Yokoyama et al., 1988).
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New studies found that more than one MTX can be produced and that the type 
depends on the G. toxicus strain. Three strains of cultured G. toxicus (FP-Gambier 
Islands, NQl-Australia, and WC1/1-Australia) yielded 3 distinct MTXs (Holmes et al., 
1990; Holmes and Lewis, 1994a). MTX-1 (LD50 0.05 pg/Kg, ip, mouse; MW 3422 Da 
for the disodium salt) and MTX-2 (LD50 0.08 pg/Kg, ip, mouse; MW 3298 Da for 
monosodium salt and 3313 for monopotassium salt) are large toxins, whereas MTX-3 is 
relatively small (MW 1060 Da for disodium salt) (Holmes and Lewis, 1994a; Lewis et 
al., 1994a), but with a .sim ilar MW to that of GTX-4A and GTX-4B (Murata et al., 
1990; Legrand et al., 1992). This MTX-1 was chromatographically identical to the 
MTX first characterized by Yasumoto et al. from a French Polynesian strain of G. 
toxicus. It remains to be determined how similar the structure of MTX-3 is to the 
structure of GTXs or the large MTXs and whether the biosynthesis of GTXs is linked to 
the production of small MTX in strains of G. toxicus which produce both toxins 
(Holmes and Lewis, 1994a).
Scaritoxin is a lipid-soluble toxin isolated from the muscular tissue of parrot fish 
(Chungue et al., 1977). It manifests symptoms physiologically similar to CTX in mice, 
but is chromatographically different (Hashimoto, 1979). It is likely that it could be a 
CTX or GTX, but its structure has not been characterized yet (Lewis and Holmes, 
1993). It could be a less polar form of CTX.
Okadaic acid (OA) (Figure 8) is a lipid-soluble, polyether carboxylic acid 
(Tachibana et al., 1981; Isobe, 1986) with a molecular formula of C44H68O13 and lethal 
toxicity to mouse (ip) at 200 pg/Kg. It was first isolated from the sponge Halichondria 
okadai and Halichondria melanodocia (Tachibana et al., 1981), and found later in the
15
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benthic dinoflagellates Prorocentrum lima and P. concavum (Dickey et al., 1990) and 
from the temperate dinoflagellate Dmophysis (Lee et al., 1989). It has been reported that 
it could be present in barracuda harvested from the Caribbean and implicated in CFP 
(Gamboa et al., 1992; Park et al., 1993); however, Lewis and Holmes (1993) suggested 
further confirmation and an estimate o f whether the detected levels were sufficient to 






Figure 8.Structure of okadaic acid.
Palytoxin has been found in trigger fish, which has been described as a ciguateric 
species by Halstead (1967). This suggests the possibility that a certain number of 
poisonings assigned to CFP may be attributed to palytoxin (Yasumoto and Murata,
1993). Lewis and Holmes (1993) suggested that palytoxin poisoning should not be 
considered as a part of the CFP syndrome since it is clinically distinguishable from it by 
the manifestation of elevated serum enzyme levels associated with severe poisoning 
episodes. However, it is recognized that mild palytoxin intoxication may be mistaken 
for CFP. Palytoxin was the most complex and largest natural toxin with a molecular 
weight of 2677 Da until the structure o f MTX was elucidated (Yasumoto and Murata,
1993).
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4. Analytical Methods*
Rapid detection of CTX-like compounds has been hampered by the lack of 
standard material due to the low amounts of CTX present in fish. Even in the moray eel, 
which is the most toxic species, CTX content is extremely low, usually only several ppb 
(ng/g) in whole bodies (0.1-5 ppb in fish flesh) (Murata et al., 1990; Lewis, 1992). 
Thus, purification of large quantities of CTX from fish has not been successful.
Production of GTXs from mass cultured dinoflagellates was once thought to be the 
only source of toxins that would have the potential of providing sufficient quantities of 
purified toxins for studies on biosynthesis, structural analysis, pharmacology, 
biotransformation, and detection (Babinchak et al., 1994). However, obtaining large 
quantities of the dinoflagellate CTX congeners has been limited by the ability to identify 
and mass culture a G. toxicus clone capable of producing high levels of these toxins. 
Production of GTXs in cultured G. toxicus appears to be strain-dependent, with most 
clones only producing MTXs (Holmes et al., 1991). No isolate has yet produced 
substantial quantities of GTXs in culture, with reported yields of less than 1 mouse 
unit/million cells (Holmes et al., 1991; Micouin et al., 1992). Chemical characterization 
and toxic potentials of toxic isolates produced by unialgal culturing of P. concavum and 
G. toxicus have been reported (Park et al., 1997). Only relatively low concentrations of 
GTXs have so far been detected from cultured compared with wild G. toxicus cells 
(Holmes and Lewis, 1992). Culturing of approximately 1000 L barely yielded 100 jxg of 
CTX-like compounds (Yasumoto, personal communication). This translates in years o f
* Portions o f this section have been reprinted with permission from Ref. 98-423 by 
courtesy of Marcel Dekker Inc. (See Appendix D).
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work and certainly is not a cost-effective approach. In the mean time, therefore, mass 
culturing will take some years to prove useful.
P-CTX-1 typically contributes approximately 90% of the toxicity of ciguateric 
carnivorous fish in the Pacific and should be considered the primary target of any 
screening program (Legrand et al., 1992; Lewis and Sellin, 1992). The task for scientists 
is to develop a method that can rapidly and selectively screen P-CTX-1 and its 
congeners (Lewis, 1992). Using a two-fold risk factor to ensure that public health is 
protected requires that the screen be capable of reliably detecting CTX-1 in fish flesh at
0.05 ppb (50 ppt) and above (Lewis, 1994).
CFP toxins are odorless and tasteless, and cannot be detected by any simple 
chemical test Thus, bioassays have been used traditionally to monitor suspicious toxic 
fish. Unfortunately, these bioassays have disadvantages such as low sensitivity, 
relatively large amounts of samples required for analysis, lack of specificity to 
distinguish toxins, and prolonged times required for analysis (Park, 1994a).
A major area of concern was the development of simple assay methods for the 
detection of CTX, especially for use in mass screening of fish from endemic areas 
(Hokama, 1985). Of particular importance was the search for an animal whose route of 
exposure was oral, so that it could reflect the mechanism of human intoxication. Of the 
37 species of animals tested for use in bioassays, only the cat, mongoose, mouse, turtle, 
and crayfish appeared to respond noticeably to oral administration of toxic fish flesh 
(Banner, 1976).
Mice are easily housed, can be readily dosed in several ways and manifest diverse 
symptoms, some of which are similar to human symptoms. Mice between 16 and 24 g
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are used and exposed ip to the toxins or suspect toxic samples emulsified in Tween. 
Toxicity is expressed in mouse units (MU), each MU being the ip LD50 dose needed to 
kill a 20 g mouse in 24 hrs (Hoffman et al., 1983; Lewis and Sellin, 1992).
An immunological approach to examine CTXs was initiated in 1977 with the 
development of a modified radioimmunoassay (RIA) employing sheep anti-CTX 
antibody (Hokama et al., 1977; Kimura et al., 1982). The antibody was prepared using 
highly purified CTX (isolated from toxic moray eel) conjugated to human serum 
albumin, which was later coupled to l25I as a label.
In 1982, Kimura et al. evaluated the above mentioned RIA method in its ability to 
distinguish toxic from non-toxic fish tissues. However, some false positives were 
reported and have subsequently been attributed to the presence of other marine toxins 
with similar structural properties to CTX (Hokama et al., 1977; Hokama, 1988; 
Yasumoto, 1989). Though proven to be effective for screening, the RIA procedure was 
economically impractical for testing fish weighing less than 9 Kg (Kimura et al., 1982).
An enzyme immunoassay (EIA) using the same sheep anti-CTX antibody was 
initiated in 1983 (Hokama et al., 1983; Hokama et al., 1984) to avoid the costly and 
tedious RIA procedure. The antibody was coupled to horseradish peroxidase (HRPO) 
instead o f 125I (Hokama et al., 1983). The method included the preparation of small 
sample disks (3 mm thickness x 3 mm diameter) placed in a well of a 96-well microtiter 
plate, labeled with anti-CTX-HRPO conjugate, and quantified with 4-chloro-1 -naphthol 
(Hokama et al, 1983). The colorimetric determination of absorbance following the 
enzymatic reaction gave values that could be compared to test-control ratios (Hokama, 
1993b). The major contribution of this procedure was the determination of the cross-
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reactivity of similar marine toxins structurally characterized as polyethers (Hokama et 
al., 1984; Tachibana et al., 1987; Yasumoto, 1987; Murata et aL, 1989). The cross­
reactivity between CTX and polyethers, such as OA, brevetoxin, MTX and monensin 
(Hokama et al., 1984), with sheep anti-CTX suggested a need for the development of 
monoclonal antibodies of increased specificity to purified CTX (Hokama et al., 1984; 
Hokama etal., 1989a) and okadaic acid (Hokama et a l, 1985).
A simplified stick enzyme immunoassay (S-EIA) was initiated (Hokama et al., 
1985; Hokama, 1985; Hokama et al., 1987; Hokama et al., 1989a) using correction 
fluid-coated skewer bamboo sticks (Hokama, 1993b). This assay used the same 
polyclonal sheep anti-CTX-HRPO as the EIA procedure (Hokama, 1993a). Fish samples 
were poked with the end of the skewer coated with the Liquid Paper. Then, the skewer 
was immersed in the fixing solution (Me0H-H202) and later in the anti-CTX-HRPO. 
The substrate (4-chloro-1 -naphthol with H2O2) was added and the intensity of the color 
was measured (Hokama, 1985; Hokama, 1993b).
Because of reported false positives results experienced in the above mentioned 
methods, which utilized the same polyclonal sheep anti-CTX antibody preparation, 
Hokama et al. (1985) developed what was reported to be a monoclonal anti-CTX 
antibody. Researchers designated the monoclonal antibody (MAb) from the hybridoma 
as MAb-CTX (5C8). The S-EIA remained the same as the original format, except that 
the HRPO was now conjugated to the MAb-CTX (Hokama et al., 1989b). The authors 
reported more specificity (less cross-reactivity) and lower background color in assessing 
toxicity values in toxic samples. This new modified method incorporated the speed and 
practicality of the stick test to the increased specificity of MAbs.
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In 1990, Hokama adopted the particulate solid-phase immunobead assay (S-PIA) 
approach, known as the "paddle test", in dealing with the detection of CTX and related 
polyethers. In this case, the antigen-antibody complex was evaluated through the ability 
of colored latex beads, to which the monoclonal antibody anti-CTX was bound, to 
recognize toxins attached to liquid-coated bamboo paddles previously exposed to toxic 
fish. When compared to the stick method (Hokama, 1985) in evaluating 26 documented 
toxic samples a 100% agreement was found, but the S-PIA was shown to be more 
sensitive than the S-EIA. The results suggested the applicability of the S-PIA for field 
use (Hokama, 1990).
Following purchase of patents rights to the "paddle test”, HawaiiChemtect 
International developed a commercial kit in which the original format was modified to 
an innovative rapid S-PIA (Ciguatect™) for the detection of toxins associated with 
ciguatera and diarrheic shellfish poisoning with application to screening programs (Park 
and Goldsmith, 1991; Park et al., 1993). The bamboo paddle device was substituted by 
a plastic strip with a membrane attached on one end. The presence or absence of the 
toxins was determined by binding the toxins to the membrane and exposing the toxin 
ladened membrane to a monoclonal antibody-colored latex bead complex. The intensity 
of the color denoted the presence o f the toxins. The sample strip was compared with 
control strips. Since CTX was not available in sufficient quantity to serve as a standard 
for the test kit, OA was used and OA equivalents were determined. The level of 
detection was 1 ng OA equivalents to 1 ng CTX on the test strip (Park, 1993; Park, 
1994a). The S-PIA can be used at the harvesting, receiving docks, processing plants, 
distribution organizations, retail outlets, and regulatory agencies (Park, 1993). The
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Ciguatect™ kit is a qualitative method and it can be used for a pass/fail response 
depending on the level of sensitivity desired. One advantage of this method is that the 
kit can be used for non-laboratory use by untrained personnel (Park, 1993).
The early studies all employed polyclonal antibodies. Monoclonal antibodies can 
provide a continuous supply of a selected antibody. The CTXs are relatively small 
haptens that are likely to have only low immunogenicity. CTXs posses a reactive 
primary hydroxyl group which can be reacted with succinic anhydride to yield a 
hemisuccinate. The latter has an available carboxyl group through which CTX can now 
be linked to a carrier protein using water soluble carbodiimide cross-linking reagent. 
This complex is expected to have considerably enhanced immunogenicity compared 
with native CTX. However, the presence of just one reactive group in the molecule 
limits the possibilities for producing a range of antibodies possessing different 
selectivities for the various CTX analogue. Attempts to produce a hemisuccinate of 
CTX-1 have met with little success (Lewis, 1994). Ideally the chosen antibodies should 
have an affinity that is directly proportional to the oral potency to humans to 
contaminating toxins and should not cross-react with compounds normally present in 
non-toxic fish.
Pure P-CTX-1 can be detected to levels below 5 ng by monitoring HPLC eluants 
with a sensitive UV detector. However, CTXs do not posses a distinctive UV 
chromophore, hampering the development of a method to selectively detect CTX in 
crude lipid extracts from fish. The primary hydroxyl group on P-CTX-1 could be used to 
attach labels to enhance detectability. However, other numerous compounds in lipid 
extracts from fish might also react with such a label; detection of labeled CTXs must be
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done in combination with subsequent separation techniques (Lewis, 1994). HPLC 
coupled to fluorescence detection provides a high sensitivity method that has the 
potential to detect natural levels of CTXs in crude extracts from fish flesh. Dickey et al. 
(1992) reported promising results by labeling CTX with novel coumarin based 
fluorescent reagents. Although sensitive detection (1 ng P-CTX-1/injection) of 
anthroylnitrile labeled CTX has been reported (Legrand et al., 1990; Legrand, 1991; 
Legrand et al., 1992), these approaches have not been extended through detection of 
CTXs in crude extracts from fish. HPLC linked to a fluorescence detector has been able 
to detect in relatively crude extracts > 40 ng DSP toxins/g shellfish, including OA (Lee 
et al., 1987), and >13 ng aflatoxin/g peanut butter or com (Park et a l, 1990). These 
approaches would require modification and significant improvements in sensitivity if 
the CTXs in crude extracts from fish are to be detected. A simple clean-up procedure 
that minimizes interference from lipids at both the labeling and detection steps is critical 
for the development of a sensitive test for CTXs. HPLC coupled to selective-ion 
monitoring ionspray mass spectrometry has shown considerable potential for the 
detection of labeled DSP toxins (Pleasance et a l, 1992). Initial studies with P-CTX-1 
indicate that such an approach could form the basis of a confirmatory analytical assay 
for CTXs in fish (Lewis et a l, 1993b). If sufficient unknown toxin is available (>25 ng), 
NMR approaches can be utilized for confirmation or for characterization of unknown 
toxins (Lewis, 1994).
New methods for the detection of P-CTXs include reverse-phase HPLC/MS and 
HPLC/MS/MS. The former was able to identify P-CTX-1 and its congeners in highly 
purified extracts from ciguateric moray eel viscera (Lewis et al., 1997). Fourteen
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congeners were identified, two with a MW of 1095.7 Da, six with a MW of 1111.6 Da, 
and six with a MW of 1127.7 Da. Eleven of these congeners were not readily detected 
by mouse bioassay. Sensitivity was further improved using HPLC/MS/MS techniques. 
Purified fish extracts were spiked with pure P-CTX-1 and C-CTX-1 and quantified by 
multiple reactant ion monitoring relative to a brevetoxin internal standard. This method 
was able to detect CTX at levels below 0.1 ppb, which is the level that can cause CFP.
Cell culture techniques offer the potential for sensitive bioassays eliminating many 
of the objectionable aspects associated with animal testing. Kogure et al. (1988) 
developed a sensitive cell-based assay for the detection of sodium channel blocking 
toxins based on the ability of the toxins to antagonize the effects of veratridine and 
ouabain on Neuro-2a cells. The original method was simplified by incorporating a 
colorimetric method based on the ability of metabolically active cells to reduce 3-[4,5- 
dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium (MTT) to a blue-colored formazan 
product (Mosmann, 1983; Jellet et al., 1992).This assay was further modified to be able 
to detect sodium enhanced ouabain/veratridine-dependent cytotoxicity. The detection 
limit of this assay is about HT4 MU, or approximately 1 pg P-CTX-1. This cell assay is 
orders of magnitude more sensitive than the mouse bioassay; however, it cannot be 
applied in the field, takes at least one day to give results, and needs special 
instrumentation and trained personnel (Manger et a l, 1993; Manger et al., 1995a, 
1995b). It could, however, be an excellent confirmatory assay for suspect samples.
5. Symptomatology
The highly potent toxins produce painful and peculiar symptoms in humans 
(Halstead, 1964). Despite more than 175 ciguateric symptoms have been reported (Sims,
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1987), they can be classified primarily in four categories: gastrointestinal, neurological, 
cardiovascular, and general symptoms. This multiphase intoxication is thought to be due 
to the presence of different ciguatera-related toxins and different ratios (Lewis and 
Sellin, 1992). The duration, severity, order, and even occurrence of these symptoms may 
vary considerably. The onset of symptoms may begin before the meal is finished but 
more often begins within the first 12 hrs (90% of the cases) (Gillespie et al., 1986) or 
within 1-6 hrs (Ruff and Lewis, 1994).
Gastrointestinal symptoms are often the first to appear with abdominal pain, nausea, 
painful defecation, diarrhea, and vomiting (Halstead, 1967; Withers, 1982; Gillespie et 
al, 1986; Gopalakrishnakone and Tan, 1987). These symptoms usually last only one or 
two days.
Neurological symptoms are usually the most bothersome and lingering complaints 
(Bagnis et al, 1979a; Gopalakrishnakone and Tan, 1987). Paresthesia, described as 
uncomfortable tingling sensations, most often develop in the extremities, oral cavity, 
and pharynx. This symptom is considered to differentiate CFP from other forms of non­
seafood poisoning or mild gastroenteritis. Temperature reversal is common. Ataxia and 
paresis most commonly manifest in the legs and less frequently in the extraocular 
muscles (Gopalakrishnakone and Tan, 1987). These symptoms, though occasionally 
lasting longer, usually decrease after one week (Withers, 1982). Not infrequently, the 
symptoms may return during periods of stress, consumption of alcoholic beverages, 
illness or malnutrition (Ho et al., 1986; Johnson and Jong, 1983).
Cardiovascular effects are also associated with CFP. They often start and disappear 
within 2 to 5 days (Gopalakrishnakone and Tan, 1987). Extra systoles may result
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indirectly by noradrenergic stimulation of myocardium as a result of CTX effects on 
neural channels (Lewis, 1988). Bradycardia and hypotension are characteristic of CFP 
(Hokama, 1988).
Other more general symptoms can persist for weeks or months in severe cases in 
which the disease can produce long-term disability. Some of these symptoms are loss of 
energy, arthralgia (especially of the knees, ankles, elbows, and shoulders), myalgia, 
headache, and pruritus (Gillespie et al., 1986).
Epidemiological studies suggest that the toxins involved in the Caribbean might 
differ from Pacific CTXs, since gastrointestinal signs are more prominent and 
neurological symptoms less prominent than the incidence typically reported in the 
Pacific (Lewis et al., 1988). Studies to date indicate that CFP in the Caribbean is 
caused by lipid-soluble polyether toxin(s) similar but probably not identical to the CTXs 
isolated from the Pacific. The instability of C-CTXs but not P-CTXs in basic conditions 
supports the contention that somewhat different toxins may be involved in the two 
regions (Vemoux etal., 1982; Vemoux and Andaloussi, 1986).
Although mortality from CFP is low, morbidity is high and symptoms may be 
debilitating and prolonged. Death rate as high as 5% has been reported, but the true 
mortality is probably much lower, perhaps on the order of 0.1% of poisonings (Bagnis et 
al., 1979a). Many of those who died ate viscera, liver or gonads, which are known to 
contain much higher levels of toxin (Gudger, 1930; Bagnis, 1970; Bagnis et al., 1979a). 
For the rare fatal cases, death apparently results from respiratory paralysis.
An initial intoxication does not confer immunity. In fact, reports of sensitization to 
the toxins are common. Repetition of multiple attacks of CFP results in a clinically
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more severe illness and more rapid onset of symptoms compared to that of patients 
experiencing the disease for the first time (Banner, 1976; Bagnis et al., 1979a; Narayan, 
1980; Ho et a l,1986).
Most people in high risk areas do not seek help for CFP. Hence, they are not 
included in any compiled statistics (Doorenbos, 1984). However, the incidence has 
probably increased due to better detection methods, diagnostic, and data recollection. 
The statistical risk of getting CFP depends on the fish species, size of fish, habitat of 
fish, harvest time, and portion ingested (Peam and Lewis, 1994)
6. Mode of Action
The action of CTXs is to open voltage-dependent sodium channels in the cell 
membrane (Rayner, 1972). The widespread distribution of sodium channels in nerve and 
muscle tissues can explain the variety of effects that are caused by CTXs in humans.
It was doubtful whether the sites of interaction for P-CTX-1 and brevetoxins 
(PbTxs) were the same (Bidard et al., 1984; Poli et al., 1985); however, in 1987, 
Lombet et al. showed that P-CTX-1, PbTx-1, PbTx-2, PbTx-3, PbTx-5, PbTx-6, PbTx- 
8, and PbTx-9 bind to a specific receptor known as site 5 (Gawley et a l, 1995). The 
affinity of P-CTX-1 for the sodium channel is at least 20-50 times higher than that of 
PbTxs. This affinity might be explained by the higher flexibility of P-CTX-1, thus 
making more favorable the interaction of binding and activity centers located on distal 
ends of the toxin. P-CTX-1 has 38 rotatable bonds versus 16 and 31 for PbTx-2 and 
PbTx-1, respectively (Baden et al., 1990; Rein et al., 1994a). Much of the information 
obtained for CTXs has been deduced from studies using PbTxs. The interaction of the 
sodium channel and site 5 toxins will be described thoroughly in the NSP section.
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7. Treatment
Diagnosis o f CFP is based on clinical symptoms, and it is sometimes supplemented 
by the bioassay o f the fish involved (Gillespie et al., 1986; Calvert, 1991). In 1988, 
intravenous mannitol was reported as a successful treatment for patients exhibiting 
acute CFP when given lg/Kg during the acute phase that lasts from 1 to approximately 
5 days. All neurologic symptoms were resolved completely, usually within 48 hours, 
although improvements were noticed within minutes. Gastrointestinal symptoms 
disappeared more slowly. However, effects of oral or ip CTX in mice provided no 
detectable benefit in signs of intoxication or time to death in in vivo experiments. The 
absence of therapeutic effects of mannitol in animal models for CFP studied to date may 
stem from species differences. Further studies should be done with a better animal 
model for CFP in humans (Lewis et al., 1993a). Until a scientifically controlled study is 
done, it is necessary to have caution in recommending any new therapy. The mechanism 
by which mannitol relieves symptoms is uncertain. It has been proposed that it might 
inhibit CTX by competition at the cellular membrane level, render the toxins inert, 
inhibit the movement of sodium through the channels opened by CTX, dissociate CTX 
from its binding site, scavenge the hydroxyl radicals in the CTX molecule, or act as an 
osmotic agent that releases water form the axon (Schwann cells) (Peam et al., 1989). It 
has been found that CTX and mannitol do not interact, leaving the osmotic theory as the 
most probable (Palafox et al., 1988; Peam et al., 1989; Ruff and Lewis, 1994).
Park (1994b) demonstrated the utility of using the Ciguatect™ test kit to monitor 
for CTX in fish harvesting areas by testing for non-mobile marine grazers. Using this 
system, ciguatoxic and non-ciguatoxic harvesting areas were identified around Hawaii.
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8. Prevention
Prevention is by far the best strategy; however the complexity of CFP makes this 
approach difficult. As the fish do not show any change in the presence of the toxins, 
there is no practical means for the consumer to determine whether the fish is toxic or 
not Moreover, none of the common methods of preparing the fish for human 
consumption inactivate or neutralize the toxins (Banner, 1965; Juranovic and Park, 
1991).
CFP can be a threat to both hotel and restaurant business and to the tourist trade in 
general. The results of intoxication may include loss of commerce for individual 
establishments and potentially for a particular location if the problem is severe enough 
(Dalzell, 1994). Local fish are avoided as a food source; for instance, sale of large 
barracuda has been banned in Florida, ambeijack and barracuda in Puerto Rico, and 
ambeijack in Hawaii (Lawrence et al., 1980). Fear of CFP has lead to decrease of local 
and exporting fishing industries and of tourism, and indirectly on human health due to 
avoidance of fresh fish consumption (despite its nutritional value) (Lewis, 1986). It is 
important to develop programs to provide some degree of assurance that seafood is free 
of contamination. It is necessary to have a screening program for identification of 
contaminated product and to separate the adulterated product to prevent cross- 
contamination.
Various strategies have been employed to decrease the risk of getting CFP, 
including a general avoidance of highly suspect species; disposal of the internal organs, 
particularly the liver; avoidance of abnormally large carnivorous fish (Juranovic and 
Park, 1991); harvesting far away from coral reefs; closure of highly toxic areas;
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detection of toxic fish prior to consumption; banning the sale of toxic species; and, 
monitoring of associated dinoflagellates (Ruff and Lewis, 1994).
9. Regulations
Yasumoto and co-workers (1984) have proposed that ingestion o f as little as 100 ng 
CTX is sufficient to be a health risk for an adult. With 0.6 ng CTX/Kg body weight, it 
is enough to observe evidence of pathological symptoms (Bagnis et al., 1987). Lewis 
and Holmes (1993) found that levels higher than 10‘10g P-CTX-l/g fish might cause 
human poisoning. Yasumoto has recommended a level of 10 MU for regulatory 
monitoring programs (equivalent to 0.35 ng P-CTX-l/g fish tissue) (Park, 1994a). Most 
cases of CFP involve consumption of the flesh of ciguateric fish that contain the 
equivalent of 0.1-5 ng P-CTX-l/g fish flesh (Lewis, 1992; Lewis and Sellin, 1992; 
Lewis et al., 1994a).
B) NEUROTOXIC SHELLFISH POISONING
1. Occurrence
Neurotoxic shellfish poisoning (NSP) is a syndrome caused by consumption of 
shellfish contaminated with brevetoxins (PbTxs). NSP toxic compounds have been 
isolated exclusively from Ptyckodiscus brevis (formerly Gymnodiniian breve) (Risk et 
al., 1979b; Steidinger, 1979; Ahmed, 1991; Ledoux and Fremy, 1994).
This organism is responsible for toxic red tides along the Gulf of Mexico coast of 
Florida and Texas (Risk et al., 1979b; Trainer et al., 1990), which are initiated in 
offshore waters, primarily in the late summer and autumn months (Risk et al., 1979b; 
Ahmed, 1991; Ledoux and Fremy, 1994). Unexpectedly, in early 1993 more than 180 
human shellfish poisonings were reported from New Zealand, caused by an organism
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similar but not identical to P. brevis (Hallegraeff, 1995). On the basis of antibody cross­
reactivity and specific receptor binding inhibition studies, the toxins associated with this 
outbreak were thought to be PbTx-Iike compounds (Poli et al., 1995).
PbTxs are responsible for massive fish kills (Baden, 1983) and accumulate in 
bivalves during bloom conditions (McFarren et al., 1965). The shellfish involved with 
NSP are basically clams, but the toxins can be found in other bivalves (Ledoux and 
Fremy, 1994). Two recent episodes of illness and death in West Indian manatees 
(O'Shea et al., 1991) and bottlenose dolphins (Geraci, 1989) suggest the possibility that 
PbTxs can accumulate to levels in prey species that may harm or kill marine mammals 
(Cattet and Geraci, 1993).
2. Source of Toxins
The marine dinoflagellate P. brevis was first incriminated as the causative 
organism in the extensive fish and other fauna lethalities in 1947 by Davis (1947). In 
the 1960s, the acute and chronic toxicology of the dinoflagellate and its extracts was 
described (Davis, 1947; McFarren et al., 1965; Abbott and Paster, 1970); and in the 
1970s, crude extracts were fractionated into distinct toxic fractions (Martin and 
Chatterjee, 1969; Risk et al., 1979a).
3. Properties of Toxins
Brevetoxins are a group of 10 phycotoxins composed of 2 skeletons of polycyclic 
polyethers o f42-47 carbon atoms: (1) Brevetoxins type A or 1: PbTx-1, PbTx-7, PbTx- 
10 and (2) Brevetoxins type B or 2: PbTx-2, PbTx-3, PbTx-4, PbTx-5, PbTx-6, PbTx-8, 
PbTx-9. Both types are lipid-soluble (Baden, 1989; Poli and Hewetson, 1992; Ledoux 
and Fremy, 1994) (Figure 9).
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Brevetoxins - Type 2(B)




PbTx-5 COCH3 CH2C(=CH2)CHO (K ring acetate)




Figure 9.Structure of brevetoxins.
PbTxs, devoid of nitrogen, are condensed from a single hydrocarbon chain to form 
complex multiring methylated polyether neurotoxins, and contain lactone functionalities 
in ring A that are essential for activity (Baden, 1989).
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PbTxs in either aqueous (Ray and Wilson, 1957; Starr, 1958; Spikes et al., 1968) or 
organic solvent solutions (Sasner et al., 1972; Trieff et al., 1975; Baden and Mende, 
1982; Poli et al., 1990a) remain potent for months. In the dry state, PbTx-2 and PbTx-3 
are stable to 300°C (Poli et al., 1990a). The type A toxins are more unstable than the 
type B toxins. Decomposition of either type of PbTx is accelerated in aqueous solution 
below pH 2 and above pH 10 (Martin and Chatteijee, 1969; Poli et al., 1990a). Aqueous 
0.1 N NaOH degrades PbTxs in minutes by saponification of the lactone ring A (Poli et 
al., 1990a; Baden et al., 1984a); ozonolysis degrades by addition and cleavage at double 
bonds (Baden, 1983); and, aqueous chlorine degrades PbTxs, presumably by oxidation 
(Poli et al., 1990a).
PbTxs and CTXs possess physical similarities such as UV spectra maxima at 208- 
213 nm, the presence of multiple alcohol and ether functional groups, similar molecular 
weights, and lipid-solvent solubilities (Baden, 1989).
PbTx-1 (MW is 867.08 Da; LDso 0.17 mg/Kg, ip, mouse) is the most potent 
ichtyotoxin among the toxins produced by P. brevis (Baden and Mende, 1982). In mice, 
PbTx-1 is more potent by iv administration than by ip injection, implying that this agent 
is partially detoxified or excreted in the bile during the first passage through the liver 
(Baden and Mende, 1982).
PbTx-2 has an LD50 in mouse (ip) of 0.2 mg/Kg and a MW of 895.09 Da (Baden 
and Mende, 1982). It is soluble in acetone, chloroform, ethyl acetate, methanol, ethanol, 
and in water only at or below 0.1 mg/mL at 37°C (Baden et al., 1981). Derivatization 
that destroys the hydrophobic character of the PbTxs, such as oxidation of the aldehyde 
to the carboxylic acid, reduces in vivo potency to nontoxic levels (Poli et al., 1986).
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From 80 Kg of shellfish, 5.4 mg of a new lipid-soluble PbTx derivative, named 
PbTx-Bl, was isolated (Ishida et al., 1995). It is a colorless amorphous solid with a MW 
of 1040.46 Da. The structures of PbTx-2 and PbTx-Bl differ only in the functional 
group of the K ring side chain. Its LD50 (ip) in mouse is 0.05 mg/Kg.
From 30 kg of toxic mussel hepatopancreas, 1.2 mg of a new PbTx-B (PbTx-2) 
analogue were isolated. It was named PbTx-B3. The terminal aldehyde is oxidized to a 
carboxylic acid, the oxepane D ring is cleaved to a keto-alcohol, and the resulting 
alcohol is esterified. PbTx-B3 did not kill mice by ip injection at a dose o f300 pg/Kg. It 
was then hypothesized that mussels may detoxify PbTx-2 to PbTx-B3, as the latter has 
never been detected in dinoflagellates. As PbTx-B3 shares the same partial structure of 
PbTx-2, but lacks the lethality of PbTx-2, it may pose serious problems in 
immunoassays and perhaps in competitive binding assays. A method that reflects 
biological activity rather than chemical features would solve this problem (Morohashi et 
al., 1995). The total synthesis of PbTx-2 has been accomplished by Nicolaou et al. 
(1995a, 1995b).
4. Analytical Methods
A principal difficulty in establishing the presence of PbTxs, and in quantifying the 
amounts present, has been the lack of an analytical procedure possessing sufficient 
sensitivity. The PbTxs can be readily detected in seawater and in shellfish using the 
standard mouse bioassay, high performance liquid chromatography, radioimmunoassay 
(RIA), and enzyme-linked immunosorbent assay (ELISA), each possessing distinct 
advantages and disadvantages (Trainer and Baden, 1991). Excellent separations of 
PbTxs are achieved by silica gel TLC; the sensitivity (>1 ppm) remains a problem (Poli
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et al., 1990a). A reverse phase liquid chromatography method provides for the 
separation of all PbTxs, with detection limits of about 5 pg (Trainer and Baden, 1991; 
Ledoux and Fremy, 1994).
A goat polyclonal antiserum was raised against PbTx-3-BSA. This antiserum was 
used to develop an RIA. The minimum detection limits for PbTx-2, -3, and -9 were 
approximately 300 pg. Cross-reactivity with PbTx-1 occurred at 100 fold higher 
concentrations. This assay was equally effective in assaying crude shellfish extracts and 
human urine. The successful development of a RIA for PbTx detection in shellfish 
extracts was an important advance in the monitoring of seafood stocks (Poli and 
Hewetson, 1992). It has a sensitivity of 2 nM or 600 pg (Baden et al., 1984a; Trainer 
and Baden, 1991), which has been further improved to 1 nM or 300 pg by Poli et al. 
(1990b). However, this assay is not readily used under field conditions, due to the 
requirement for radioisotopes and expensive equipment for evaluation of results.
An ELISA to detect PbTxs using polyclonal antibodies was developed by Baden 
and co-workers (Trainer and Baden, 1991; Baden et al., 1995) with a sensitivity of 0.04 
pM. This assay could be applied to the detection of PbTxs in dinoflagellate cells and 
seawater, and progress is being made with respect to detection in biological matrixes 
(Trainer and Baden, 1991; Baden et a l, 1995).
Using PbTx-2, PbTx-3, PbTx- 6  and 6  synthetic derivatives, epitopes on polyclonal 
antibodies raised on rabbits and goats using PbTx-2-BSA and PbTx-3-BSA, 
respectively, were located on rings H and A, respectively. This could have implications 
in using these antibodies which may not adequately detect toxin metabolites if 
molecules are altered in fish. This problem may be overcome by developing assays that
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incorporate two or more different specific antibodies. The K ring was not an epitope, 
which was somehow expected since C-42 was the site of conjugation to the carrier 
protein. Both antibodies cross-reacted with PbTx-2, PbTx-3, and PbTx-9, all type B 
toxins (Poli et al., 1995).
Two PbTx-3-KLH goat antisera were obtained by a different group with specificity 
towards 3 epitopes: the A ring lactone region of the molecule, the H ring, and the K ring 
(Melinek et al., 1994). Antibodies produced in goats using PbTx-3-BSA have also been 
reported (Baden et al., 1984b) as well as rabbit antibodies with different binding 
properties from those expressed by goats (Levine and Shimizu, 1992).
Binding assays have been developed taking advantage of the affinity and 
competition of 3[H]-PbTx-3 and PbTxs to rat brain synaptosomes with voltage-sensitive 
sodium channels. Bound 3 [H]-PbTx-3 is determined in the pellet using a rapid 
centrifugation technique, and the radioactivity is estimated using liquid scintillation 
techniques. Free 3 [H]-PbTx-3 may be determined by counting directly an aliquot of the 
supernatant prior to aspiration (Baden et al., 1988).
Since a major consequence of Florida's red tides is fish kills, ichthyotoxicity assays 
are useful in extrapolation to toxic episodes in the marine environment (Baden and 
Mende, 1982). A fish bioassay using Gambitsia affinis has been used, putting each fish 
into contact with dilutions of toxins or suspect samples in minimal ethanol solution, and 
the LCso is assessed after 24 hrs (Baden et al., 1988; Baden et al., 1994).
5. Symptomatology
Symptoms in humans include tingling and numbness of the lips, tongue, throat and 
perioral area, muscular aches, gastrointestinal upset, and dizziness (Ahmed, 1991). An
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unusual feature of P. brevis is the formation by wave action of toxic aerosols which can 
lead to respiratory asthma-like symptoms, burning of the conjunctivae, and induction of 
non-productive coughing and sneezing (Baden et al., 1984b). No deaths have been 
reported from this relatively mild form of poisoning (Watters, 1995), but the debilitating 
effects are substantial (Steidinger, 1983).
PbTxs are potent ichthyotoxins. The signs and symptoms in fish include violent 
twisting and corkscrew swimming, defecation and regurgitation, pectoral fin paralysis, 
caudal fin curvature, loss of equilibrium, vasodilatation, and convulsions, culminating 
in death due to respiratory failure (Baden, 1989).
6. Mode of Action
The PbTxs induce a long-lasting excitation of the sodium channel. The action site 
is the same as that of CTXs (Ledoux and Fremy, 1994). Catterall and Gainer (1985) 
demonstrated that PbTxs do not interfere with binding of sodium channel-specific 
neurotoxins which bind at sites 1,2,3, or 4.
The sodium channel isolated from rat brain consists of 3 separate and different 
protein subunits: a , (31, and 02 in a 1:1:1 ratio. Each a  subunit consists of 4 
homologous domains (I to IV), each one composed of six transmembrane peptide 
sequences (S1-S6), with the S4 sequence being the most charged (Figure 10) (Catterall, 
1992).
The PbTx-2 molecule tail HUK ring system (or GHIJ ring system of PbTx-1) (side 
chains included) is thought to interact with the S5-S6 extracellular loop of Domain IV, 
providing the orientation to permit insertion of the lactone portion o f the toxin (head) 
into the cytoplasmic side of the channel, essentially crossing the membrane and reaching
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the inactivation loop (IFM particle between IIIs6-IVsi), or another hydrogen bond donor 
such as a serine hydroxyl, resulting in channel opening at normal resting potential with 
subsequent inhibition of inactivation (the head of the toxins physically obstructs the 
normal motion of the IFM particle). This explains why modification of the lactone 
functionality in ring A to an open diol destroys binding activity, toxicity, and single 
channel activity (Baden et al., 1994; Rein et al., 1994a; Rein et al., 1994b; Gawley et 
al., 1995). The remainder of the molecule in between the tail and the lactone group may 
act merely as a spacer of limited mobility (Baden et al., 1995) (Figures 11 and 12).
PbTx-1, PbTx-2, and P-CTX-1 have in common several characteristics: trans/syn 
stereochemistry along the structure; oxygen atoms alternating between the top and 
bottom forming a bridge between rings (5- to 9-membered); regions of rigid, semirigid, 
and flexible character; PbTxs have a lactone group in one end and an enone function on 
the other, whereas P-CTX-1 has a vicinal allylic diol which may be oxidized in situ 
probably by cytochrome P450 to an enone and the spirocyclic acetal on the other end 
may be opened to form a dihydroxyketone or a hemiacetal. This suggests the presence 
of electrophilic groups on either end of the toxins. These common features can explain 
why the 3 toxins bind to the same site at the sodium channel (Baden et al., 1990; 
Gawley et al., 1995).
The PbTxs are flexible, with the A backbone being much more flexible than the 
brevetoxin B backbone, due to the presence of the 4 (D-G) medium-sized rings (Baden 
et al., 1998). Detailed comparison of PbTx-1 and PbTx-2 backbones revealed still more 
similarities, such as the presence of bent and straight conformations and their 
approximate length from end to end (25-27 A) (Baden et al., 1994; Rein et al., 1994a).
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IS1-S6 IIS1-S6 m S l- S 6  IVS1-S6
S5 -  S6 hydrophobic loop
SI - S3 
neutral
IFM particle
S 5 -S 6
hydrophobic
The a  subunit is composed o f  domains I-IV with six transmembrane a  helices (S1-S6). 
Phosphorylation sites are illustrated by ’p’ in circles; the inactivation particle by the Ti' in 
the circle; a critical phosphorylation site by the diamond with the ’p’ in it.
Adapted from Catterall, 1992, with permission.
Figure lO.Functional map of the a  subunit of the voltage-gated sodium channel.
Domain in
Domain IV Domain II
Domain I
The tail of brevetoxin is near the IVS5-S6 loop. 
Adapted from Taylor, 1994, with permission.
Figure 11.Three-dimensional structure of the voltage-gated sodium channel.
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Domain III
IFM particle
Position of IFM particle, 
'inactivated'
The tail o f brevetoxin is near the IVS5-S6 loop and the 
head near the IFM particle.
Adapted from Taylor, 1994, with permission.
Figure 12.Hypothetical model of the binding of brevetoxins to site 5 of the voltage-
gated sodium channel.
The G ring of PbTx-1 and the H ring of PbTx-2 exhibit a preference for the boat- 
chair conformation, which is apparently necessary for binding and which provides for an 
overall straight conformation (Baden et al., 1996). Because the GHIJ rings of PbTx-1 
and the HUK rings of PbTx-2 (including the side chains) have the same carbon skeleton, 
differing only in a double bond and the location of two angular methyl groups, and 
because the side chains of both toxins are structurally similar, it is assumed that these 
portions of the toxins occupy the same region of the binding site (Rein et al., 1994a; 
Baden et al., 1996). The A ring lactones are also similar in the two toxins. It is then 
presumed that the heads and tails for the two types occupy the same regions of the 
receptor when they are bound (Baden et al., 1996).
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7. Treatment
The ability to detect the toxins in human urine suggests potential for the diagnosis 
of NSP and for the monitoring of human exposure. A polyclonal antiserum against the 
PbTx polyether backbone protected rats against the toxic effects of PbTxs when it was 
administered prophytactically (Poli and Hewetson, 1992).
8. Pharmacokinetics
It is necessary to identify the organ systems likely to be targeted by the toxins. 
Previous studies by Poli et al (1990b) determined how PbTx-3 distributes, concentrates, 
and eliminates after iv administration of 3[H]-PbTx-3 to rats. 3[H]-PbTx-3 was rapidly 
cleared from the blood and distributed into skeletal muscle, liver, and intestinal tract. 
Elimination occurred mainly by fecal route. TLC confirmed the presence of PbTx-3 
metabolites in fecal extracts. It seems that the skeletal muscle is a storage compartment 
for the toxins rather than a site of metabolism, from which it is slowly released prior to 
clearance by the liver. They found that the liver concentrated PbTx-3 given 
intravenously, suggesting that the liver received PbTx-3 from hepatic circulation. Ninety 
one percent of PbTx-3 administered intravenously was eliminated in 6  days (Poli et al., 
1990b).
In a new study where the toxin was administrated orally at sub-lethal dosages (18.6 
pg/Kg) to rats, it was found that PbTx-3 was distributed widely in the body, but 
concentrated primarily in the liver as a natural consequence of the toxin having been 
carried there as a first pass through the portal circulation from the intestine (Cattet and 
Geraci, 1993). It was eliminated in equivalent quantities through the urine and feces, the 
former believed to be the primary elimination route when PbTx-3 is absorbed through
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the gastrointestinal tract Seventy eight percent of ingested toxin was eliminated in 6  
days (Cattet and Geraci, 1993). This is the route by which a marine mammal would 
become exposed to the toxins.
In a separate experiment, l4 [C]-PbTx-3 was given orally to fish. Radioactivity was 
greatest in the hepatobiliary system, demonstrating the key role this system plays in the 
detoxification and elimination of PbTxs. Muscle tissue and the gastrointestinal tract also 
accumulated the toxin (Washburn et al., 1994).
9. Regulations
Proposed local guidelines mandate a legal limit of 80 pg of toxin/100 g shellfish 
tissue (20 MU/100 g; 4 pg/mouse), currently analyzed by the traditional mouse bioassay 
by the Florida Department of Natural Resources and Public Health agencies to detect 
toxic shellfish as a result of red tides caused by P. brevis (Baden et al., 1984b; Trainer 
and Baden, 1991).
Commercial bivalves are considered safe to eat 1-2 months after the termination of 
a bloom, but little quantitative evidence is available on either the rates of accumulation 
or depuration of the toxins in marine vectors (Baden et al., 1984b).
C) PREPARATION OF MONOCLONAL ANTIBODIES
In 1986, Kohler and Milstein were awarded the Nobel Prize in recognition for their 
contribution to the development of the procedure for the production o f monoclonal 
antibodies (Kohler and Milstein, 1975). The objective of the monoclonal approach for 
the production of antibodies relies on the selection of antibody-producing cells of 
monoclonal origin isolated from several of such cells present in vivo after administration 
of a compound recognized as foreign (Liddell and Cryer, 1991).
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Monoclonal antibodies produced by a single clone of B cells offer particular 
advantages such as uniform affinity and specificity of binding, homogeneity, and the 
ability to be produced in unlimited quantities (Deshpande, 1996).
1. Antigens and Immunogens
An antigen is a compound which has the ability to selectively bind to an 
immunoglobulin, whereas an immunogen is a compound which has the capacity, upon 
administration to a recipient, to elicit an immune response. For a compound to be 
immunogenic, it should not only be recognized as foreign to the recipient, but should 
also be of sufficient molecular size (more than 1000 Da). A compound of low 
molecular weight is called a hapten; it can bind to immunoglobulins but cannot 
stimulate B cells to differentiate and produce antibodies. Therefore, haptens can be 
antigenic, but not immunogenic. For haptens to be immunogenic, they need to be 
coupled to large molecules such as proteins (Liddell and Cryer, 1991).
Regardless of the protein carrier used, the same functional groups are available for 
attachment to the hapten, such as:
• Carboxyl groups of the C terminal and of aspartic and glutamic acid residues
• Amino groups of the N terminal and lysine residues
• Imidazo functions of histidine residues
• Phenolic functions of tyrosine residues
• Sulfhydryl groups of cysteine residues.
The functional groups o f the hapten govern the selection of the method to be used 
to conjugate it to the functional groups of the carrier. Amino groups of lysines and N- 
terminal amino acids are generally the most abundant functional groups on the surface
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of proteins that are susceptible for conversion to other functionalities. The amino group 
is a strong nucleophile in the protein. Since the protonated species (NH3*) is not 
reactive, the rate increases with increasing pH as the free amine (NH2) is formed (Wong, 
1991).
In general, the coupling should be performed in such a way that the antigen of 
interest stays in as native a condition as possible (Harlow and Lane, 1988). Higher 
affinity antibodies will be obtained if the linkage of hapten to protein is spaced at 6 A or 
greater so that the antibody does not recognize the carrier as part of its epitope, but T 
cell help from the carrier is still available. Carrier proteins most commonly used are 
keyhole limpet hemocyanin (KLH) or bovine serum albumin (BSA). Unfortunately, 
most of the immune response is directed to the carrier. Typical conjugation levels of 2 0 - 
40 haptens/mole protein are required for an efficient immune response (Campbell, 
1991).
It is absolutely essential to select the proper point of attachment of the haptenic 
molecule to the carrier protein in order to produce an antibody of desired specificity and 
cross-reactivity. This is ruled by the Landsteiner’s principle, which explains that the 
antibody specificity is directed primarily at that position of the hapten farthest removed 
from the functional group used to link it to the carrier protein. Thus, antibody specificity 
is directed towards that position of the hapten molecule that is most accessible to the 
circulating macrophages and lymphocytes. Therefore, depending on the specificity 
required for the antibody and eventual use, great care must be taken to ensure that those 
groups that distinguish a molecule from its precursors, metabolites, and/or analogs are 
used for conjugation to carrier protein (Landsteiner, 1945).
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The antigenic determinants are approximately 5-30 A long, a length that 
corresponds to sequences of about six to eight hexose units, nucleotides, or amino acids. 
Some laboratories report epitopes are typically comprised of 15 amino acids, but that 
most of the binding energy is provided by five to six of these residues (Mayforth, 1993).
2. Immunization
An animal can make antibodies against a wide range of molecular structures. If an 
animal is exposed to a completely new immunogen mixed with Freund’s complete 
adjuvant, it will make a small amount of antibodies (primary response). The antibody 
response to a primary immunization follows a characteristic pattern: lag phase, followed 
by a logarithmic increase in antibody levels, then a plateau before levels decline (Liddell 
and Cryer, 1991). The primary antibody responses often are very weak. An increase in B 
cells bearing surface antibodies specific for the antigen is first detected 5-6 days after 
the primary injection of the immunogen. The specific antibody is usually detected in the 
serum from around 7 days after the injection. It persists at a low level for a few days, 
typically reaching peak titer around day 10. The first antibodies produced are of the IgM 
type, characterized by high avidity but low affinity for the antigen. This is followed by a 
peak of IgG class antibodies as a rule higher than the IgM one. The IgG class antibodies 
display lower avidity, but are characterized by much higher affinity for the antigen than 
the IgM type (Deshpande, 1996). A single booster injection, given after the primary 
antibody response has subsided, will act on the cells which carry immunological 
memory and will lead to a secondary antibody response which is faster, stronger (more 
antibody is made), and qualitatively different (different types of antibody molecules are 
made and they generally bind the antigen with a higher affinity) (Zola, 1987). A 3 to 4
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week interval between the primary immunization and booster injections is generally 
effective for mice. Freund's incomplete adjuvant is used in booster injections, since it 
has some of the adjuvant action with a lower risk of anaphylaxis (Zola, 1987). The 
antibody response, especially against antigens which are only weakly immunogenic, 
may be increased by giving numerous booster injections. The immune response to the 
third and subsequent booster injections typically mirrors that of the secondary injection. 
High antibody titers can be repeatedly induced following booster injections provided 
they are properly spaced throughout the lifetime of the immunized animal (Deshpande, 
1996). Most anim als will remain effectively primed for at least a year after receiving the 
first injection.
The myelomas in general use are from BALB/C strain of mice, and is thus 
convenient to use this strain for immunization (Zola, 1987). Animals are not given their 
primary immunization until they are 4-6 weeks old (Campbell, 1991). Either sex of 
animal can be used; however, the main advantage of using females is that they fight less 
in the cage (Liddell and Cryer, 1991; Davis, 1995). Fighting often results in wounds 
which can become infected and divert the immune response (Campbell, 1991).
The route of immunization is primarily governed by three factors: the volume to be 
delivered, the buffers and other components that will be injected with the immunogen, 
and how quickly the immunogen should be released into the lymphatics or circulation 
(Harlow and Lane, 1988; Deshpande, 1996). The objective is to create a slow release 
depot of immunogen, so the site should not be high in vascular areas that can quickly 
remove and metabolize the immunogen (Liddell and Cryer, 1991). Cells injected ip very 
rapidly reach the spleen, and this route is probably almost as effective as iv and
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technically simpler. The sc route is probably best for stimulation of local lymph nodes 
preferentially (Deshpande, 1996).
In practice, most immunogens are administered together with substances known to 
increase the recipient’s response. Such substances are known as adjuvants (Liddell and 
Cryer, 1991). Adjuvants stimulate the immune response and antibody production non- 
specifically by increasing the efficiency of antigen presentation and the number of 
collaborating and secreting cells involved. They can effectively reduce the required 
immunogen dose and enhance immunogenicity by allowing antibody response to weakly 
immunogenic molecules. They may change the mode of immune response, e.g., 
tolerance against immunity, alter isotype pattern of antibody responses, act as 
immunogen depots for prolonged antigen stimulation, protect the immunogen from 
rapid removal and breakdown, thereby reducing the need for repeated injections, 
increase the average avidity and affinity of the antibody response, and induce the 
formation of a granuloma which is rich in macrophages and immunocompetent cells 
(Zola, 1987; Liddell and Cryer, 1991; Deshpande, 1996).
Freund’s complete adjuvant is distinguished by the presence of a heat-killed 
preparation of Mycobacterium tuberculosis suspended in a light mineral oil base which 
also contains emulsifying agents. The presence of Mycobacterium enhances the local 
inflammatory response and for this reason secondary injections of immunogen should 
be given in the presence o f Freund’s incomplete adjuvant from which Mycobacterium 
has been excluded (Liddell and Cryer, 1991).
Measurement of antibodies in the serum of the immuni sed mouse serves as a guide 
to successful immunization, particularly since individual mice can differ greatly in their
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response to the same antigen (Zola, 1987). A fresh booster injection is often inefficient 
if a high antibody titer is still present from previous injections. It is therefore a waste of 
tim e and immunogen to give increasingly high booster injections to compensate for an 
increasing titer. Comparing the titers of antibodies isolated after successive injections 
allows the antibody response to be monitored. Samples of the serum should be taken 7 
tol4 days after an injection. Test bleeds are normally assayed against the antigen itself 
by enzyme immunoassays. However, when assessing the quality of the sera, the assay 
should resemble as closely as possible the technique for which the antibodies are being 
raised (Harlow and Lane, 1988).
3. Fusion
Three factors will influence the decision to proceed with the production of 
monoclonal antibodies: (1 ) are the antibodies recognizing the antigen of interest?, (2 ) is 
the immune response strong?, and (3) is a screening method already developed? 
(Harlow and Lane, 1988)
All the available mouse fusion partners have their origins in the BALB/C mouse 
(Campbell, 1991). Myelomas are neoplasms of antibody-producing cells, each tumor 
representing the proliferation of a single clone of antibody-forming cells (Liddell and 
Cryer, 1991).
The myeloma line to be used for hybridization and its hybrids must grow 
continuously in vitro. It must also confer on hybrids the ability to secrete 
immunoglobulin in quantity, but preferably should not code for its own immunoglobulin 
(Goding, 1996). The myeloma must bear a genetic marker that enables selective growth 
of hybrids rather than unhybridized myeloma cells (Campbell, 1991). The selection
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system used almost universally is the HAT (hypoxanthine, aminopterin, thymidine) 
system (Zola, 1987; Campbell, 1991).
Aminopterin blocks the main biosynthetic pathways of purine and pyrimidine 
synthesis (for formation of nucleic acids) in animal cells principally by inhibition of the 
enzyme dehydrofolate reductase which is critical for the de novo synthesis of GMP, 
AMP, and TMP (Zola, 1987; Campbell, 1991; Mayforth, 1993). There are, however, 
salvage pathways by which exogenous nucleosides may be utilized instead by normal 
cells. The pyrimidine pathway involves the enzyme thymidine kinase (TK) and utilizes 
otogenous thymidine. The purine pathway utilizes the enzyme hypoxanthine guanine 
phosphoribosyl transferase (HGPRT) with exogenous hypoxanthine. Cell lines can be 
made deficient in either one of these enzymes by growth and selection in the toxic base 
analogues bromodeoxyuridine (which selects TK negative cells) or 8 -azaguanine or 6 - 
thioguanine (which select HGPRT negative cells). Mutant cells which lack one of the 
enzymes required for the salvage pathway cannot multiply in the presence of 
aminopterin and die out (Zola, 1987). Mutant myelomas, lacking the enzyme HGPRT, 
will multiply in the absence of aminopterin, but die out in HAT medium. Fusion 
products, which have the HGPRT gene from the normal spleen cell fusion “parent,” 
survive in HAT medium. This system is referred to as half-selective, since only one of 
the fusion partners has a genetic defect and is selected against by the medium. Spleen 
cells will not grow in culture without special stimuli and conditions, so that there is no 
need to select against unfused spleen cells (Zola, 1987). Nearly all rodent cell lines 
currently in use have been selected on 8 -azaguanine and are consequently HGPRT 
negative. Most of the cell lines are prefixed with the letters “Ag” for azaguanine
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resistance. The SP2/0-Agl4 line was originally selected from P3-X63-Ag8 by fusion 
with non-immunized mouse spleen cells leading to a cell line which no longer made or 
secreted antibody. These cells have almost twice the normal amount of DNA of a 
normal mouse cell but have remained stable throughout the years. These cells are 
slightly adherent and tend to stick slightly to plastic (Campbell, 1991). The myeloma 
lines have occasionally been reported to revert to cells which grow in HAT (Zola, 
1987). One single surviving myeloma cell in any culture is likely to outgrow the 
hybridomas (Campbell, 1991).
hi mouse fusions, the preferred lymphocyte donor is the spleen, in which 
approximately 30-40% of cells are B-lymphocytes. One spleen yields about 5 x 107 to 2 
x 108 nucleated cells (Liddell and Cryer, 1991). It is estimated that even in the most 
efficient fusions, only about 1% of the starting cells are fused, and only about 1 in 1 0 s of 
these form viable hybrids (Harlow and Lane, 1988; Liddell and Cryer, 1991).
When cells are brought into close contact, fusion of membranes will occur, but this 
will be a very rare effect The frequency of fusion can be increased by a variety of 
agents. Polyethylene glycol (PEG) is now used almost universally, since it is easier to 
use and more effective. The fusion process is inevitably traumatic to cell membranes, 
and the procedure should be designed to minimize this damage. One useful indicator of 
how well the procedure has been handled is the viability of the cell mixture after fusion 
(Zola, 1987). While the exact mechanisms of fusion are not fully understood, it is 
thought that the main function of the hydrophilic PEG solution is to occupy the physical 
free water space leading to the agglutination of the cells. This occurs at concentrations 
of PEG in the region o f40-50% with short exposure time (Campbell, 1991).
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The first m itotic division after fusion will lead to a population of daughter cells that 
cany both sets of parent cell chromosomes in the same nucleus. Often, however, at 
subsequent divisions chromosomes are lost in ones and twos until a new stable cell line 
is formed carrying some chromosomes from each parent (Liddell and Cryer, 1991).
Good fusions are better handled in 96 well tissue culture plates at densities in the 
region of 10s cells/well. This means that statistically it is not likely to have more than 
one clone in each well (Campbell, 1991).
Two main types of medium are used for hybridoma production: Dulbecco’s 
modified eagle's medium (DMEM) and Rosewell Park Memorial Institute-1640 (RPMI- 
1640). Both contain amino acids, vitamins, salts, and nutrients in varying proportions. 
DMEM has pyruvate, where RPMI does not; and DMEM has more bicarbonate buffer 
so that it may be more useful if for some reason it has to spend long periods of time in 
the absence of CO2 (Campbell, 1991).
Feeder cells, or conditioned medium of very high quality, are quite essential for 
fusion of cells, expansion from microwells, and cloning of hybridomas (Campbell, 
1991). Cells are not used to growing alone at high dilutions and must be provided with 
nutrients in addition to those supplied by the medium and fetal bovine serum (FBS). 
The exact composition of these nutrients is unknown, but they act as growth factors 
(Campbell, 1991). Cell-cell interaction was thought to play an important role, but 
conditioned medium has also been used successfully to improve hybridoma growth, 
suggesting that the effect is dependent on the production of soluble factors (Liddell and 
Cryer, 1991). The most commonly used feeder cells are thymocytes, splenocytes or 
peritoneal macrophages (Campbell, 1991; Liddell and Cryer, 1991).
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4. Screening of hybridoma supernatants
The vast majority of wells will not contain the desired antibody. The purpose of 
screening is to discover which wells contain hybridomas that secrete the antibody of 
desired specificity. In mouse, screening is ready at about 10 to 14 days after fusion. The 
wells are fed and 2  days later (enough time to build a saturating titer of antibody in the 
culture supernatant), aliquots of the supernatants are tested in the screening assay for the 
presence of the desired antibody (Coligan et al., 1991).
Successful fusions will produce between 200 and 20,000 hybridoma colonies. A 
good screening procedure must reduce the number o f cultures that must be maintained 
to a reasonable level, identify potential positives in 48 hours or less, and be easy enough 
to perform for all the needed wells. All screening procedures must be tested and 
validated before the fusion has begun. After the fusion, there is seldom enough time to 
try out new ideas or to refine methods. The test bleeds should be used to set up and test 
the screening assay (Harlow and Lane, 1988).
5. Cloning
The objective of cloning is to ensure that the cells producing antibody comprise a 
monoclonal population. This is because in the original fusion well, the hybridoma cells 
may have descended from several fusion products. Cloning involves the setting up of 
single-cell cultures, each cell intended to grow into a colony of identical cells (Harlow 
and Lane, 1988).
Three different approaches may be used: limiting dilution in liquid culture, 
semisolid agar cultures, and selective isolation of antigen-reactive cells using a 
fluorescence-activated cell sorter (Harlow and Lane, 1988). Cloning by limiting dilution
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is the simplest and most popular method of hybridoma cloning. In this method, a 
suspension of hybridoma cells is plated out in individual culture wells at a dilution such 
that, statistically, the most probable number of cells in any particular well is 1 (Liddell 
and Cryer, 1991).
Soft agar cloning is very rarely used and has largely historical interest because the 
original fusion of Kohler and Milstein used this method (Campbell, 1991). Cloning in 
soft agar offers no advantages over the limiting dilution procedures and is considered by 
some to be less convenient and more complicated (Zola, 1987; Liddell and Cryer, 1991; 
Goding, 1996). This kind of cloning offers technical difficulties in that it is necessary to 
have molten agar for suspension of the cells and the cells are obviously vulnerable to 
heat shock above 37°C. In addition, batches of agar are highly variable and some may 
be toxic (Campbell, 1991). The resultant clones can be tested for antibody production 
following their transfer to liquid medium. Alternatively it has been possible to 
demonstrate specific immunoglobulin secretion by clones directly in their solid agar 
growth support using techniques such as hemolytic overlays (Liddell and Cryer, 1991).
In the mouse system, fused cells which carry an initial double load of chromosomes 
tend to take longer to replicate. These cells lose chromosomes very fast and if these 
chromosomes include either chromosome 1 2 , which codes for the immunoglobulin 
heavy chain locus, or mouse chromosome 6  which codes for the k light chain locus, the 
ability to secrete the appropriate antibody will be lost. Cells which have lost 
chromosomes tend to outgrow their neighbors (Campbell, 1991). In a fully developed 
mouse B lymphocyte secreting antibody as much as half of the protein synthesizing 
apparatus may be occupied with the synthesis of antibody. Thus, fused cells making
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detectable amounts of antibody divert so much energy into this process that they are 
presumed to have less energy left for multiplication and secretion. Consequently, the 
cells secreting antibody are at a disadvantage compared to those not secreting antibody 
(Campbell, 1991; Liddell and Cryer, 1991).
6. Antibody Characterization
Determination of class and subclass of monoclonal antibodies is important because 
several immunochemical and functional properties of antibodies depend on the isotype. 
Isotyping is a basis for the selection of antibody purification, conjugation, 
fragmentation, and storage procedures. It is also useful to control lot to lot consistency, 
detect contamination by another antibody, and identify hybridoma switch variants 
(Davis, 1995). Routine methods for isotyping involve isotype-specific antibodies. The 
antibodies can be either polyclonal raised against a purified immunoglobulin and 
absorbed against other immunoglobulin isotypes to eliminate cross-reactive antibodies, 
or monoclonal antibodies with a single isotype-specific epitope (Davis, 1995).
7. Antibody purification
For the majority of applications, there is no need to purify the immunoglobulin 
from either culture supernatant or ascitic fluid (Zola, 1987). Monoclonal antibodies can 
just be titrated and used directly (Campbell, 1991). If purification is required, the 
method should be selected to match the degree of purity needed (Zola, 1987). 
Purification is necessary if the antibodies are to be labeled, since the greater the purity 
of the labeled antibody the greater the signal-to-noise ratio in the assay. Polyclonal 
antisera require affinity purification before labeling but this is not so critical with 
monoclonal antibodies (Liddell and Cryer, 1991).
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Most culture supernatants contain protein from bovine serum that might interfere 
with some applications o f monoclonal antibodies (Liddell and Cryer, 1991). If the 
monoclonal antibody was grown in serum free medium, then it is more readily purified 
(Campbell, 1991).
Ammonium sulfate precipitation is a classic method for subfractionating serum 
proteins. While it may give slight purification, it is really a method for concentrating 
antibodies (Campbell, 1991). All classes of antibodies precipitate as nondenatured salt 
complexes between 40 and 50% (w/v) saturated ammonium sulfate (SAS). Smaller 
amounts of albumin, a  globulins, and (3 globulins also precipitate, but the vast majority 
of precipitated protein is y globulin. Water molecules bind to proteins through hydrogen 
bonds, keeping proteins in solution. If the ammonium sulfate attracts enough water 
away from the proteins, the latter lose their water of solvation and come out of solution. 
Protein precipitates are dissolved in buffer and dialyzed to remove residual ammonium 
sulfate (Goers, 1993).
D) IN  VITRO IMMUNIZATION
Monoclonal antibodies to weakly immunogenic antigens (haptens) are difficult to 
produce in vivo (Enriquez et al., 1991). To try to overcome this problem, a new method 
was developed. In vitro immunization is defined as a primary, antigen-specific 
activation of cultured B cells resulting in a clonal expansion and maturation of specific 
lymphocytes (Moller and Borrebaeck, 1988). When in vivo immunized splenocytes are 
stimulated in vitro, the proper term is in vitro stimulation. These secondary responses in 
vitro are dependent on the stimulation of memory B cells obtained after in vivo 
immunization (Reading, 1982).
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The advantages of murine m vitro immunization are the following: (a) the 
immunization takes only 5 days when using unprimed mice, (b) the normal cellular 
control of the immune response to self-antigens or weak immunogens does not function 
in vitro (immunosuppression, B cell inactivation, natural down-regulation), (c) 
extremely low amounts of immunogen are needed, and (d) suitable lymphokines can be 
added to supplement the medium (Borrebaeck, 1986).
The binding of an antigen to antigen-specific B lymphocytes is a necessary step in 
the initiation of the immune response; however, this would be insufficient in initiating 
an antigen-specific B cell response. In order to achieve B cell activation it is necessary 
to undergo three steps: induction/activation (from resting B cell or G0 phase to late Gi 
phase), proliferation, and differentiation. Moreover, the cooperation of T helper cells 
and accessory cells (macrophages/monocytes) with B cells is needed and regulated by 
major histocompatibility class II (MHC II) molecules. The functions of T helper cells 
and accessory molecules can also be mediated by soluble antigen-nonspecific growth 
and differentiation factors that bind to receptors other than surface immunoglobulins on 
B cells (Borrebaeck, 1986). Interleukin-1 (IL-1), IL-2, IL-4, and IL-5 are involved in the 
proliferative stage of murine B cells, whereas EFN-y, EL-2, IL-4, IL-5, IL-6 , and IL-10 
are involved in B cell differentiation (Moller and Borrebaeck, 1988).
A thymus dependent antigen is described as that which requires cooperation 
between helper T-cells, accessory cells and B cells in a MHC-restricted fashion. The B 
cells should carry complementary membrane bound immunoglobulins (Moller and 
Borrebaeck, 1988). Macrophages are required for most T-dependent antigens acting in 
both antigen presentation and in stimulation of B cell proliferation (Reading, 1982).
56
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Since the in vitro immunization should parallel the antigen-specific activation of B 
cells in vivo, T cell derived lymphokines have to be used when working with thymus- 
dependent antigens. These lymphokines are usually derived from thymocytes or mixed 
lymphocytes cultures (MLC) (Borrebaeck, 1986; Moller and Borrebaeck, 1988). The 
MLC of MHC-disparate mouse thymocytes from BALB/C and C57BL/6 mice contains 
IL-2, IL-4, IL-5, and allogeneic helper factors (AHF). It also contains factors with 
isotype regulatory effects, e.g., B cell differentiation factor p (BCDFp) which induces 
IgM secretion in BCL1 cells and B cell differentiation factor (3 (BCDFp) which 
significantly increases the secretion of IgGl from LPS stimulated murine B cells. The 
EL-4 thymoma cells stimulated with a phorbol ester yield a supernatant containing a 
variety of lymphokines with B cell growth and differentiation-inducing activities (IL-2, 
IL-4, IL-5, EL-6 ) (Borrebaeck, 1986; Moller and Borrebaeck, 1988). The optimal 
concentration of supernatants derived from MLC and EL-4 cultures is 33% and 25%, 
respectively (Borrebaeck and Moeller, 1986).
The optimal antigen stimulation period for in vitro im m unization is five days, after 
which splenocytes can be used for hybridization with myeloma cells (Reading, 1982). 
The doses of immunogen used to elicit an immune response in vitro vary over a wide 
range; however, commonly used doses are in the range of 1-2 pg/mL (Borrebaeck,
1986). It has been found that there is no need to fractionate spleen cells into B and non- 
B cells before or after the in vitro immunization. In fact, it has been found that this can 
give a lower number of surviving hybrid clones (Borrebaeck, 1986).
During in vitro stimulation, B cells may be activated by serum proteins commonly 
used to supplement the medium. This may lead to antigen-nonspecific hybridomas.
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Therefore, rabbit serum has been used instead to reduce this effect (Borrebaeck, 1986). 
Polyclonal B cell activators in the presence of antigen can serve as a second signal to 
stimulate specific responses (Reading, 1982). During some in vitro immunizations, a 
polyclonal activator called N-acetyl-muramyl-L-alanyl-D-isoglutamine (MDP) or 
adjuvant peptide has been used to supplement the medium (Boss, 1984). In these cases, 
five to ten times antibody forming cells have been detected after the in vitro 
immunization (Borrebaeck, 1986). The exact mechanism by which MDP transduce a 
stimulatory signal into cells are still unclear (Kalyuzhin et al., 1996).
It is important to mention that just 30-35% of the initial number of splenocytes 
survive the in vitro stimulation period. This percentage includes newly synthesized blast 
cells derived from clonally activated B lymphocytes (Borrebaeck, 1986).
An interesting point is that over 30% of the reported in vitro immunizations 
showed production of IgG monoclonal antibodies. This proves that an isotype switch 
can be obtained in vitro during the 5-day stimulation period (Borrebaeck, 1986).
It has been reported that in vitro immunization of splenocytes from in vivo- 
immunized mice can stimulate more B cell clones that the in vivo immunization alone 
and may produce high affinity monoclonal antibody variants using an in vivo/in vitro 
immunizing protocol (Wallen and Borrebaeck, 1991).
E) THIS STUDY
Current methods for the detection of CTXs and PbTxs are expensive, time- 
consuming, require trained personnel and special laboratory equipment In the case of 
CTX, the problem is more complex from the lack of standard material. For both groups 
of toxins, rapid detection methods are required to monitor fish/shellfish tissue and
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dinoflagellate extracts. This project proposes the use of the CTX-related toxin PbTx-2 
to produce cross-reacting monoclonal antibodies for both CTX and PbTx. Previous 
research has shown that CTX cross-reacts with both polyclonal antibodies for PbTx-2 
and PbTx-3 (Levine and Shimizu,1992; Baden et al., 1995). However, no attempt has 
been made to study in detail this cross-reactivity. The advantages of using PbTxs to 
immunize mice and produce monoclonal antibodies are that they are commercially 
available and they resemble CTXs in symptoms onset and mechanisms of action. 
Appropriate screening and cloning will allow the production of antibodies with the 
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Figure 13.Structure of brevetoxin-2 and Pacific ciguatoxin-1 .
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The ultimate use for these monoclonal antibodies is to provide a new 
immunochemical diagnostic tool based on an ELISA and S-PIA formats for the rapid 
detection o f ciguatera-related toxins in fish, shellfish, and dinoflagellate extracts, that 
will address the present need for a field method of rapid use. The commercial 
availability of the antigen PbTx-2, resembling CTX in structure and mode of action, will 
facilitate the production of monoclonal antibodies which will provide for a continuous 
supply of antibodies of high specificity and the study of antibody cross-reactivity with 
CTX-like compounds.
The project’s objectives were the following: (1) to produce monoclonal antibodies 
to PbTxs and CTXs using PbTx-2 immunogenic conjugates, (2) to prepare different 
protein-PbTx-2 conjugates for immunization of mice, (3) to evaluate traditional and 
novel methods of stimulation of murine splenocytes for the preparation of monoclonal 
antibodies, and (4) to evaluate the use o f alternative screening assays for the detection of 
anti-PbTx-2 antibodies.
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MATERIALS AND METHODS
A) MATERIALS
Brevetoxin-2 was purchased from Chiral Corp. (Miami, FL). Rosewell Park 
Memorial Institute-1640 (RPMI-1640) medium, Dulbecco’s modified eagle's medium 
(DMEM) high glucose, hypoxanthine, thymidine, aminopterin, sodium pyruvate, L- 
glutamine, dimethylsulfoxide (DMSO), Freund’s complete adjuvant (FCA), Freund’s 
incomplete adjuvant (FIA), nystatin, gentamicin, penicillin G/streptomycin sulfate, non- 
essential amino acids, 2-mercaptoethanol, Tween 20, 3-[4,5-dimethylthiazoI-2-yl]-2,5- 
diphenyl-tetrazolium (MTT), veratridine, ouabain, Hepes, sodium bicarbonate, sodium 
phosphate dibasic, potassium phosphate monobasic, potassium chloride, sodium 
chloride, sodium borohydride, bovine serum albumin (suitable for ELISA), bovine 
serum albumin (BSA) (fraction V), ovalbumin (OVA), Limulits polyphemus 
hemocyanin (LPH), keyhole limpet hemocyanin (KLH), cold water fish gelatin, trypan 
blue, red blood cell lysing buffer (ammonium chloride), polyethylene glycol (50%, 1450 
MW), N-acetyl-muramyl-L-alanyl-D-isoglutamine (muramyl dipeptide, MDP), phorbol- 
12-myristate-13 -acetate (PMA), goat anti-mouse IgG (H&L and y chain specific, affinity 
purified)-horseradish peroxidase (HRPO), goat anti-mouse IgG (Fab)-HRPO, rabbit 
anti-goat IgG (H&L)-HRPO, and the monoclonal antibodies isotyping kit were 
purchased from Sigma Chemical Co. (St. Louis, MO). Goat anti-mouse IgG (H&L and y 
chain specific)-HRPO were purchased from Jackson Immunoresearch (West Grove, 
PA). Syringes, needles (21 G), and serum separator tubes were from Becton-Dickinson 
(Franklin Lakes, NJ). Dynatech Immulon-2 96-well flat bottom microtiter plates and 
Spectrum dialysis tubing (25,000 MWCO) were purchased from Fisher (Pittsburgh,
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PA). Sterile plasticware used for fusion, cloning, and tissue culture included 25 and 75 
cm2 polystyrene tissue culture flasks, 15 and 50 mL sterile conical centrifuge tubes 
(Coming Inc., Coming, NY), 1, 5, and 10 mL pipettes, sterile 24-well tissue culture 
plates (flat bottom) and sterile 96-well tissue culture plates (flat and round bottom) 
(Costar, Cambridge, MA), and cryovials (Nalge Nunc International, Milwaukee, WI). 
Heat inactivated fetal bovine serum (FBS) was obtained from Hyclone (Logan, UT). 
Bicinchoninic acid (BCA) protein assay kit was purchased from Pierce (Rockford, IL). 
2,2'-azino-di-(3 -ethylbenzthiazoline-6-sulfonate) (ABTS), and 3,3',5,5'- 
tetramethylbenzidine (TMB) were purchased from Kirkegaard and Perry Laboratories 
(Gaithersburg, MD). Sp2/0-Agl4, NS-1, EL-4, and Neuro-2a cells were purchased from 
American Type Culture Collection (ATCC, Rockville, MD). Female BALB/C and 
C57BL/6 mice were obtained from the School of Veterinary Medicine, Louisiana State 
University (LSU). Water used was purified using a Laboratory Reagent Grade Water 
system (Continental Water Systems Corporation, Metaire, LA). Formulations of 
solutions and media are shown in Appendix A.
Centrifugation of cells was performed using a CRU-5000 centrifuge (Damon/IEC 
Division, Needham Heights, MA) and for serum separator tubes in a Biofuge 13 
microcentrifuge (Baxter Scientific Products, Deerfield, EL). Microtiter plate optical 
densities were measured with a model MCC/340 ELISA reader from Titertek (Flow 
Laboratories, McLean, VA). Cells were grown in a water-jacketed controlled 
atmosphere incubator (Forma Scientific Inc., Marietta, OH) and viewed using a Diavert 
inverted microscope (Carl Zeiss, Thomwood, NY). Cell counting was performed using 
a Bright-Line hemacytometer (Fisher, Pittsburgh, PA). Tissue culture manipulations
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were done in a BBL Biohazard cabinet (Becton Dickinson, Franklin Lakes, NJ). Upon 
freezing, cells were first stored in an ultra-low freezer (-80°C) (Forma Scientific Inc., 
Marietta, OH) overnight and then transferred to liquid nitrogen storage containers.
B) METHODS
1. Preparation of Monoclonal Antibodies
a. Preparation of Brevetoxin-2 Protein Conjugates
Due to its small molecular weight (895 Da), brevetoxin-2 (PbTx-2) was bound to 
proteins such as bovine serum albumin (BSA), ovalbumin (OVA), keyhole limpet 
hemocyanin (KLH), and Limulus polyphemus hemolymph (LPH). The immunogenic 
conjugate was prepared by incubation of 100 (ig of PbTx-2 in 200 (iL of ethanol and 10 
mg of LPH, KLH or BSA in 1 mL H2O at pH 9 (pH adjusted with potassium carbonate) 
at room temperature (ca. 25°C) for 1 hr. Addition of 15 mg of sodium borohydride in 
500 pL H2O followed, and the reaction continued overnight at ca. 25°C. The pH was 
adjusted to 7.4 with 1 M formic acid, and the reaction proceeded for 1 more hr (ca. 
25°C) (Levine and Shimizu, 1992). The mixture was dialyzed against 3 changes of 
phosphate buffered saline (PBS) (pH 7.4) at 4°C using a Spectrum dialysis membrane.
The conjugate prepared for screening purposes (ELISA) was made with BSA for 
KLH-PbTx-2 and LPH-PbTx-2 immunized mice, and with OVA for BSA-PbTx-2 
immunized mice, to prevent the screening of antibodies which would recognize the 
carrier protein used for immunization.
The protein concentration of the dialyzed conjugates was measured using the BCA 
protein assay kit (Pierce). Conjugates were stored at -20°C after adjustment of the 
protein concentration to 1 mg/mL.
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b. Immunizations
Approval for the safe handling of mice was granted by the Institutional Animal 
Care and Use Committee and the Institutional Review Board of the Louisiana State 
University Agricultural Center.
Since individual mice can differ greatly in their response to the same antigen (Zola,
1987), fifteen female BALB/C mice were used. Each mouse (at least 12 weeks old) was
✓
immunized by intraperitoneal (ip) (100 pL) and/or subcutaneous (sc) (100 pL) routes 
with an emulsion of 1 mg of conjugate in 1 mL sterile phosphate buffered saline 
(PBS)/FCA (1:1). Blood samples were taken 7 to 10 days after each injection to monitor 
the production of specific antibodies (Zola, 1987). Test bleeds were obtained from the 
retro-orbital plexus using Pasteur pipettes. Blood was centrifuged at 1500 g  for 10 min 
to separate the serum, which was assayed against the appropriate protein conjugate by 
an indirect enzyme-linked immunosorbent assay (ELISA) (next section).
The number of booster injections (in PBS/FIA, 1:1) depended on the titer of the 
serum, and continued until the antibody activity was high. Three to four days before the 
fusion with myeloma cells, the immunized mouse showing the highest antibody titer 
was given a final ip boost without adjuvant
For injections, mice were picked up by the tail, near the base, and placed on a grid. 
When the tail was pulled gently, the animal held onto the grid with its feet, and it could 
then be picked up by grasping the loose skin over the shoulders with the thumb and 
forefinger, while the tail was held with the little finger (Campbell, 1991).
To collect blood from the retro-orbital plexus, mice were anesthetized using 30% 
isoflurane/70% oxygen. Each mouse was laid on its side on the table, holding its head
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steady with the index finger and thumb of the same hand. The eye lids were carefully 
separated until the eye bulb stood out clearly. A Pasteur pipette was inserted into the 
connective tissue sac at the inner angle of the eye, pushing it past the bulb of the eye and 
towards the back of the orbit. While doing this, the pipette was rotated evenly while 
applying light pressure. Once the pipette had penetrated the plexus, it was withdrawn 
about 1 nmrij so that blood could flow. The pipette was held softly while collecting the 
blood. If blood flow ceased, gentle rotation or an up-and-down movement of the pipette 
caused the blood flow to restart (Peters and Baumgarten, 1992).
c. Screening for Anti-Brevetoxin-2 Antibodies
An indirect ELISA format was used for screening of antibodies against PbTx-2. In 
this format, 50-100 fiL of BSA-PbTx-2 or OVA-PbTx-2 conjugate (5-10 |xg/mL) in 
PBS were bound to the wells of a 96-well polystyrene microtiter plate and incubated for 
2 hrs at 37°C or overnight at 4°C. The contents of the plate were discarded by inverting 
it quickly over a container with 0.1N NaOH to inactivate the brevetoxin molecule. The 
plate was washed with PBS-Tween 20 (PBST) (3x, 5 min each) to remove excessive 
reagents. The plate was then blocked with 120 (xL of 1% BSA in PBS (for KLH-PbTx-2 
and LPH-PbTx-2 immunized mice) or 1% cold water fish gelatin in PBS (for BSA- 
PbTx-2 im m unized  mice) for 1 hr at 37°C. Then, the contents of the plate were 
removed, and the plate was washed with PBST (3x, 5 min each). Later, 50-100 pL of 
serum or tissue culture supernatants were added and incubated 1 hr at 37°C. The 
contents of the plate were again removed and washed as previously described. Addition 
of 50-100 jxL of the goat anti-mouse-IgG (H&L or y)- HRPO (1:1000 - Sigma - or 
1:5000 - Jackson Immunoresearch - in 1% BSA or gelatin-PBST) followed, with
65
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
incubation for 1 hr at 37°C. The plate was washed again, followed by addition of 50-100 
|iT. ABTS or TMB substrate with incubation for 30 min at room temperature (ca. 25°C). 
The plate was read at an absorbance o f405 nm for ABTS or 620 nm for TMB using an 
ELISA reader (Appendix B). 
d. Fusion
d.1. Propagation of Myeloma Cells and Preparation of Mice for Fusion
One week before fusion, the myeloma cells (Sp2/0-Agl4 or NS-1) were removed 
from liquid nitrogen and thawed. Three to four days before fusion, each mouse was 
given a final boost (ip) without adjuvant One day before fusion, the media was prepared 
and the myeloma cells were divided into two 75 cm2 tissue culture flasks containing 25 
mL of medium.
d.2. Harvesting of Spleen Cells
On the day of the fusion (Day 0), the mouse was bled and transported to the LSU 
School o f Veterinary Medicine. Before starting the fusion, the media and the 
polyethylene glycol were placed in a 37°C water bath.
The mouse was killed by cervical dislocation and swabbed liberally with 70% 
alcohol before placing it inside the hood. Once inside, a sterile 100 mm tissue culture 
grade Petri dish was opened and a sterile collector was put on the bottom part Ten mL 
of washing medium were passed through the collector. The mouse was placed right side 
down in the top part of the Petri dish (the spleen is located on the left part of the body). 
A small incision was made in the skin to expose the abdominal wall (using forceps and 
scissors). The skin was pulled well out of the way to avoid loose hair getting into the 
mouse. Using a new pair of sterile scissors and forceps, a small incision was now made
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in the abdominal wall. Using new forceps and scissors, the spleen was removed from 
the animal and placed on the collector. Fatty and connective tissue (fibroblasts) adhering 
to the spleen were removed. Using new sterile forceps and scissors, the spleen was 
gently separated. This was done rapidly until further separation of small fragments did 
not release any more cells. With the pestle of a sterile 10 mL syringe, the tissue was 
pressed into the collector in an effort to release more cells. New 10 mL of washing 
medium were added to the Petri dish through the collector. The collector was removed 
so that the cell suspension could be transferred into a SO mL sterile centrifuge tube (V 
bottom), leaving clumps behind. The cells remaining in the Petri dish were washed with 
new 10 mL of washing medium and combined with the first 20 mL in the centrifuge 
tube. Since some clumps were inevitably transferred to the tube, they were allowed to 
settle (2 min), and the medium with cells was transferred into a new centrifuge tube, 
leaving the clumps behind. The tube with splenocytes was centrifuged (200 g, 5 min). 
d3. Preparation of Splenocytes and Myeloma Cells for Fusion
While the splenocytes were centrifuged, the flask with myeloma cells was observed 
under the microscope to ensure that cells were viable and healthy. The contents of the 
flask were transferred into a sterile 50 mL centrifuge tube, and the myeloma cells were 
centrifuged (200 g, 5 min). The tube with splenocytes was removed from the centrifuge 
and the medium was removed with a pipette. The cell pellet was gently dislodged, and 
the red blood cells were lysed by resuspending the pellet in 2 mL of lysing buffer 
(ammonium chloride solution) for 5 min at room temperature, followed by the addition 
of 18 mL of washing medium and centrifugation. While the red blood cells were being 
lysed, the tube with myeloma cells was removed from the centrifuge, the medium
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removed, and the ceil pellet dislodged. New 20 mL of washing medium were added to 
this pellet and the suspension was centrifuged (200 g, 5 min) again. At this point, the 
hemacytometer, Trypan blue, and microcentrifuge tubes were brought into the hood. 
One hundred pL of trypan blue were added into two microcentrifuge tubes. The tubes 
were removed from the centrifuge, the media removed, and the cell pellets dislodged. 
New 10 mL of washing medium were added to each tube to prepare a cell suspension. 
Both cells suspensions were counted using a hemacytometer and trypan blue.
d.4. Cell Fusion
To perform the cell fusion, the cell ratio selected was 1:5 (myeloma:splenocytes). 
The volume of myeloma cell suspension containing 20% of the total viable white cell 
content of the spleen cell suspension was added to the centrifuge tube containing the 
splenocytes and this mixed cell suspension was centrifuged again at 200 g  for 5 minutes. 
The PEG was brought inside the hood and put inside a beaker with water (37°C). The 
centrifuge tube with the mixed cell suspension was removed from the centrifuge, the 
medium removed, and the cell pellet dislodged. This tube was placed inside the beaker 
with warm water and 1 mL PEG was added slowly to the cell pellet drop-by-drop over 1 
min, while resuspending the cells by stirring with the end of the pipette. The stirring 
continued for an additional minute. The dilution process started by keeping the 
centrifuge tube inside the beaker with water and adding 6 mL of washing medium, 
slowly and mixing with the pipette. New 12 mL of washing medium were added, 
followed by mixing, and by addition of new 22 mL of washing medium. This cell 
suspension was centrifuged (150 g  for 5 min). The tube was removed from the 
centrifuge, the medium was removed, and the cell pellet was carefully dislodged.
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Enough conditioned-HT medium was added to the cell pellet to prepare a cell 
suspension of approximately 1.5-2.5 x 106 cells/mL. Ninety-six well tissue culture 
plates (flat bottom) were labeled with plate number, date, and name of researcher. One 
hundred pL of the cell suspension were added to each well, changing tips between 
plates. The plates were incubated for 24 hrs (37°C, 5% CO2) before feeding them.
d.5. Feeding and Screening of Fusion Plates
On the day following the fusion (day 1), the wells were observed under an inverted 
microscope to evaluate cell viability. One hundred pL of conditioned medium-HAT 
were added to each well, and the plate was returned to the incubator. On days 2, 3, and 
7, half the volume of each well (100 pL) was removed using a Pasteur pipette connected 
to a vacuum. The cells were fed with 100 pL of conditioned medium-HAT and returned 
to the incubator. On day 10, the same feeding protocol was followed but now using 
complete medium-HT. Starting on day 12, supernatants of wells at least 25% confluent 
and yellow were screened for antibody production. Ideally, the supernatant was taken at 
least after 2 days of last feeding to build a saturating amount of antibodies. These wells 
were fed with 100 pL of complete-HT medium and returned to the incubator.
The specific efficiency was determined for each fusion: (number of wells 
producing positive responses in screening/number of wells exhibiting cell growth) x 
100.
e. Expansion
When each candidate hybridoma was 25-50% confluent in the 96-well fusion plate, 
it was expanded to a well in a 24-well plate by resuspending the cells in the fusion plate 
with a sterile tip and transferring the entire contents (after taking an aliquot for cloning).
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The well in the 96-well fusion plate was fed with 100 pL of conditioned-HT medium as 
a back up. The 24-well plate was incubated (5% CO2, 37°C) and each well was fed with 
500 pL complete-HT medium when the medium started to turn yellow. After addition of 
the 500 pL, the plate was incubated and when the medium started to turn yellow again, 
1 mL of complete-HT medium was added. When each well was almost confluent and 
yellow, the cell suspension was divided into 2 wells and fed with 1 mL complete-HT 
medium. When they were almost confluent and yellow, both wells were frozen using 
10% DMSO/Complete-HT medium and stored at -80°C.
f. Cloning
Cloning was performed by the limiting dilution method. Two sterile 96-well tissue 
culture plates (flat bottom) were used for each selected fusion well. One hundred pL of 
conditioned medium-HT were added to each well of both plates. The candidate 
hybridoma was resuspended in its well with a pipette tip. Fifty pL of this cell suspension 
were taken and added into well A1 of both 96-well plates. Fifty pL of conditioned 
medium were added to well A1 to adjust the volume to 200 pL. The contents of well A1 
were mixed and 100 pL were transferred to well B l, mixed 4x, 100 pL transferred to 
well C l, and so on. The residual 100 pL from well HI were added into the 
corresponding well in the 24-well plate. Using a 12-channel micropipette, new 100 pL 
of conditioned medium-HT were taken and added into column 1, mixed 4x, 100 pL 
were transferred to column 2, mixed 4x, 100 pL transferred to column 3, and so on. The 
residual 100 pL from column 12 were added back into column 1 of each plate. The 
plates were wrapped in commercial plastic wrap (Handi wrap) and placed in the
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incubator for 7 days, being careful not to move the plates during that time. After 7 days, 
the cloning plates were examined under the microscope searching for colonies arising 
from 1 cell. Each plate was fed with 100 pL of complete-HT medium and returned to 
the incubator. When selected wells showed at least 30% confluence and were slightly 
yellow, the supernatants were screened for antibody production. Selected wells were fed 
with 100 pL of complete-HT medium after taking the aliquot for screening. Positive 
wells were expanded into 24-well plates and were rescreened and frozen,
g. Expansion and Freezing after Cloning
When the cell suspension in the 24-well plate was almost confluent and yellow, it 
was divided into 2 wells and 1 mL of complete-HT medium was added. Once almost 
confluent, one well was frozen and the contents of the second well were transferred into 
a 25 cm2 flask (2 mL from well plus 8 mL of new complete-HT medium). The tissue 
culture flask was left in the incubator for 5 days (to build a saturating amount of 
antibodies). The cell suspension was centrifuged (200 g, 5 min) and the supernatant 
collected into a 50 mL centrifuge tube for precipitation of the antibodies.
Ammonium sulfate (2.9 g) was added slowly into the tube containing the 10 mL of 
supernatant (50% saturation). The tube was left overnight at 4°C. The supernatant was 
then centrifuged (1500 g, 30 min), the pellet collected and resuspended in 1 mL PBS. 
This protein solution was dialyzed against several changes of PBS (4°C) to remove 
excessive ammonium sulfate. The dialyzed protein solution was stored at -20°C.
2. Competitive ELISA
In this format, 100 pL of BSA-PbTx-2 or OVA-PbTx-2 conjugate (5 pg/mL) were 
bound to the wells of a 96-well polystyrene microtiter plate and incubated for 2 hrs at
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37°C or overnight at 4°C. The contents of the plate were discarded by inverting it 
quickly over a container with 0.1N NaOH to inactivate the brevetoxin molecule. The 
plate was washed with PBST (3x, S min each) to remove excessive reagents. The plate 
was then blocked with 120 pL of 1% BSA in PBS (for KLH-PbTx-2 and LPH-PbTx-2 
immunized mice) or 1% cold water fish gelatin in PBS (for BSA-PbTx-2 immunized 
mice) for 1 hr at 37°C. Then, the contents of the plate were removed, and the plate was 
washed with PBST (3x, 5 min each). Later, 50 pL of free PbTx-2 (1:2 serial dilutions in 
PBS) or PBS only (Ao) and 50 pL of serum or tissue culture supernatants were added 
and incubated 1 hr at 37°C. The contents of the plate were again removed and washed as 
previously described. Addition of 100 pL of the goat anti-mouse-IgG (y)-HRPO (1:5000 
in 1% BSA or gelatin-PBST) followed, with incubation for 1 hr at 37°C. The plate was 
washed again, followed by addition of 100 pL TMB substrate with incubation for 30 
min at room temperature (ca. 25°C). The plate was read at an absorbance of 620 nm 
using an ELISA reader (Appendix B).
Competition curves were analyzed to determine the four parameters defining the 
sigmoidal curves, as described by Christopoulos and Diamandis (1996):
y = a-d + d 
1 + (x/c)b
where y is the response measurement (A/Ao), x is the PbTx-2 concentration, a is the y- 
intercept, b is the slope at the inflection point, c is the concentration giving 50% 
reduction in y (ICso), and d is the value of y at infinite (saturating) x (background 
absorbance). The equations were determined using Excel/Solver (Microsoft Corp., 
Redmond, WA) and the four parameters were estimated by minimizing the sum of
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squares of the data. Graphs were constructed by plotting A/Ao vs. Log [PbTx-2] 
(pg/mL).
To determine the dilution of serum, it is important to consider the following. If too 
much antibody is used, it will be in excess to that required to saturate the antigen; 
therefore, a quantity of free antibody will bind to the competitor, but there will still be 
an amount left to react 'vith the solid-phase antigen. Thus, competition would only 
occur where extremely high concentrations of competitor are used. To avoid this 
problem, a dilution yielding about 70% of the m aximum plateau absorbance in the 
serum titer figures was used (Crowther, 1995).
3. Isotyping ELISA
a. Antigen-specific Isotyping ELISA
A mouse monoclonal antibody isotyping kit was used to isotype sera of immunized 
mice. In this format, 100 pL of BSA-PbTx-2 or OVA-PbTx-2 conjugate (5 pg/mL) 
were bound to 6 wells/sample of a polystyrene microtiter plate and incubated for 2 hrs at 
37°C or overnight at 4°C. The contents of the plate were discarded by inverting it 
quickly over a container with 0.1N NaOH to inactivate the brevetoxin molecule. The 
plate was washed with PBST (3x, 5 min each) to remove excessive reagents. The plate 
was then blocked with 120 pL of 1% BSA in PBS (for KLH-PbTx-2 and LPH-PbTx-2 
immunized mice) or cold water fish gelatin in PBS (for BSA-PbTx-2 immunized mice) 
for 1 hr at 37°C. Then, the contents of the plate were removed, and the plate was 
washed with PBST (3x, 5 min each). Later, 100 pL of serum were added to the 6 wells 
and incubated 1 hr at 37°C. The contents of the plate were again removed and washed as 
previously described. Addition of 100 pL of one of the goat anti-mouse isotyping
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antibodies/well/sample (IgGl, IgG2a, IgG2b, IgG3, IgM, IgA) (1:1000 in PBS) 
followed, with incubation for I hr at 37°C. The plate was washed once again and 
addition of 100 pL of the rabbit anti-goat-IgG (H&L)-HRPO (1:5000 in PBST) 
followed, with incubation for 1 hr at 37°C. The plate was washed again, followed by 
addition of 100 pL TMB substrate with incubation for 10 min at room temperature (ca. 
25°C). The plate was read using an ELISA reader and an absorbance of 620 nm 
(Appendix B). Sera was considered to contain a specific isotype if its absorbance was at 
least three times the absorbance of the negative control (pre-immune serum),
b. Capture Isotyping ELISA
A mouse monoclonal antibody isotyping kit was used to isotype sera and 
supernatants. In this format, 100 pL of each isotyping antibody (IgGl, IgG2a, IgG2b, 
IgG3, IgM, IgA) (1:1000 in PBS) per sample were bound to a 96-well polystyrene 
microtiter plate and incubated for 2 hrs at 37°C or overnight at 4°C. The contents of the 
plate were removed, and the plate was washed with PBST (3x, 5 min each). Later, 100 
pL of serum or tissue culture supernatant were added and incubated 1 hr at 37°C. The 
contents of the plate were removed and the wells were washed as previously described. 
Addition of 100 pL of goat anti-mouse-IgG (Fab)-HRPO (1:5000 in PBST) followed, 
with incubation for 1 hr at 37°C. The plate was washed again, followed by addition of 
100 pL TMB substrate with incubation for 10 min at room temperature (ca. 25°C). The 
plate was read at an absorbance of 620 nm using an ELISA reader (Appendix B). Sera 
was considered to contain a specific isotype if its absorbance was at least three times the 
absorbance of the negative control (1% BSA-PBST).
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4. In vitro Stimulation
a. Preparation of Mixed Lymphocyte Culture
Thymuses from female BALB/C and C57BL/6 mice (5-7 weeks old) were co­
cultivated at 4-5 x 106 cells/mL (Appendix A). The cells were incubated for 48 hrs at 
37°C using a 5% CO2 incubator. After the 2 days, the supernatant was harvested and 
filter-sterilized (0.22 pm) before storing in aliquots. The sterile supernatant can be 
stored at -70°C (Borrebaeck and Moeller, 1986), but even at -20°C can remain active for 
periods of over 6 months (Reading, 1982).
b. Preparation of EL-4 Derived Supernatant
The EL-4 cell line was propagated in culture medium containing 10% FBS 
(Appendix A). After propagation, the cells were harvested, washed, and plated at 1 x 
106 cells/mL in culture medium containing 1% FBS and 10 ng PMA per mL medium 
(Appendix A). The cells were incubated for 40 hrs at 37°C in a 5% CO2 incubator. 
Afterwards, the supernatant was collected and filter-sterilized (0.22 pm) before storing 
in aliquots. This supernatant can be stored at -70°C.
c. In vitro Stimulation Procedure
A spleen of a previously immunized mouse (BSA-PbTx-2) was aseptically 
removed into a sterile Petri dish, and a cell suspension was prepared using a sterile mesh 
and the plunger of a sterile 10 mL syringe. The cells were washed once and counted 
using a hemacytometer. The splenocytes were plated at 4-7 x 106 cells/mL in in vitro 
stimulation medium with 1 pg of filter-sterilized antigen (BSA-PbTx-2 or PbTx-2) per 
mL of medium (Fusions 10 and 11). The cells were incubated for 5 days at 37°C in a 
5% CO2 incubator. After the incubation period, the cells were harvested and the red
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blood cells were lysed using ammonium chloride. The cells were then washed once and 
counted using a hemacytometer (Borrebaeck and Moeller, 1986). Afterwards, the 
splenocytes were used for fusion with myeloma cells following the previously described 
procedure.
S. Cytotoxicity Assay
Mouse Neuro-2a cells were grown and maintained at 37°C in a CO2 (5%) 
atmosphere in 25 cm2 tissue culture flasks in the appropriate medium (Appendix A). 
Cells were harvested from culture flasks with a trypsin/EDTA solution (0.25%/0.2%) in 
PBS, and subcultured (1:3 or 1:4) as required (Manger et al., 1995a, 1995b).
For bioassay, 96-well tissue culture plates (flat bottom) were inoculated with 200 
pL/well of a suspension of IxlO5 cells/mL in medium and incubated 24 hrs at 37°C, 
5% CO2 . Each culture well then received 10 pi of PbTx-2 standard (1:2 serial dilutions 
in culture medium), 10 pL o f aqueous stock of 10 mM ouabain, and 10 pL of aqueous 
stock of 1 mM veratridine (pH 2). Samples were tested in replicates of 3, with and 
without ouabain/veratridine (O/V). At least 8 wells were used as ouabain/veratridine 
controls and untreated controls (medium only). Cultures were incubated at 37°C for 4 or 
20 hrs and analyzed for sodium channel enhancing activity. This assay was modified to 
test for the presence of anti-PbTx-2 antibodies in tissue culture supernatants by adding 5 
pi of PbTx-2 standard (0.25 ng/well), 5 pL of tissue culture supernatant, 10 pL of 10 
mM ouabain, and 10 pL of 1 mM veratridine (pH 2). Thereafter, samples followed the 
same treatment as the original method.
Assessment of cytotoxicity was performed by replacement of the overlaying medium 
(230 pL) with 60 pi of a 1:6 dilution of MTT stock (5 mg/mL PBS, pH 7.4) in medium
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(Manger et al., 1995a, 1995b). Plates were then incubated 30 min at 37°C. The 
overlying medium was removed and replaced with 100 fxl DMSO, and the plates were 
read immediately using a test wavelength of 540 with an automated multiwell ELISA 
reader (Manger et a l 1995a, 1995b).
Specific cytotoxic activity was determined by comparing the average absorbance 
reading of the test samples with O/V to the absorbance of the O/V controls. Values were 
reported as % O/V control. Non-specific cytotoxicity was determined by comparing the 
average absorbance reading of the test samples without O/V with the absorbance of the 
negative control (medium only).
For the modification procedure, specific cytotoxicity was determined by comparing 
absorbance readings of the samples with tissue culture supernatants, O/V, and PbTx-2, 
with the absorbance readings of samples containing PbTx-2 and O/V, but no tissue 
culture supernatants. An increase in the absorbance of samples containing tissue culture 
supernatants was considered to be the result of neutralizing activity of the anti-PbTx-2 
antibodies on free PbTx-2.
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RESULTS
Fifteen female BALB/C mice were used for immunization in an attempt to produce 
monoclonal antibodies against PbTx-2 which could cross-react with ciguatoxin-related 
compounds. Table 1 shows the different protein conjugates used for immunization and 
the status for each mouse.
Table 1.Female BALB/C mice used for immunization.
Mouse# Protein conjugate used Status
1 LPH-PbTx-2 Used for fusion 1
2 LPH-PbTx-2 Used for fusion 2
3 LPH-PbTx-2 Used for fusion 3
4 LPH-PbTx-2 Used for fusion 3
5 KLH-PbTx-2 Never responded
6 KLH-PbTx-2 Never responded
7 KLH-PbTx-2 Used for fusion 4
8 KLH-PbTx-2 Used for fusion 5
9 KLH-PbTx-2 Never responded
10 KLH-PbTx-2 Used for fusion 6
11 KLH-PbTx-2 Used for fusion 7
12 BSA-PbTx-2 Used for fusion 8
13 BSA-PbTx-2 Used for fusion 9
14 BSA-PbTx-2 Used for fusion 10
15 BSA-PbTx-2 Used for fusion 11
Mice 5, 6, and 9 did not respond to the immunization of KLH-PbTx-2 protein 
conjugate. This is not unusual. In fact, this is why it is common to immunize several 
animals. The results of the mice which responded are summarized below for each fusion 
and by groups depending on the protein conjugate used for immunization.
Several conditions were changed in each fusion; therefore, general conditions will 
be summarized at the beginning of each fusion.
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A) LPH-PbTx-2
1. Fusion 1
The general conditions o f fusion 1 are summarized below:
• Myeloma cell line: Sp2/0-Agl4
• ELISA for screening: 50 pL volumes and ABTS for color development
• BSA-PbTx-2 prepared as described in Materials and Methods.
Mouse 1 was immunized with LPH-PbTx-2. Table 2 shows the immunization 
schedule.
Table 2.Immunization schedule for mouse 1 using LPH-Brevetoxin-2 (PbTx-2) for
preparation of anti-PbTx-2 antibodies.




1st immunization 100 pg ip + 100 pg sc FCAb 1 11
1st boost 100 pg ip + 100 pg sc FIAC 29 36
2nd boost 100 pg ip + 100 pg sc FIA 57 64
3rd boost 50 pg ip + 50 pg sc FIA 95 103
Final boost 50 pg ip None 127 131
a sc - subcutaneous; ip - intraperitoneal
b FCA - Freund’s complete adjuvant 
c FIA - Freund’s incomplete adjuvant
Figure 14 shows the response of mouse 1 after each injection with LPH- 
Brevetoxin-2. It is clear that the mouse was responding to repeated injections of the 
LPH-PbTx-2 conjugate. The secondary labeled antibody used for detection of mouse 
antibodies recognizes both the heavy and light chains of IgG antibodies; therefore, it 
may also recognize the constant light chains of IgM and IgA antibodies.
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Figure 14.Antibody production response of mouse 1 after each immunization with LPH- 
Brevetoxin-2 (PbTx-2). Plates were coated with BSA-PbTx-2 at 5 pg/mL. Each serum 
was diluted 1:1000. Goat anti-mouse IgG (H&L)-HRPO was diluted 1:5000. TMB was 
used for color development. Plotted points are the means of triplicate determinations.
Variation from the mean was typically 5% or less.
Since it was important to determine the presence of mouse anti-PbTx-2 IgG 
antibodies (preferred antibody isotype for use in an ELISA), the serum obtained the day 
of the fusion was serially diluted to determine its titer and detected using a y chain 
specific labeled antibody. The titer can be defined in different ways. For the purpose of 
this study it was defined as that dilution giving absorbance readings two times greater 
than the background levels (pre-immune serum diluted 1:100). Both the immune and 
pre-immune sera were tested using BSA and BSA-PbTx-2 coated plates, respectively, as 
controls. LPH coated plates were used to determine the response induced by the carrier 
protein in an effort to qualitatively compare this response to that of PbTx-2 (Figure 15).
The titer of IgG PbTx-2 antibodies in the serum collected the day of the fusion was 
1:102,400. This indicates that mouse anti-PbTx-2 IgGs were present, which correlates 
with the presence of activated B cells secreting antibodies o f the desired isotype and
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specificity. Since immune sera in BSA coated plates gave absorbance readings of less 
than 0.1, the response observed with BSA-PbTx-2 coated plates was due to antibodies 
reacting to some portion of the PbTx-2 molecule. The use of pre-immune serum with 
BSA-PbTx-2 coated plates gave absorbance readings of less than 0.1; therefore, the 
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Figure 15.Titer of serum collected the day of the fusion of mouse 1 immunized with 
LPH-Brevetoxin-2 (PbTx-2). Plates were coated with BSA-PbTx-2, BSA, and LPH at 5 
pg/mL. Goat anti-mouse IgG (y)-HRPO was diluted 1:5000. TMB was used for color 
development. Plotted points are the means of triplicate determinations. Variation from
the mean was typically 5% or less.
Even though the titer of anti-PbTx-2 IgG antibodies was high, it may be considered 
relatively low when compared with the concentration of antibodies against LPH, the 
carrier protein, which after a 1:409,600 dilution still showed a high absorbance. This 
may be a problem in the fusion process because the final boost activates not only B cells
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specific for PbTx-2, but also those specific for LPH. This problem cannot be avoided 
for PbTx-2, which is too small to elicit an immune response by itself. It should also be 
noted that there are B cells to an infinite  amount of compounds present at the same time. 
This may reduce the probability of fusing desired B cells.
To further assure that the response observed was due to mouse anti-PbTx-2 IgG 
antibodies, a competitive immunoassay (Materials and Methods) was performed in the 
serum obtained the day of the fusion. Serial dilutions of PbTx-2 (0.0012 to 160 pg/mL) 
were added to diluted serum (1:1000). The absorbance reading obtained when no PbTx- 
2 was added, was designated Ao. The competition curve was analyzed to determine the 
four parameters defining sigmoidal curves (a, b, c, d) as explained in Materials and 
Methods (Figure 16).
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Figure 16.Computer-generated best fit competition curve for serum collected the day of 
the fusion of mouse 1 (immunized with LPH-Brevetoxin-2 [PbTx-2]). Plates were 
coated with BSA-PbTx-2 at 5 pg/mL. Goat anti-mouse IgG (y)-HRPO was diluted 
1:5000. TMB was used for color development Plotted points are the means of duplicate 
determinations. Variation from the mean was typically 5% or less.
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As shown in Figure 16, mouse anti-PbTx-2 IgG antibodies were present in the 
serum obtained the day of the fusion. Should no specific antibodies have been present, 
no competition would have been observed. The concentration of free PbTx-2 reducing 
the response (A/Ao) by 50% (IC50) was 20.48 pg/mL.
This competition immunoassay proved the presence of mouse anti-PbTx-2 IgG 
antibodies only; however, to determine the specific IgG isotype(s) and if other isotypes 
specific for PbTx-2 were present, the serum obtained the day of the fusion was isotyped 
using an antigen-specific ELISA (Appendix B). Isotypes of LPH antibodies in the same 
serum were also determined. In addition, a capture isotyping ELISA (Appendix B) was 
performed to show that at the time of the fusion a high number of antibodies were 
present, which correlates with the presence of B cells specific for molecules other than 
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Figure 17. Antigen-specific and capture isotyping for serum collected the day of the 
fusion of mouse 1 (immunized with LPH-Brevetoxin-2 [PbTx-2]). Serum was diluted
1:1000 for testing.
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Figure 17 shows that IgGl and IgM antibodies specific for PbTx-2 were present the 
day of the fusion; a qualitative comparison of both isotypes shows the predominance of 
IgGl antibodies. In the case of LPH coated plates, IgGl and IgM anti-LPH antibodies 
were present. The capture isotyping ELISA detects all antibodies present in the serum, 
with no preference for their specificity. As expected, all isotypes were detected. This is 
because the mouse is constantly producing antibodies to protect itself from foreign 
compounds.
The fusion was performed four days after the last boost Sp2/0-Agl4 myeloma 
cells were used for fusion. The splenocytes cell suspension had a total of 8.0 x 107 cells. 
A 1:5 fusion ratio was selected; therefore, 1.6 x 107 myeloma cells were used. The 
mixed cells were suspended in 60 mL of conditioned media-HT to obtain a cell density 
of 1.6 x 106 cells/mL. Since 100 jiL were plated per well, the cell density was 1.6 x 105 
cells/well. A total of 6 plates was used. The feeding schedule after day 0 was followed 
as described in Materials and Methods.
The wells in the fusion plates showing growth were consecutively numbered 
among the 6 plates and screened. After screening of the wells showing hybridoma 
growth (349 wells), 12 wells were originally scored as positive. After expansion and 
rescreening, just 6 wells showed an absorbance at least twice the background. 
Therefore, the fusion efficiency was 1.7 %. Table 3 lists those fusion wells considered 
positive and the absorbance they showed after rescreening.
Each positive fusion well was cloned using the limiting dilution method. Seven 
days after cloning, the cloning plates (2/fusion well) were evaluated microscopically for 
the presence of colonies arising from 1 cell. When the selected cloning wells were at
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least 30% confluent, they were rescreened for antibody production. Since more than 1 
positive cloning well was obtained per fusion well, the criteria for selection of positive 
wells in cloning plates was to use only 2 to 4 wells containing a colony arising from a 
single cell and with a high absorbance. The numbers assigned to cloning wells are 
numbers given to wells containing single colonies among all the plates (12) used for 
cloning. Table 4 shows the absorbance of each cloning well the day it was expanded and 
its isotype.
Table 3.Wells derived from fusion 1 (mouse 1 immunized with LPH-Brevetoxin-2) 
selected for cloning. The ELISA for screening was performed using SO pL volumes, 
goat anti-mouse IgG (H&L)-HRPO at 1:1000 and ABTS for color development.
Fusion well 
number
Absorbance of fusion well 







Since all cloning wells within each group showed a similar response, a 
representative cloning well derived from each fusion well was selected for further 
studies. The criteria for selection was to use that well showing the highest absorbance in 
the screening test These selected cloning wells were expanded into a 25 cm2 tissue 
culture flask as described in Materials and Methods. The dialyzed protein solutions were 
used in a new ELISA to test the binding properties of the antibodies.
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Table 4.Cloning wells derived from fusion 1 (mouse 1 immunized with LPH- 
Brevetoxin-2). The ELISA for screening was performed using 50 pL volumes, goat anti­
mouse IgG (H&L)-HRPO at 1:1000 and ABTS for color development Isotyping was






cloning well the 
day of screening
















151 391 0.976 IgM




295 490 0.400 IgM
634 0.913 IgM
636 0.813 IgM
As part of the controls used for this ELISA, plates were coated not only with BSA- 
PbTx-2, but also with irrelevant proteins such as BSA, LPH, OVA, and KLH. The 
results of these assays showed non-specific positive responses. Figure 18 shows the 
results of this ELISA diluting the ammonium sulfate precipitates 1:100 and 1:1000. 
Cloning well 333 (derived from fusion well 7) contains antibodies specific for LPH, the 
protein used to conjugate PbTx-2 for immunizations. Therefore, the absorbance 
readings obtained through the screening process were due to non-specific binding of 
anti-LPH antibodies in the supernatant
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Figure 18. Ammonium sulfate precipitates of cloned hybridoma supernatants obtained 
from fusion 1 (mouse 1 immunized with LPH-Brevetoxin-2). Precipitates were diluted 
1:100 and 1:1000 for testing. Goat anti-mouse IgG (H&L)-HRPO was diluted 1:1000.
TMB was used for color development
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This non-specific binding occurs when the concentration of any antibody in the 
supernatant is high. The supernatants were not diluted for screening because the 
concentration of antibodies in supernatants is usually I to 10 pg/mL; therefore, if the 
screening method is not highly sensitive and then the supernatants are diluted, no 
absorbance would be measured. This may be a problem, as in this example, were non­
specific background was high. However, it is better to have false negatives than to 
discard possible specific clones because the supernatants were diluted too much and no 
absorbance was read.
The rest of the cloned wells contain IgM antibodies. Even though wells 119(530), 
151(391), and 295(634) gave high backgrounds, they also gave a noticeable higher 
absorbance reading for LPH. This means they recognize the immunizing protein used 
for conjugation of PbTx-2. Figure 17 showed that in fact anti-LPH IgM antibodies were 
present in the serum collected the day of the fusion. It is likely that these antibodies 
were shown to be positive because o f their high avidity.
Wells 88(10) and 287(604) gave almost the same absorbance with irrelevant 
proteins and even uncoated plates. It is then unlikely that the antibodies were in fact 
recognizing a similar region in all these proteins. The problem here was the nature of 
IgM antibodies (high avidity).
Figure 17 showed that anti-PbTx-2 and anti-LPH IgGl and IgM antibodies were 
present in the serum collected the day of the fusion, and a qualitative comparison shows 
that more LPH antibodies were present This may explain why antibodies to LPH were 
preferentially fused. The question now is why were IgM antibodies of unknown 
specificity detected. A possible explanation could be the presence of polyreactive
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antibodies or the high avidity of IgM molecules, topics which will be discussed in the 
Discussion of Results section.
The next step was to determine if the serum was behaving as hybridoma 
supernatants (binding to different proteins). When the titer of the serum was performed 
(Figure 15), it was determined that no antibodies against BSA were present the day of 
the fusion; but, as expected, antibodies against LPH were present However, it was 
important to incorporate the other irrelevant proteins used in Figure 18. Figure 19 shows 
the results of this experiment
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Figure 19.Response of serum collected the day of the fusion of mouse 1 (immunized 
with LPH-Brevetoxin-2 [PbTx-2]) with different coating antigens at 5 pg/mL. Serum 
was diluted 1:1000 for testing. Goat anti-mouse IgG (H&L)-HRPO was diluted 1:5000.
TMB was used for color development
As observed in Figure 19, the serum was reacting only to the components of the 
immunogen, that is LPH and PbTx-2. However, no specificity was observed to foreign
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antigens such as unconjugated B SA  or OVA or KLH. A  major disadvantage of 
monoclonal antibodies is that if there is cross-reactivity, it is likely to be high and hard 
to avoid. In polyclonal antibodies this may not be a problem, phenomenon observed in 
Figure 19, where antibodies giving high background were not detected.
To assure that no potential antibodies have been missed, the original supernatants 
(before cloning) collected just before freezing the cells were tested in a competitive 
assay using 20 pg/mL of PbTx-2 as a competitor (Figure 20).
Fusion well number
Figure 20.Competition assay using tissue culture supernatants from fusion 1 (mouse 1 
immunized with LPH-Brevetoxin-2 [PbTx-2]) and PbTx-2 at 20 pg/mL. Plates were 
coated with BSA-PbTx-2 at 5 pg/mL. Goat anti-mouse IgG (H&L>HRPO was diluted 
1:5000. TMB was used for color development
As expected, no competition was observed in the supernatants already confirmed to 
contain antibodies to LPH. For the rest of the IgM antibodies, this ELISA showed no
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competition or evidence of anti-PbTx-2 antibodies; therefore, this explains why no anti- 
PbTx-2 antibodies were obtained after cloning. To further reassure that no potential 
antibodies were discarded, a highly sensitive cytotoxicity assay was used. A standard 
curve with serial dilutions of PbTx-2 was prepared to test the effect of PbTx-2 on 
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PbTx-2 without O/V- 20 hrs
Figure 21 .Brevetoxin-2 (PbTx-2) standard curve using two incubation periods and 
ouabain/veratridine (O/V) dependence. Plotted points are the means of triplicate 
determinations. Variation from the mean was typically 5% or less.
Figure 21 shows that PbTx-2 produced a response that was both dose and time 
dependent. However, it is important to note that without ouabain and veratridine there
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was no cell death. This is because the toxin does not produce cell death by itself in the 
times of incubation used in the cytotoxicity assay. Therefore, the assay is dependent 
upon the presence of the sodium channel activator (veratridine) and the Na+-K+ pump 
inhibitor (ouabain).
To test if the IgM antibodies showing no apparent specificity towards PbTx-2 could 
inhibit the death of Neuro-2a cells when added together with PbTx-2, a single 
concentration was selected. If a high concentration is used, the antibodies may not be 
able to neutralize this activity; therefore, the lowest detectable concentration was used, /.
e., 0.25 ng PbTx-2 with 20 hrs incubation. To assure that the concentrated supernatants 
were not toxic to the cells in a non-specific form, the absorbance readings were 
compared to those of cells receiving no toxin (just regular medium). It was found that 
no cell death occurred non-specifically. For the specific cytotoxicity assay, the 
concentrated ammonium sulfate precipitates were used. It was found that none of the 
antibodies tested neutralized the activity of PbTx-2 (data not shown). This was expected 
since PbTx-2 has a very high affinity for the sodium channel and antibodies in the 
supernatants would need to have an extremely high affinity to compete. If a high affinity 
antibody towards PbTx-2 would have been present in the first place, it would have been 
detected with the ELISA analyses conducted earlier. Even tough the antibodies were 
tested in a concentrated form to possibly compensate for the low affinity, no effect was 
observed. It can be concluded that these IgM antibodies do not recognize PbTx-2.
Since mouse anti-PbTx-2 IgG antibodies were present in the serum of mouse 1, 
then it was just a matter of statistical probability. The next step was to perform a new 
fusion following the same conditions used for fusion 1.
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2. Fusion 2
The general conditions of fusion 2 are summarized below:
• Myeloma cell line: Sp2/0-Agl4
• ELISA for screening: 50 pL volumes and ABTS for color development
• BSA-PbTx-2 prepared as described in Materials and Methods.
For this fusion, mouse 2 immunized with LPH-PbTx-2 was used. The 
immunization schedule is shown in Table 5.
Table 5.hnmunization schedule for mouse 2 using LPH-Brevetoxin-2 (PbTx-2) for
preparation of anti-PbTx-2 antibodies.




1st immunization 100 pg ip + 100 pg sc FCAb 1 11
1st boost 100 pg ip + 100 pg sc FIAC 29 36
2nd boost 100 pg ip + 100 pg sc FIA 57 64
3rd boost 50 pg ip + 50 pg sc FIA 95 103
4th boost 50 pg ip FIA 218 225
5th boost 50 pg ip FIA 244 251
Final boost 50 pg ip None 284 287
a sc - subcutaneous; ip - intraperitoneal 
b FCA - Freund’s complete adjuvant 
0 FIA - Freund’s incomplete adjuvant
Figure 22 shows the development of the immune response for mouse 2 after each 
injection with LPH-Brevetoxin-2. It is clear that mouse 2 was responding to repeated 
injections of the LPH-PbTx-2 conjugate. This ELISA detects IgG, IgM, and IgA 
antibodies.
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Figure 22.Antibody production response of mouse 2 after each immunization with LPH- 
Brevetoxin-2 (PbTx-2). Plates were coated with BSA-PbTx-2 at 5 pg/mL. Each serum 
was diluted 1:1000. Goat anti-mouse IgG (H&L)-HRPO was diluted 1:5000. TMB was 
used for color development Plotted points are the means of triplicate determinations. 
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Figure 23.Titer of serum collected the day o f the fusion of mouse 2 immunized with 
LPH-Brevetoxin-2 (PbTx-2). Plates were coated with BSA-PbTx-2, BSA, and LPH at 5 
pg/mL. Goat anti-mouse IgG (y)-HRPO was diluted 1:5000. TMB was used for color 
development Plotted points are the means of triplicate determinations. Variation from
the mean was typically 5% or less.
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To determine the titer of mouse anti-PbTx-2 IgG antibodies only (preferred 
antibody isotype for use in an ELISA), the serum obtained the day of the fusion was 
serially diluted and detected with secondary antibodies specific for the y heavy chain of 
murine antibody molecules. Controls included immune and pre-immune sera in BSA 
and BSA-PbTx-2 coated plates, respectively, and LPH coated plates to determine the 
response induced by the carrier protein (Figure 23).
The titer of PbTx-2 IgG antibodies in the serum collected the day of the fusion was 
1:51,200, confirming the presence of antibodies of desired specificity and isotype. 
Immune sera in BSA coated plates and pre-immune serum in BSA-PbTx-2 coated plates 
gave absorbance readings of less than 0.1; therefore, the response observed in Figure 23 
for the BSA-PbTx-2 coated plates was due to antibodies reacting to some portion of the 
PbTx-2 molecule and to antibodies present only after injections of the conjugate were 
given to the mouse. Once again, the concentration of anti-LPH antibodies was 
remarkably higher to that of PbTx-2, phenomenon which may cause a decrease in the 
fusion efficiency.
To confirm that the response observed was the result of mouse anti-PbTx-2 IgG 
antibodies, competition studies were performed in the serum obtained the day of the 
fusion. Serial dilutions of PbTx-2 were incubated with diluted serum (1:1000) using 
BSA-PbTx-2 coated plates (Figure 24). Mouse anti-PbTx-2 IgG antibodies were present 
in the serum collected the day of the fusion. The I C 5 0  was 2.9 pg/mL. This assay 
showed that mouse anti-PbTx-2 IgG antibodies were present in the serum; however, to 
determine the specific IgG isotype(s) and if other isotypes specific for PbTx-2 were 
present, an antigen-specific isotyping assay was used (Appendix B).
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Figure 24.Computer-generated best fit competition curve for serum collected the day of 
the fusion of mouse 2 (immunized with LPH-Brevetoxin-2 [PbTx-2]). Plates were 
coated with BSA-PbTx-2 at 5 pg/mL. Goat anti-mouse IgG (y)-HRPO was diluted 
1:5000. TMB was used for color development. Plotted points are the means of duplicate 
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Figure 25 Antigen-specific and capture isotyping for serum collected the day of the 
fusion of mouse 2 (immunized with LPH-Brevetoxin-2 [PbTx-2]). Serum was diluted
1:1000 for testing.
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Isotypes of LPH antibodies in the same serum were also determined, together with 
the isotypes present in the whole serum (Appendix B). The results of these isotyping 
experiments are summarized in Figure 25. It shows that mainly IgGl and IgM 
antibodies specific for PbTx-2 were present in the serum collected the day of the fusion; 
a qualitative comparison of both isotypes shows the prevalence of IgGl antibodies. In 
the case of LPH coated plates, IgGl, IgG2a, and IgM antibodies predominated. As 
expected, ail isotypes were detected in the whole serum.
The fusion was performed three days after the last immunization. Sp2/0-Agl4 
myeloma cells were used for fusion. The splenocytes cell suspension had a total of 1.4 x 
108 cells. A 1:5 fusion ratio was selected; therefore, 2.8 x 107 myeloma cells were used. 
The mixed cells were suspended in 100 mL of conditioned media-HT to obtain a cell 
density of 1.7 x 106 cells/mL. Since 100 pL were plated per well, the cell density was
1.7 x 105 cells/well. A total of 10 plates was used. The feeding schedule after day 0 was 
followed as described in Materials and Methods.
After approximately 14 days, supernatants were screened for anti-PbTx-2 antibody 
production. However, after three screenings of the wells showing growth (80), no 
positive wells were detected. The fusion itself may have not worked properly, since 
from 960 wells usually more than 80 wells would be expected to show cell growth.
Even though no antibody producing cells were obtained in this fusion, the serum 
was analyzed in an ELISA using different coating proteins just to indicate that it was 
behaving properly (Figure 26).
Figure 26 shows that the serum collected the day of the fusion was reacting to 
PbTx-2 and LPH, phenomenon previously shown in Figures 23 and 25. Therefore, it
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was again a matter of statistical probability. A new fusion was necessary using the same 
conditions for fusion 2, but collecting two spleens to increase the probability of 
selecting desired hybridomas.
1.5
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Figure 26.Response of serum collected the day of the fusion of mouse 2 ( im m u n iz e d  
with LPH-Brevetoxin-2 [PbTx-2]) with different coating antigens at 5 fi.g/mL. Serum 
was diluted 1:1000 for testing. Goat anti-mouse IgG (H&L)-HRPO was diluted 1:5000.
TMB was used for color development.
3. Fusion 3
The general conditions of fusion 3 are summarized below:
• Myeloma cell line: Sp2/0-Agl4
• ELISA for screening: 50 |xL volumes and ABTS for color development
• BSA-PbTx-2 prepared as described in Materials and Methods.
Mice 3 and 4 were immunized with LPH-Brevetoxin-2. The immunization 
schedule is shown in Table 6.
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Table 6.hnmunization schedule for mice 3 and 4 using LPH-Brevetoxin-2 (PbTx-2) for
preparation of anti-PbTx-2 antibodies.




1st immunization 100 fig ip + 100 pg sc FCAb 1 11
1st boost 100 pg ip + 100 pg sc FIAC 29 36
2nd boost 100 pg ip + 100 pg sc FIA 57 64
3rd boost 50 pg ip + 50 pg sc FIA 95 103
4th boost 50 pgip FIA 218 225
5th boost 50 pgip FIA 244 251
Final boost 50 pgip None 306 309
a sc - subcutaneous; ip - intraperitoneal
b FCA - Freund’s complete adjuvant 
c FIA - Freund’s incomplete adjuvant
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Figure 27.Antibody production response of mice 3 and 4 after each immunization with 
LPH-Brevetoxin-2 (PbTx-2). Plates were coated with BSA-PbTx-2 at 5 pg/mL. Each 
serum was diluted 1:1000. Goat anti-mouse IgG (H&L)-HRPO was diluted 1:5000. 
TMB was used for color development Plotted points are the means of triplicate 
determinations. Variation from the mean was typically 5% or less.
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The immune response for mouse 4  seemed unusual. It reached a maximum and 
later decreased after repeated injections. This may be due to the presence of anti-PbTx-2 
antibodies in the serum still in circulation at the time of the last injections. If this is true, 
those antibodies remaining in circulation bind to the immunogen used in the boost, and 
so they decrease the amount of immunogen available for activation of new B cells. The 
immune response for mouse 3 was typical, increasing after each injection. This assay 
detects the presence of either IgG, IgM or IgA murine antibodies.
The presence of mouse anti-PbTx-2 IgG and anti-LPH IgG antibodies, was 
determined by titrating the serum collected the day of the fusion and using a secondary 
labeled antibody specific for the y heavy chain of the murine antibody molecules. BSA 
coated plates were used as a control with immune sera, and BSA-PbTx-2 coated plated 
with pre-immune sera. LPH coated plates were used to determine the response induced 
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Figure 28.Titer of serum collected the day of the fusion of mouse 3 immunized with 
LPH-Brevetoxin-2 (PbTx-2). Plates were coated with BSA-PbTx-2, BSA, and LPH at 5 
pg/mL. Goat anti-mouse IgG (y)-HRPO was diluted 1:5000. TMB was used for color 
development. Plotted points are the means of triplicate determinations. Variation from
the mean was typically 5% or less.
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Figure 29.Titer of serum collected the day of the fusion of mouse 4 immunized with 
LPH-Brevetoxin-2 (PbTx-2). Plates were coated with BSA-PbTx-2, BSA, and LPH at 5 
fxg/mL. Goat anti-mouse IgG (y)-HRPO was diluted 1:5000. TMB was used for color 
development Plotted points are the means of triplicate determinations. Variation from
the mean was typically 5% or less.
The titer of PbTx-2 IgG antibodies in the serum collected the day of the fusion was 
1:25,600 for mouse 3 and 1:6,400 for mouse 4. No absorbance readings higher than 0.1 
were detected for immune sera in BSA coated plates or pre-immune sera in BSA-PbTx- 
2 coated plates; therefore, the response observed with immune sera in BSA-PbTx-2 
coated plates was due to antibodies recognizing the PbTx-2 molecule only and to 
antibodies present only after injection of the LPH-PbTx-2 conjugate. In both mice, a 
high concentration of LPH antibodies was observed.
To prove that the response observed was due to mouse anti-PbTx-2 IgG antibodies, 
competition studies were performed in the serum obtained the day of the fusion. Serial 
dilutions of PbTx-2 were incubated with mouse serum 3 (1:400) and mouse serum 4 
(1:200) (Figure 30). Mouse anti-PbTx-2 IgG antibodies were present in the sera of these 
mice collected the day of the fusion. The I C 5 0  was 7.14 jxg/mL for mouse 3 and 0.14
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|ig/mT. for mouse 4. It is important to mention that even though the immune response of 
mouse 4 decreased with time, specific anti-PbTx-2 IgG antibodies were present and had 
a higher affinity (lower IC50) for the free toxin as compared with mouse 3, which 
showed a higher titer but a higher IC50. Therefore, in these mice, the titer did not 
correlate with affinity.
Figure 3 0 .Computer-generated best fit competition curves for sera collected the day of 
the fusion of mice 3 and 4 (immunized with LPH-Brevetoxin-2 [PbTx-2]). Plates were 
coated with BSA-PbTx-2 at 5 pg/mL. Goat anti-mouse IgG (y)-HRPO was diluted 
1:5000. TMB was used for color development Plotted points are the means of duplicate 
determinations. Variation from the mean was typically 5% or less.
The competition assay (Figure 30) showed that mouse anti-PbTx-2 IgG antibodies 
were present in the sera collected the day of the fusion; however, it was important to 
determine the specific IgG isotype(s) and if other isotypes specific for PbTx-2 were 
present This was determined using an antigen-specific isotyping ELISA (Appendix B). 
Isotypes of LPH antibodies were also determined. In addition, a capture isotyping 
ELISA (Appendix B) was performed to show that at the time of the fusion a high
e
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number of antibodies of unknown specificity were present The results of these 
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Figure 31. Antigen-specific and capture isotyping for serum collected the day of the 
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Figure 32.Antigen-specific and capture isotyping for serum collected the day of the 
fusion of mouse 4 (immunized with LPH-Brevetoxin-2 [PbTx-2]). Serum was diluted
1:1000 for testing.
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Figures 31 and 32 show that IgGl antibodies specific for PbTx-2 were present in 
the serum collected the day of the fusion of mice 3 and 4. In the case of LPH coated 
plates, IgGl and IgM antibodies recognizing LPH were detected. The capture isotyping 
ELISA detects all antibodies present in the serum, and, as expected, all isotypes were 
detected.
The fusion was performed three days after the last immunization. Sp2/0-Agl4 
myeloma cells were used for fusion. The splenocytes cell suspension had a total of 2.2 x 
108 cells. A 1:5 ratio was selected; therefore, 4.4 x 107 myeloma cells were used. The 
mixed cells were suspended in 150 mL of conditioned media-HT to get a cell density of
1.8 x 106 cells/mL. Since 100 pL were plated per well, the cell density was 1.8 x 105 
cells/well. A total of 15 plates were used, from which 513 wells showed growth and 17 
supernatants were initially scored as positive. After expansion and rescreening, just 7 
wells showed an absorbance at least twice the background. Therefore, the fusion 
efficiency was 1.4 %. Table 7 lists those fusion wells considered positive and the 
absorbance they showed after rescreening.
Table 7.Wells derived from fusion 3 (mice 3 and 4 immunized with LPH-Brevetoxin-2) 
selected for cloning. The ELISA for screening was performed using 50 pL volumes, 
goat anti-mouse IgG (H&L)-HRPO at 1:1000 and ABTS for color development
Fusion well 
number
Absorbance of fusion well 
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Each of the positive fusion wells was cloned and evaluated for the presence of 
single colonies as previously described. Selected wells were rescreened for antibody 
production and those showing the highest absorbance were selected for expansion, 
isotyping, and freezing. Table 8 shows the absorbance of each cloning well the day it 
was expanded and its isotype.
Table 8.Cloning wells derived from fusion 3 (mice 3 and 4  immunised with LPH- 
Brevetoxin-2). The ELISA for screening was performed using 50 fiL volumes, goat anti­
mouse IgG (H&L)-HRPO at 1:1000 and ABTS for color development Isotyping was






cloning well the 
day of screening
Isotype of cloned 
wells
126 4 0.342 IgM
83 0.532 IgM
167 15 0.463 IgM
68 0.621 IgM
282 7 0.323 IgM
34 0.632 IgM
286 53 0.823 IgM
124 0.725 IgM
321 92 0.259 IgM
132 0.356 IgM
451 29 0.543 IgM
78 0.635 IgM
476 145 0.287 IgM
163 0.321 IgM
A representative cloning well obtained from each fusion well was selected for 
further studies. Selected hybridomas were expanded in a 25 cm2 tissue culture flask, and 
the antibodies were precipitated using ammonium sulfate. The dialyzed protein 
solutions were used in a new ELISA to test the binding properties of the antibodies.
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As part of the controls used for this ELISA, plates were coated with BSA-PbTx-2 
but also with irrelevant proteins such as BSA, LPH, OVA, and KLH. Unexpected 
results were found again. Figure 33 shows the results of this ELISA diluting the 
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Fusion well number (Selected cloning well number)
Figure 33. Ammonium sulfate precipitates of cloned hybridoma supernatants obtained 
from fusion 3 (mice 3 and 4 immunized with LPH-Brevetoxin-2). Precipitates were 
diluted 1:100 and 1:1000 for testing. Goat anti-mouse IgG (H&L)-HRPO was diluted 
1:1000. TMB was used for color development
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Figure 33 shows that all cloning wells tested are of the IgM isotype and present 
high avidity, as demonstrated with binding even in uncoated plates. A possible 
explanation is that these antibodies come from non-specific B cells fused with myeloma 
cells. As shown in Figures 31 and 32, IgM antibodies were present in the whole serum. 
Therefore, these antibodies belong to some B cells present in the spleens of these mice. 
It is certain that these antibodies are not specific for the proteins tested in this assay; 
however, the only way to know their specificity would be to test the supernatants with 
all the compounds that may be foreign to the mice, which is impossible and 
unnecessary.
To determine if the sera were reacting as the hybridoma supernatants, the same 
coating proteins were used (Figure 34).
EH1 Mouse 3 
H  Mouse 4
BSA BSA-PbTx-2 OVA OVA-PbTx-2 KLH LPH 
Coating antigen
Figure 34.Response of sera collected the day of the fusion of mice 3 and 4 (immunised 
with LPH-Brevetoxin-2 [PbTx-2]) with different coating antigens at 5 pg/mL. Serum 
was diluted 1:1000 for testing. Goat anti-mouse IgG (H&L)-HRPO was diluted 1:5000.
TMB was used for color development
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As observed in Figure 34, both sera were reacting to the components of the 
immunogen, that is LPH and PbTx-2. However, no specificity was observed for foreign 
antigens such as unconjugated BSA or OVA, or KLH. It is important to note the high 
concentration of LPH antibodies present in the sera.
To assure that no potential antibodies have been missed, the original supernatants 
(before cloning) collected just before freezing the cells were tested in a competitive 
assay using 20 pg/inL of PbTx-2 as a competitor (Figure 35).
Fusion well nnmber
Figure 35.Competition assay using tissue culture supernatants from fusion 3 (mice 3 and 
4 immunized with LPH-Brevetoxin-2 [PbTx-2]) and PbTx-2 at 20 pg/mL. Plates were 
coated with BSA-PbTx-2 at 5 pg/mL. Goat anti-mouse IgG (H&L)-HRPO was diluted 
1:5000. TMB was used for color development.
None of the supernatants showed competition with free PbTx-2; therefore, this 
explains why no anti-PbTx-2 antibodies were obtained after cloning. To further reassure 
that no potential antibodies were discarded, a highly sensitive modified cytotoxicity
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assay was used to test if  anti-PbTx-2 antibodies were present in the tissue culture 
supernatan ts. As expected, the modified cy to tox icity  assay confirmed that no antibodies 
specific for PbTx-2 were present in the concentrated tissue culture supernatants (data 
not shown).
This fusion yielded no specific antibodies for PbTx-2. Several IgM antibodies of 
unknown specificity were detected because of their high avidity. The next step was to 
perform a new fusion, but now using a new immunogen (KLH-PbTx-2) to determine if 
it was more likely to obtain the desired antibodies, and a different myeloma cell line.
B) KLH-PbTx-2
1. Fusion 4
The general conditions of fusion 4 are summarized below:
• Myeloma cell line: NS-1
• ELISA for screening: 50 pL volumes and ABTS for color development
• BSA-PbTx-2 prepared as described in Materials and Methods.
For this fusion, mouse 7 was used. It was immunized with KLH-Brevetoxin-2. The 
immunization schedule is shown in Table 9. Figure 36 shows the development of the 
immune response of mouse 7 after each injection with KLH-Brevetoxin-2. Mouse 7 was 
responding to repeated injections of the KLH-PbTx-2 conjugate. These anti-PbTx-2 
antibodies could be IgG, IgM, and/or IgA. To determine the presence and relative 
concentration o f mouse anti-PbTx-2 IgG antibodies only, the serum obtained the day of 
the fusion was serially diluted and was detected using a secondary labeled antibody 
specific for the y chain of murine antibodies. BSA and BSA-PbTx-2 coated plates were
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used as controls using immune and pre-immune sera, respectively. KLH coated plates 
were used to determine the response induced by the carrier protein (Figure 37).
Table 9.Immunization schedule for mouse 7 using KLH-Brevetoxin-2 (PbTx-2) for
preparation of anti-PbTx-2 antibodies.




1st immunization 100 pg ip + 100 pg sc FCA6 1 8
1st boost lOOpgip FIAC 28 35
2nd boost 100 pg ip FIA 56 63
3rd boost 100 pg ip FIA 77 84
4th boost 100 pg ip FIA 98 105
Final boost _ 5 0 j s u b ---------- None 117 120
a sc - subcutaneous; ip - intraperitoneal 
b FCA - Freund’s complete adjuvant 
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Figure 36 Antibody production response of mouse 7 after each immunization with 
KLH-Brevetoxin-2 (PbTx-2). Plates were coated with BSA-PbTx-2 at 5 pg/mL. Each 
serum was diluted 1:1000. Goal anti-mouse IgG (H&L)-HRPO was diluted 1:5000. 
TMB was used for color development. Plotted points are the means of triplicate 
determinations. Variation from the mean was typically 5% or less.
110






1/400 1/25600 1/102400 1/4096001/100 1/1600 1/6400
BSA-PbTx-2
1/200 1/800 1/3200 1/12800
Serum dilution
1/51200 1/204800
Figure 37.Titer of serum collected the day of the fusion of mouse 7 immunized with 
KLH-Brevetoxin-2 (PbTx-2). Plates were coated with BSA-PbTx-2, BSA, and KLH at 
5 ng/mL. Goat anti-mouse IgG (y)-HRPO was diluted 1:5000. TMB was used for color 
development Plotted points are the means of triplicate determinations. Variation from
the mean was typically 5% or less.
The titer of anti-PbTx-2 IgG antibodies in the serum collected the day of the fusion 
was 1:25,600. This indicates that mouse anti-PbTx-2 IgGs were present in a relatively 
high concentration. Both control plates gave absorbance readings of less than 0.1. This 
suggests that the specific response observed in BSA-PbTx-2 coated plates using 
immune serum was due to antibodies reacting to some epitope in the PbTx-2 molecule 
only and that those antibodies were not present in the mouse before immunizations. 
KLH coated plates detected the presence of a high concentration of anti-KLH IgG 
antibodies.
To further affirm that the response observed was due to mouse anti-PbTx-2 IgG 
antibodies, competition studies were performed in the serum obtained the day of the 
fusion. Diluted serum (1:500) was incubated with serial dilutions of PbTx-2 using BSA- 
PbTx-2 coated plates (Figure 38).
I l l
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Figure 3 8. Computer-generated best fit competition curve for serum collected the day of 
the fusion of mouse 7 (immunized with KLH-Brevetoxin-2 [PbTx-2]). Plates were 
coated with BSA-PbTx-2 at 5 pg/mL. Goat anti-mouse IgG (y)-HRPO was diluted 
1:5000. TMB was used for color development. Plotted points are the means of duplicate 
determinations. Variation from the mean was typically 5% or less.
As shown in Figure 38, mouse anti-PbTx-2 IgG antibodies were present in the 
serum collected the day of the fusion. In fact, these antibodies seem to have a high 
affinity for free PbTx-2, which can be deduced from the low concentration of free 
PbTx-2 necessary to reach 50% competition (IC50 0.09 pg/mL).
The competition assay (Figure 38) showed that mouse anti-PbTx-2 IgG antibodies 
were present in the serum. To know the specific IgG isotype(s) and if other isotypes 
specific for PbTx-2 were present, the serum obtained the day of the fusion was isotyped 
using an antigen-specific ELISA (Appendix B). Isotypes of KLH antibodies were also 
determined. In addition, a capture isotyping ELISA was performed to determine all 
isotypes present in the whole serum (Appendix B). The results of these isotyping 
experiments are summarized in Figure 39.
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Figure 39 Antigen-specific and capture isotyping for serum collected the day of the 
fusion of mouse 7 (immunized with KLH-Brevetoxin-2 [PbTx-2]). Serum was diluted
1:1000 for testing.
Figure 39 reveals that IgGl, IgG3, and IgM antibodies specific for PbTx-2 were 
present in the serum collected the day of the fusion; a qualitative comparison of these 
isotypes shows the predominance of IgGl antibodies. In the case of KLH coated plates, 
IgGl, IgG2a, IgG2b, IgG3, and IgM antibodies were present. The capture isotyping 
ELISA detects all antibodies present in the whole serum, with no preference for their 
specificity. As expected, all isotypes were detected.
The fusion was performed three days after the last immunization. NS-1 myeloma 
cells were used for fusion. The splenocytes cell suspension had a total of 9.2 x 107 cells. 
A 1:5 ratio was selected; therefore, 1.8 x 107 myeloma cells were used. The mixed cells 
were suspended in 55 mL of conditioned media-HT to get a cell density of 2 x 106 
cells/mL. Since 100 pL were plated per well, the cell density was 2 x 10s cells/well. A 
total of 5.5 plates was used, from which 403 wells showed growth, and initially 10 wells
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were scored as positive. After expansion and rescreening, just 6 wells showed an 
absorbance at least twice the background. Therefore, the fusion efficiency was 1.5 %. 
Table 10 lists those fusion wells considered positive and the absorbance they showed 
after rescreening.
Table 10.Wells derived from fusion 4 (mouse 7 immunized with KLH-Brevetoxin-2) 
selected for cloning. The ELISA for screening was performed using 50 pL volumes, 
goat anti-mouse IgG (H&L)-HRPO at 1:1000 and ABTS for color development.
Fusion well 
number
Absorbance of fusion well 







Each of the positive fusion wells was cloned, and selected clones were expanded, 
isotyped, and frozen (Table 11). The numbers assigned to cloning wells were numbers 
given to wells containing single colonies among the 12 plates used for cloning.
A representative cloning well (derived from each fusion well) showing the highest 
absorbance was selected for further studies. Hybridoma cells were expanded in a 25 cm2 
tissue culture flask, and the antibodies were precipitated using ammonium sulfate. The 
dialyzed protein solutions were used in a new ELISA to test the binding properties of 
the antibodies. As part of the controls used for this ELISA, plates were coated with 
BSA-PbTx-2 but also using irrelevant proteins such as BSA, LPH, OVA, and KLH.
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Once again, unexpected results were found. Figure 40 shows the results of this ELISA 
diluting the ammonium sulfate precipitates 1:100 and 1:1000.
Table 11 .Cloning wells derived from fusion 4 (mouse 7 immunized with KLH- 
Brevetoxin-2). The ELISA for screening was performed using 50 pL volumes, goat anti­
mouse IgG (H&L)-HRPO at 1:1000 and ABTS for color development Isotyping was
performed using a commercial k it
Fusion well Cloning well Absorbance of Isotype of cloned
number number cloning well the wells
day of screening
21 37 0.740 IgM
40 1.559 IgM
83 24 0.703 IgM
29 0.785 IgM
106 0.647 IgM
91 47 0.595 IgM
196 70 0.572 IgM
328 115 1.123 IgM
154 0.893 IgM
343 2 1.020 IgM
92 0.847 IgM
124 1.597 IgM
Wells 21(40), 91(47), 328 (115), and 343(124) contained antibodies specific for the 
protein used to conjugate PbTx-2 (KLH); therefore, the absorbance readings obtained 
through the screening process were due to non-specific binding of anti-KLH antibodies 
in the supernatants to the plate.
Wells 83(29) and 196(70) gave almost the same absorbance with irrelevant proteins 
and even uncoated plates. It is then unlikely that the antibodies were recognizing some 
region of all these proteins. This problem could be due to the nature of IgM antibodies 
(high avidity).
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Figure 40. Ammonium sulfate precipitates of cloned hybridoma supernatants obtained 
from fusion 4 (mouse 7 immunized with KLH-Brevetoxin-2). Precipitates were diluted 
1:100 and 1:1000 for testing. Goat anti-mouse IgG (H&L)-HRPO was diluted 1:1000.
TMB was used for color development
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At this point, it was important to determine if  the serum was reacting as the 
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Coating antigen
KLH LPH
Figure 41 .Response of serum collected the day o f the fusion of mouse 7 (immunized 
with KLH-Brevetoxin-2 [PbTx-2]) with different coating antigens at 5 pg/mL. Serum 
was diluted 1:1000 for testing. Goat anti-mouse IgG (H&L)-HRPO was diluted 1:5000.
TMB was used for color development
As shown in Figure 41, the serum was reacting to the constituents of the 
immunogen, that is KLH and PbTx-2. However, no reaction was observed for foreign 
antigens such as unconjugated BSA or OVA, or LPH.
To assure that no potential antibodies have been missed, the original supernatants 
(before cloning) collected just before freezing the cells were tested in a competitive 
assay using 20 pg/mL of PbTx-2 as a competitor (Figure 42).
No competition was observed in any of the supernatants tested. Those containing 
antibodies to KLH were expected to lack competition activity towards free PbTx-2. For
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the rest of the IgM antibodies, this ELISA showed no evidence of anti-PbTx-2 
antibodies.
Fusion well number
Figure 42.Compedtion assay using tissue culture supernatants from fusion 4 (mouse 7 
immunized with KLH-Brevetoxin-2 [PbTx-2]) and PbTx-2 at 20 [ig/mL. Plates were 
coated with BSA-PbTx-2 at 5 pg/mL. Goat anti-mouse IgG (H&L)-HRPO was diluted 
1:5000. TMB was used for color development.
A sensitive cytotoxicity assay was used to assure that no potential supernatants 
were discarded. A standard curve showing the effect of PbTx-2 on Neuro-2a cells was 
reported in fusion 1 (Figure 21). A modified cytotoxicity assay procedure (Materials 
and Methods) would test for the potential neutralizing activity of anti-PbTx-2 
antibodies, if  they were present However, none of the supernatants tested neutralized 
the activity of free PbTx-2 (data not shown). This was expected since PbTx-2 has a very 
high affinity for the sodium channel and antibodies in the supernatants would need to 
have a high affinity to compete for PbTx-2.
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Since mouse anti-PbTx-2 IgG antibodies were present in the serum of mouse 7, B 
cells would have been expected to fuse; however, these hybridomas were either lost due 
to overgrowth of non-producer cells or fibroblasts, or loss of specific chromosomes. 
They may have not been present in the first place. The presence of non-specific binding 
led to the selection of antibodies of unrelated specificity. The next step was to perform a 
new fusion following the same conditions used for fusion 4, but using Sp2/0-Agl4 
myeloma cells again.
2. Fusion 5
The general conditions of fusion 5 are summarized below:
• Myeloma cell line: Sp2/0-Agl4
• ELISA for screening: 50 pL volumes and ABTS for color development
• BSA-PbTx-2 prepared as described in Materials and Methods.
This fusion was performed using mouse 8 which was immunized with KLH- 
Brevetoxin-2. The immunization schedule is shown in Table 12.
Table 12.1mmunization schedule for mouse 8 using KLH-Brevetoxin-2 (PbTx-2) for
preparation of anti-PbTx-2 antibodies.




1st immunization 100 pg ip + 100 pg sc FCAb 1 8
1st boost 100 pg ip FIAC 28 35
2nd boost 100 pg ip FIA 49 56
Final boost 100 pg ip None 93 97
“ sc - subcutaneous; ip - intraperitoneal 
b FCA - Freund’s complete adjuvant 
c FIA - Freund’s incomplete adjuvant
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Figure 43 Antibody production response of mouse 8 after each immunization with 
KLH-Brevetoxin-2 (PbTx-2). Plates were coated with BSA-PbTx-2 at 5 pg/mL. Each 
serum was diluted 1:1000. Goat anti-mouse IgG (H&L>HRPO was diluted 1:5000.
TMB was used for color development Plotted points are the means of triplicate 
determinations. Variation from the mean was typically 5% or less.
Figure 43 shows that mouse 8 responded to consecutive injections of KLH-PbTx-2. 
Antibodies detected in this assay may be IgG, IgM, and/or IgA. Their detection was due 
to the fact that the secondary labeled antibody used for detection of murine antibodies 
was raised against the whole IgG molecule. Therefore, they could cross-react with the 
constant regions of the light chains of IgM and IgA antibodies.
Since it was important to determine the presence of mouse anti-PbTx-2 IgG 
antibodies and their relative concentration, the serum obtained the day of the fusion was 
serially diluted to determine its titer and detected using a secondary labeled antibody 
specific for y constant chains of murine antibodies (Figure 44). Control plates were used
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Figure 44.Titer of serum collected the day of the fusion of mouse 8 immunized with 
KLH-Brevetoxin-2 (PbTx-2). Plates were coated with BSA-PbTx-2, BSA, and KLH at 
5 pg/mL. Goat anti-mouse IgG (y)-HRPO was diluted 1:1000. TMB was used for color 
development Plotted points are the means of triplicate determinations. Variation from
the mean was typically 5% or less.
The titer of anti-PbTx-2 IgG antibodies in the serum collected the day of the fusion 
was 1:51,200. Since immune sera in BSA coated plates gave absorbance readings of less 
than 0.1, the response observed was the result of antibodies reacting to some epitope in 
the PbTx-2 molecule. The use of pre-immune serum in BSA-PbTx-2 coated plates gave 
absorbance readings of less than 0.1; therefore, the response observed in BSA-PbTx-2 
coated plates with immune serum (Figure 44) was the result of antibodies produced after 
injections of KLH-PbTx-2. If PbTx-2 antibodies had been present before 
immunizations, this control plate would have given absorbances higher than 0.1.
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KLH coated plates showed the presence of a high concentration of anti-KLH IgG 
antibodies. A qualitative comparison of anti-KLH and anti-PbTx-2 IgG antibodies 
demonstrates that the latter are present in a lower proportion. This was expected because 
the response o f the mouse was directed mainly towards the carrier protein due to its 
size.
To assure that the response observed was due to mouse anti-PbTx-2 IgG antibodies 
in the serum, competition studies were performed in the serum by incubating serial 
dilutions of PbTx-2 with diluted serum (1:500) (Figure 45).
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Figure 45.Computer-generated best fit competition curve for serum collected the day of 
the fusion of mouse 8 (immunized with KLH-Brevetoxin-2 [PbTx-2]). Plates were 
coated with BSA-PbTx-2 at 5 pg/mL. Goat anti-mouse IgG (y)-HRPO was diluted 
1:5000. TMB was used for color development. Plotted points are the means of 
duplicate determinations. Variation from the mean was typically 5% or less.
As shown in Figure 45, increasing concentrations of free PbTx-2 resulted in higher 
competition for the antibodies present in the serum. The I C 5 0  was 8.41 pg/mL. To
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determine the specific IgG isotype(s) and if other isotypes specific for PbTx-2 were 
present in the serum, an antigen-specific isotyping ELISA was used (Appendix B). 
Isotypes of KLH antibodies were also determined. In addition, a capture isotyping 
ELISA was performed to determine which isotypes were present in the whole serum 
(Appendix B). The results of these isotyping experiments are summarized in Figure 46.
EH Whole serum 
■  PbTx-2 specific 
—: KLH specific
IgGl IgG2a IgG2b IgG3 IgM IgA 
Isotyping Antibody
Figure 46.Antigen-specific and capture isotyping for serum collected the day of the 
fusion of mouse 8 (immunized with KLH-Brevetoxin-2 [PbTx-2]). Serum was diluted
1:1000 for testing.
Figure 46 shows that IgGl, IgM, and IgA antibodies specific for PbTx-2 were 
present the day of the fusion; a qualitative comparison of these isotypes shows the 
predominance o f IgGl antibodies. In the case of KLH coated plates, IgGl and IgM 
antibodies predominated. The capture isotyping ELISA detects all antibodies present in 
the serum, with no preference for their specificity. As expected, all isotypes were 
detected.
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The fusion was performed four days after the last immunization. Since the 
myeloma cell line made no difference, Sp2/0-Agl4 were used again for this and 
subsequent fusions. Their advantage is that they tend to slightly bind to the plate, 
making feedings and cloning easier. Also, they do not secrete light chains so they cannot 
incorporate them into the newly synthesized antibodies.
The splenocytes cell suspension had a total of 1.1 x 108 cells. A 1:5 ratio was 
selected; therefore, 2.2 x 107 myeloma cells were used. The mixed cells were suspended 
in 70 mL of conditioned media-HT to get a cell density of 1.9 x 106 cells/mL. Since 100 
jiL are plated per well, the cell density was 1.9 x 105 cells/well. A total of 7 plates was 
used, from which 549 wells showed growth and 27 supernatants were initially scored as 
positive. After expansion and rescreening, just 7 wells showed an absorbance at least 
twice the background. Therefore, the fusion efficiency was 1.3 %. Table 13 lists those 
fusion wells considered positive and their absorbance after rescreening.
Table 13.Wells derived from fusion 5 (mouse 8 im m unized w ith K LH -Brevetoxin-2) 
selected for cloning. The ELISA for screening w as performed using 50 pL volumes, 
goat anti-mouse IgG (H&L)-HRPO at 1:1000 and ABTS for color development.
Fusion well 
number
Absorbance of fusion well 
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Each positive fusion well was cloned. When the selected cloning wells were at 
least 30% confluent, they were rescreened. Since more than 1 positive cloning well was 
found per fusion well, the criteria for selection of positive wells in cloning plates was to 
use only 2 to 4 wells containing a colony arising from a single cell and with a high 
absorbance. Instead of using consecutive numbers among all the plates used for cloning, 
numbers were assigned to both cloning plates derived from each fusion well. Table 14 
shows the absorbance of each cloning well the day it was screened and its isotype.
Table 14.Cloning wells derived from fusion 5 (mouse 8 immunized with KLH- 
Brevetoxin-2). The ELISA for screening was performed using SO jxL volumes, goat anti­
mouse IgG (H&L)-HRPO at 1:1000 and ABTS for color development Isotyping was






cloning well the 
day of screening
Isotype of cloned 
wells
19 24 0.123 IgGl
27 0.121 IgGl
117 11 0221 IgM
17 0.229 IgM
129 8 0.736 IgM
10 0.836 IgM
24 0.316 IgM
205 4 0.277 IgM
11 0.153 IgM
15 0.369 IgM
212 5 0.469 IgM
15 1.314 IgM
20 1.196 IgM




532 7 0.345 IgM
12 0.403 IgM
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One cloning well derived from each fusion well was selected for further studies. 
The selected cloning well had the highest absorbance in its group. Selected wells were 
rescreened using BSA-PbTx-2, BSA, OVA-PbTx-2, OVA, LPH, and KLH as coating 
antigens to try to determine the specificity of the antibodies (Figure 47).
It was found that supernatants 19(24) and 259(15) contained IgG antibodies 
reacting to KLH (this was the carrier protein used for immunization), and so the 
absorbance initially detected using BSA-PbTx-2 coated plates was only background. 
After a 1:1000 dilution of the precipitates, the high background disappeared.
Wells 117(17), 129(10), 205(15), 212(15) and 532(12) gave almost the same 
absorbance with irrelevant proteins and even uncoated plates. It is then unlikely that the 
antibodies were recognizing a common region in all these proteins. The problem here 
was the nature of IgM antibodies (high avidity), which led to the selection of 
hybridomas without desired specificity.
Figure 46 showed that IgGl and IgM antibodies for PbTx-2 and LPH were present 
in the serum collected the day of the fusion, and a qualitative comparison shows that 
more KLH antibodies were present This may explain why antibodies to KLH were 
preferentially fused.
The next step was to determine if the serum was reacting as the hybridoma 
supernatants (binding to different proteins). When the titer of the serum was performed 
(Figure 44), it was determined that no antibodies against BSA were present the day of 
the fusion but, as expected, antibodies against KLH were present. However, it was 
important to incorporate the other irrelevant proteins used in Figure 47. Figure 48 
summarizes the results of this experiment
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Figure 47. Ammonium sulfate precipitates of cloned hybridoma supernatants obtained 
from fusion S (mouse 8 immunized with KLH-Brevetoxin-2). Precipitates were diluted 
1:100 and 1:1000 for testing. Goat anti-mouse IgG (H&L)-HRPO was diluted 1:1000.
TMB was used for color development
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Figure 48.Response of serum collected the day of the fusion of mouse 8 (immunized 
with KLH-Brevetoxin-2 (PbTx-2) with different coating antigens at 5 pg/mL. Serum 
was diluted 1:1000 for testing. Goat anti-mouse IgG (H&L)-HRPO was diluted 1:5000.
TMB was used for color development
As expected, antibodies to KLH predominated in the serum; however, anti-PbTx-2 
antibodies were also present It was then apparent that even though anti-PbTx-2 
antibodies were present, there was a higher statistical probability to obtain hybridomas 
secreting anti-KLH antibodies.
To assure that no potential antibodies have been missed, the original supernatants 
(before cloning) collected just before freezing the cells were tested in a competitive 
assay using 20 pg/mL of PbTx-2 as a competitor (Figure 49).
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Figure 49. Competition assay using tissue culture supernatants from fusion 5 (mouse 8 
immunized with KLH-Brevetoxin-2 [PbTx-2]) and PbTx-2 at 20 (j.g/mL. Plates were 
coated with BSA-PbTx-2 at 5 pg/mL. Goat anti-mouse IgG (H&L)-HRPO was diluted 
1:5000. TMB was used for color development.
As expected, no competition was observed in the supernatants already shown to 
contain antibodies to KLH. For the rest of the IgM antibodies, this ELISA showed no 
competition or evidence of anti-PbTx-2 antibodies.
To further reassure that no potential antibodies were discarded, a highly sensitive 
cytotoxicity assay was used. A standard curve with PbTx-2 was previously reported to 
test the effect of the toxin on Neuro-2a cells (Figure 21). This Figure showed that PbTx- 
2 in the presence of ouabain and veratridine caused a dose and time-dependent effect. 
The modification of this method (Materials and Methods) showed that no tissue culture 
supernatants contained anti-PbTx-2 antibodies that could neutralize the activity of
129
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PbTx-2 (data not shown). This was expected because antibodies o f high affinity (nM or 
pM) would be required to compete for PbTx-2.
Once again, statistical probability hampered the selection of monoclonal anti-PbTx- 
2 antibodies. A new fusion was performed modifying the conditions used in fusion 5 by 
using a more sensitive screening assay and a new conjugate to coat the plates.
3. Fusion 6
The general conditions of fusion 6 are summarized below:
• Myeloma cell line: Sp2/0-Agl4
• ELISA for screening: 100 pL volumes and TMB for color development
• BSA-PbTx-2 prepared as described in Materials and Methods, but duplicating the 
amount of PbTx-2 and reducing the concentration of BSA from 10 mg to 4 mg.
Mouse 10 was immunized with KLH-PbTx-2. The immunization schedule is 
shown in Table 15.
Table 15.1mmunization schedule for mouse 10 using KLH-Brevetoxin-2 (PbTx-2) for
preparation of anti-PbTx-2 antibodies.




1st immunization 100 pg ip + 100 pg sc FCA^ 1 8
1st boost 100 pg ip FIAC 28 35
2nd boost 100 pg ip FIA 49 56
3rd boost 100 pg ip FIA 92 99
4th boost 100 pg ip FIA 152 159
Final boost 100 pg ip None 181 185
8 sc - subcutaneous; ip - intraperitoneal
b FCA - Freund’s complete adjuvant 
c FIA - Freund’s incomplete adjuvant
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Figure 50. Antibody production response of mouse 10 after each immunization with 
KLH-Brevetoxin-2 (PbTx-2). Plates were coated with BSA-PbTx-2 at 5 fig/mL. Each 
serum was diluted 1:1000. Goat anti-mouse IgG (H&L)-HRPO was diluted 1:5000. 
TMB was used for color development Plotted points are the means of triplicate 
determinations. Variation from the mean was typically 5% or less.
The immune response of mouse 10 seemed unusual in that it decreased after the 
fourth boost. This may be the result of a high titer of antibodies present at the time of 
the booster injection; these antibodies would bind the immunogen, and so the amount of 
immunogen left for activation of new B cells would be decreased. However, it is evident 
that anti-PbTx-2 antibodies appeared after the second boost with KLH-PbTx-2. The 
isotype(s) of these antibodies was uncertain at this time because the secondary labeled 
antibody used to detect murine antibodies was raised against the whole IgG molecule. 
Therefore, it can cross-react with constant regions in the light chains of IgM and IgA
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antibodies. To get a better idea of the relative concentration of PbTx-2 IgG antibodies 
only, the titer of the serum was obtained by serial dilution and by using a secondary 
labeled antibody specific for the y heavy chain of murine IgGs (Figure 51). Controls in 
this experiment included the use of pre-immune serum in BSA-PbTx-2 coated plates, 
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Figure 51 .Titer of serum collected the day of the fusion of mouse 10 immunized with 
KLH-Brevetoxin-2 (PbTx-2). Plates were coated with BSA-PbTx-2, BSA, and KLH at 
5 g.g/mL. Goat anti-mouse IgG (y)-HRPO was diluted 1:1000. TMB was used for color 
development Plotted points are the means of triplicate determinations. Variation from
the mean was typically 5% or less.
The titer of PbTx-2 IgG antibodies in the serum collected the day of the fusion was 
1:1,600. Since BSA-PbTx-2 and BSA control plates gave absorbance readings of less 
than 0.1, the response observed in Figure 51 using BSA-PbTx-2 coated plates and 
immune serum was due to antibodies reacting to some portion of the PbTx-2 molecule
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only and to antibodies present in mouse 10 after immunizations with KLH-PbTx-2. 
KLH coated plates showed a high concentration of anti-KLH IgG antibodies; this may 
reduce the fusion efficiency.
To confirm that the response observed was due to mouse anti-PbTx-2 IgG 
antibodies, competition studies were performed in the serum collected the day of the 
fusion. Serial dilutions of PbTx-2 were added to diluted serum (1:200) as described in 
Materials and Methods (Figure 52).
Log [Brevetoxm-2] (ug/mL)
0.8
% 0 .6 -  
0.4 -
0.001 0.10.01 1 10 1000100
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— Calculated curve
Figure 52.Computer-generated best fit competition curve for serum collected the day of 
the fusion of mouse 10 (immunized with KLH-Brevetoxin-2 [PbTx-2]). Plates were 
coated with BSA-PbTx-2 at 5 pg/mL. Goat anti-mouse IgG (y)-HRPO was diluted 
1:5000. TMB was used for color development. Plotted points are the means of 
duplicate determinations. Variation from the mean was typically 5% or less.
As shown in Figure 52, mouse anti-PbTx-2 IgG antibodies were detected in the 
serum collected the day of the fusion. The IC50 was 3.77 pg/mL. This competition 
immunoassay (Figure 52) showed that mouse anti-PbTx-2 IgG were present; however, 
to determine the specific IgG isotype(s) and if other isotypes specific for PbTx-2 were
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present, the serum obtained the day of the fusion was isotyped using an antigen-specific 
ELISA (Appendix B). Isotypes of KLH antibodies were also determined. In addition, a 
capture isotyping ELISA was performed to qualitatively determine the presence of 
antibodies in the serum without regard for their specificity (Appendix B). The results of 
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Figure 53 Antigen-specific and capture isotyping for serum collected the day of the 
fusion of mouse 10 (immunized with KLH-Brevetoxin-2 [PbTx-2]). Serum was diluted
1:1000 for testing.
Figure 53 shows that IgGl, IgG3, and IgM antibodies specific for PbTx-2 were 
present in the serum collected the day of the fusion; a qualitative comparison of these 
isotypes shows the predominance of IgGl antibodies. In the case o f KLH coated plates, 
IgGl, IgG2a, IgG2a, IgG3, and IgM antibodies were present The capture isotyping
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ELISA detects all antibodies present in the serum, with no preference for their 
specificity. As expected, all isotypes were detected. Figure 51 showed that anti-KLH 
IgG antibodies predominated over anti-PbTx-2 IgG antibodies. This isotyping assay 
(Figure 53) showed that the proportion of anti-KLH antibodies was high as compared to 
anti-PbTx-2 antibodies. This would likely represent a problem in the fusion process, 
since by statistical probability more B cells specific for KLH would fuse.
The fusion was performed four days after the last immunization. Sp2/0-Agl4 
myeloma cells were used for fusion. The splenocytes cell suspension had a total of 1 x 
108 cells. A 1:5 fusion ratio was selected; therefore, 2 x 107 myeloma cells were used. 
The mixed cells were suspended in 60 mL of conditioned media-HT to obtain a cell 
density of 2 x 106 cells/mL. Since 100 pL were plated per well, the cell density was 2 x 
10s cells/well. A total of 6 plates was used. The feeding schedule was followed as 
described in Materials and Methods.
After screening of the wells showing hybridoma growth (272 wells), 25 wells were 
originally scored as positive. After expansion and rescreening, just 7 wells showed an 
absorbance at least twice the background. Therefore, the fusion efficiency was 2.6 % 
Table 16 lists those fusion wells considered positive and the absorbance they showed at 
their rescreening after initial expansion.
Each of the positive fusion wells was cloned as previously described in Materials 
and Methods. The numbering system among cloning plates was changed. Numbers were 
assigned to cloning wells containing 1 colony in both plates used per fusion well. 
Numbering was restarted in each cloning plate group. Table 17 shows the absorbance of 
each cloning well the day it was expanded and its isotype.
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Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Table 16. Wells derived from fusion 6 (mouse 10 immunized with KLH-Brevetoxin-2) 
selected for cloning. The ELISA for screening was performed using 100 pL volumes, 
goat anti-mouse IgG (H&L)-HRPO at 1:1000 and TMB for color development
Fusion well 
number
Absorbance of fusion well 








Table 17.Cloning wells derived from fusion 6 (mouse 10 immunized with KLH- 
Brevetoxin-2). The ELISA for screening was performed using 100 pL volumes, goat 
anti-mouse IgG (H&L)-HRPO at 1:1000 and TMB for color development Isotyping
was performed using a commercial kit.
Fusion well Cloning well Absorbance of Isotype of cloned
number number cloning well the wells
day of screening
19 4 0.355 IgM
11 0.290 IgM
21 9 0.568 IgM
15 0.602 IgM
49 5 0.573 IgM
8 0.517 IgM
86 7 0.237 IgGl
13 0.221 IgGl
225 2 0.302 IgGl
14 0.296 IgGl
240 3 0.433 IgM
10 0.392 IgM
270 6 0.197 IgGl
15 0.215 IgGl
A representative cloning well derived from every fusion well was expanded, and 
antibodies in the supernatants were precipitated using ammonium sulfate (50%
136
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
saturation). The dialyzed protein solutions were used in a new ELISA to test the binding 
properties of the antibodies. As part of the controls used for this ELISA, plates were 
coated with BSA-PbTx-2 but also with irrelevant proteins such as BSA, LPH, OVA, 
and KLH. Once again, unforeseen results were discovered. Figure 54 shows the results 
of this ELISA diluting the ammonium sulfate precipitates 1:100 and 1:1000.
Wells 86(7), 225(2), and 270(15) contain anti-KLH IgG antibodies. When the 
ammonium sulfate precipitates were diluted 1:100, a high background can be observed; 
however, 1:1000 dilutions show a decrease in background. In the screening process the 
tissue culture supernatants were not diluted; therefore, the absorbance readings obtained 
at every screening stage were just the result of non-specific binding due to high 
concentrations of anti-KLH antibodies.
Wells 19(4), 21(15), 49(5), and 240(3) show almost the same absorbance readings 
with the different coating proteins tested and even in uncoated plates. These wells 
contain IgM antibodies of unknown specificity.
Once again, it was important to check if the serum was behaving as the hybridoma 
supernatants. To determine this, the same coating proteins were used (Figure 55).
As shown in Figure 55, the serum was reacting to the components of the 
immunogen, that is KLH and PbTx-2. However, no reaction was observed for foreign 
antigens such as BSA or OVA alone or LPH. It is important to note that the response of 
anti-KLH antibodies was high, and the presence of anti-PbTx-2 antibodies is low, as 
previously shown in Figures 51 and 53. To assure that no potential antibodies have been 
missed, the original supernatants (before cloning) collected just before freezing the cells 
were tested in a competitive assay using PbTx-2 (20pg/mL) as a competitor (Figure 56).
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Figure 54.Ammonium sulfate precipitates of cloned hybridoma supernatants obtained 
from fusion 6 (mouse 10 immunized with KLH-Brevetoxin-2). Precipitates were 
diluted 1:100 and 1:1000 for testing. Goat anti-mouse IgG (H&L)-HRPO was diluted 
1:1000. TMB was used for color development.
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Figure 55.Response of serum collected the day of the fusion of mouse 10 (immunized 
with KLH-Brevetoxin-2 [PbTx-2]) with different coating proteins at 5 pg/mL. Serum 
was diluted 1:1000 for testing. Goat anti-mouse IgG (H&L)-HRPO was diluted 1:5000.
TMB was used for color development.
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Figure 56.Competition assay using tissue culture supernatants from fusion 6 (mouse 10 
immunized with KLH-Brevetoxin-2 [PbTx-2]) and PbTx-2 at 20 pg/mL. Plates were 
coated with BSA-PbTx-2 at 5 pg/mL. Goat anti-mouse IgG (H&L)-HRPO was diluted 
1:5000. TMB was used for color development
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As expected, no competition was observed in the supernatants containing 
antibodies to KLH. For the rest of the IgM antibodies, this ELISA showed no 
competition or evidence of anti-PbTx-2 antibodies; therefore, this explains why no anti- 
PbTx-2 antibodies were obtained after cloning. To further reassure that no potential 
antibodies were discarded, a highly sensitive cytotoxicity assay was used. The standard 
curve of PbTx-2 showing its effects on Neuro-2a cells was previously reported (Figure 
21). The modified cytotoxicity assay confirmed that no antibodies specific for PbTx-2 
were present in the concentrated tissue culture supernatants (data not shown).
Since mouse anti-PbTx-2 IgG antibodies were detected in the serum of mouse 10, 
then it was just a matter of statistical probability. The next step was to perform a new 
fusion using the same conditions of fusion 6.
4. Fusion 7
The general conditions of fusion 7 are summarized below:
• Myeloma cell line: Sp2/0-Agl4
• ELISA for screening: 100 pL volumes and TMB for color development
• BSA-PbTx-2 prepared as described in Materials and Methods, but duplicating the 
amount of PbTx-2 and reducing the concentration of BSA from 10 mg to 4 mg.
Mouse 11 was immunized with KLH-Brevetoxin-2. The immunization schedule is 
shown in Table 18. Figure 57 shows the response of mouse 11 after each injection with 
KLH-Brevetoxin-2. After the first boost, the response of the mouse was evident. It 
produced anti-PbTx-2 antibodies, and their concentration remained high. The isotype of 
these antibodies is not known, since this assay could detect IgG, IgM, and IgA 
antibodies.
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Table lSJmmunization schedule for mouse 11 using KLH-Brevetoxin-2 (PbTx-2) for
preparation of anti-PbTx-2 antibodies.




1st immunization 100 pg ip + 100 pg sc FCAb 1 8
1st boost 100 pg ip FIAC 28 35
2nd boost 100 pg ip FIA 49 56
3rd boost B=£oo FIA 92 99
4th boost 100 pg ip FIA 152 159
Final boost 100 pg ip None 181 185
a sc - subcutaneous; ip - intraperitoneal 
b FCA - Freund’s complete adjuvant 




20  40  60  80 100 120 140 160 180 2000
B leeding 
T B oost
Days after first immunization
Figure 57.Antibody production response of mouse 11 after each immunization with 
KLH-Brevetoxin-2 (PbTx-2). Plates were coated with BSA-PbTx-2 at 5 pg/mL. Each 
serum was diluted 1:1000. Goat anti-mouse IgG (H&L)-HRPO was diluted 1:5000. 
TMB was used for color development Plotted points are the means of triplicate 
determinations. Variation from the mean was typically 5% or less.
Since it was important to determine the presence of mouse anti-PbTx-2 IgG 
antibodies (preferred isotype), the serum obtained the day of the fusion was serially
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diluted to determine its titer and was detected with a secondary labeled antibody specific 
for murine y heavy chains (Figure 58). Controls included the use of BSA-PbTx-2 and 
BSA coated plates with pre-immune serum and immune serum, respectively. The titer 
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Figure 58.Titer of serum collected the day of the fusion of mouse 11 immunized with 
KLH-Brevetoxin-2 (PbTx-2). Plates were coated with BSA-PbTx-2 at 5 pg/mL. Goat 
anti-mouse IgG (y)-HRPO was diluted 1:1000. TMB was used for color development 
Plotted points are the means o f triplicate determinations. Variation from the mean was
typically 5% or less.
The titer of PbTx-2 IgG antibodies in the serum collected the day of the fusion was 
1:12,800. Controls gave absorbance readings of less than 0.1, confirming that the 
response was specific for PbTx-2 and that it was the result of injections with KLH- 
PbTx-2. The titer of KLH IgG antibodies could not be determined because even after a 
1:409,600 dilution, their concentration remained high.
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To further prove that the response observed was due to mouse anti-PbTx-2 IgG 
antibodies, competition studies were performed in the serum obtained the day of the 
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Figure 5 9. Computer-generated best fit competition curve for serum collected the day of 
the fusion of mouse 11 (immunized with KLH-Brevetoxin-2 [PbTx-2]). Plates were 
coated with BSA-PbTx-2 at 5 pg/mL. Goat anti-mouse IgG (y)-HRPO was diluted 
1:5000. TMB was used for color development. Plotted points are the means of duplicate 
determinations. Variation from the mean was typically 5% or less.
As shown in Figure 59, mouse anti-PbTx-2 IgG antibodies were present in the 
serum collected the day of the fusion. The IC50 was 14.38 pg/mL. This competition 
immunoassay confirmed that mouse anti-PbTx-2 IgG antibodies were present in the 
serum of mouse 11 after the final boost; however, to determine the specific IgG 
isotype(s) and if other isotypes specific for PbTx-2 were present, the serum obtained the 
day of the fusion was isotyped using an antigen-specific ELISA (Appendix B). Isotypes
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of KLH antibodies were also determined. In addition, a capture isotyping ELISA was 
performed to show which isotypes were present in the whole serum (Appendix B). The 
results of these isotyping experiments are summarized in Figure 60.
Figure 60 .Antigen-specific and capture isotyping for serum collected the day of the 
fusion of mouse 11 (immunized with KLH-Brevetoxin-2 [PbTx-2]). Serum was diluted
1:1000 for testing.
Figure 60 shows that IgGl antibodies specific for PbTx-2 were present in the 
serum collected the day of the fusion. In the case of KLH coated plates, IgGl, IgG2a, 
IgG2b, IgG3, and IgM antibodies were detected. The capture isotyping ELISA detects 
all antibodies present in the serum, with no preference for their specificity. As expected, 
all isotypes were detected in the whole serum. Figure 58 showed that more anti-KLH 
IgG antibodies were present in the serum. This isotyping experiment (60) confirms these 
results. All this may be problematic after the fusion, since more B cells specific for 
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The fusion was performed four days after the last immunization. Sp2/0-Agl4 
myeloma cells were used for fusion. The splenocytes cell suspension had a total of 1.2 x 
10® cells. A 1:5 fusion ratio was selected; therefore, 2.4 x 107 myeloma cells were used. 
The mixed cells were suspended in 70 mL of conditioned media-HT to obtain a cell 
density of 2.1 x 106 cells/mL. Since 100 pL were plated per well, the cell density was
2.1 x 105 cells/well. A total of 7 plates was used.
After screening o f the wells showing hybridoma growth (295 wells), 36 
supernatants were originally scored as positive. After expansion and rescreening, just 8 
wells showed an absorbance at least twice the background. Therefore, the fusion 
efficiency was 2.7 %. Table 19 lists those fusion wells considered positive and the 
absorbance they showed when they were rescreened after the initial expansion.
Table 19.Wells derived from fusion 7 (mouse 11 immunized with KLH-Brevetoxin-2) 
selected for cloning. The ELISA for screening was performed using 100 pL volumes, 
goat anti-mouse IgG (H&L)-HRPO at 1:1000 and TMB for color development.
Fusion well Absorbance of fusion well









Each of the positive fusion wells was cloned. Seven days after cloning, the cloning 
plates were evaluated microscopically for the presence of colonies arising from 1 cell.
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When the selected cloning wells were 30% confluent, they were rescreened for antibody 
production. Many positive wells were obtained during the screening process; therefore, 
the selection criteria was to expand only 2 to 4 wells arising from a single colony and 
with the highest absorbances. The numbering format of fusion 6 was followed. Selected 
positive wells were expanded, isotyped, and frozen. Table 20 shows the absorbance of 
each cloning well the day it was expanded and its isotype.
Table 20.Cloning wells derived from fusion 7 (mouse 11 immunized with KLH- 
Brevetoxin-2). The ELISA for screening was performed using 100 jiL volumes, goat 
anti-mouse IgG (H&L)-HRPO at 1:1000 and TMB for color development Isotyping
was performed using a commercial kit.
Fusion well Cloning well Absorbance of Isotype of cloned
number number cloning well the 
day of screening
wells
1 2 0.486 IgGl
12 0.599 IgGl
22 0.508 IgGl
44 20 0.252 IgM
24 0.197 IgM
45 13 0.601 IgGl
17 0.798 IgGl
72 5 0.190 IgG2b
9 0.238 IgG2b
100 16 0.892 IgM
22 0.681 IgM
225 3 0.415 IgM
18 0.379 IgM
261 2 0.913 IgM
18 1.027 IgM
275 7 0.275 IgM
13 0.213 . . IgM
A representative cloning well derived from each fusion well was selected for 
further studies. The criteria for selection was to use that cloning well (within cloning
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wells derived from the same fusion well) showing the highest absorbance. Selected 
cloning wells were expanded in a 25 cm2 tissue culture flask. These supernatants were 
centrifuged to remove cell debris, and the cleared supernatants were then precipitated 
using ammonium sulfate (50% saturation), as described in Materials and Methods. The 
dialyzed protein solutions were used in a new ELISA to test the binding properties of 
the antibodies.
As part of the controls used for this ELISA, plates were coated with BSA-PbTx-2 
but also with irrelevant proteins such as BSA, LPH, OVA and KLH. At this point, 
unexpected results were found since the positive response obtained for BSA-PbTx-2 
was not specific. Figure 61 shows the results of this ELISA diluting the ammonium 
sulfate precipitates 1:100 and 1:1000.
Wells 1(12), 45(17), and 72(9) contain IgG antibodies specific for the protein used 
to conjugate PbTx-2 (KLH); therefore, the absorbance readings obtained through the 
screening process were due to non-specific binding of anti-KLH IgG antibodies in the 
supernatant. The rest of the cloned wells were IgMs. Even though wells 44(20), 
100(16), and 225(3) gave high backgrounds, they also gave a noticeable higher 
absorbance reading for KLH. This suggests that they recognize the immunizing protein 
used for conjugation of PbTx-2. Wells 261(18) and 275(7) gave almost the same 
absorbance with irrelevant proteins and even uncoated plates. Binding to uncoated 
plates proved that these antibodies were not recognizing a particular region in all the 
coating proteins tested. The high avidity of IgM antibodies accounts for this problem. 
The specificity of these antibodies will remain unknown, unless a wider spectrum of 
proteins could be tested, which is unnecessary.
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Figure 61. Ammonium sulfate precipitates of cloned hybridoma supernatants obtained 
from fusion 7 (mouse 11 immunized with KLH-Brevetoxin-2). Precipitates were 
diluted 1:100 and 1:1000 for testing. Goat anti-mouse IgG (H&L)-HRPO was diluted 
1:1000. TMB was used for color development
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At this point, it was important to determine if the serum was behaving as the 
hybridoma supernatants. To test this, the same coating proteins were used (Figure 62).
1.5
amAueatA< 0.5
BSA BSA-PbTx-2 OVA OVA-PbTx-2 KLH LPH
Coating antigen
Figure 62.Response of serum collected the day of the fusion of mouse 11 (immunized 
with KLH-Brevetoxin-2 [PbTx-2]) with different coating antigens at 5 pg/mL. Serum 
was diluted 1:1000 for testing. Goat anti-mouse IgG (H&L)-HRPO was diluted 1:5000.
TMB was used for color development
As shown in Figure 62, the serum was reacting to the components of the 
immunogen, that is KLH and PbTx-2, which was expected. However, no reaction was 
observed for foreign antigens such as BSA or OVA alone or LPH. It is important to 
note the higher proportion of KLH antibodies as compared to antibodies against PbTx-2. 
This was also shown in Figures 58 and 60.
To assure that no potential antibodies have been missed, the original supernatants 
(before cloning) collected just before freezing the cells were tested in a competitive 
assay using 20 pg/mL of PbTx-2 as a competitor (Figure 63).
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Fosion well number
Figure 63.Competition assay using tissue culture supernatants from fusion 7 (mouse 11 
immunized with KLH-Brevetoxin-2 [PbTx-2]) and PbTx-2 at 20 pg/mL. Plates were 
coated with BSA-PbTx-2 at 5 pg/mL. Goat anti-mouse IgG (H&L)-HRPO was diluted 
1:5000. TMB was used for color development.
As expected, no competition was observed in the supernatants containing 
antibodies to KLH. For the rest of the IgM antibodies, this ELISA showed no 
competition or evidence of anti-PbTx-2 antibodies; therefore, this explains why no anti- 
PbTx-2 antibodies were obtained after cloning (they were not present in the first place).
To further reassure that no potential antibodies were discarded, a highly sensitive 
cytotoxicity assay was used. The standard curve of PbTx-2 using Neuro-2a cells was 
previously reported (Figure 21). This Figure shows that PbTx-2 together with ouabain 
and veratridine causes a dose and time dependent death of Neuro-2a cells. To test if 
tissue culture supernatants contained anti-PbTx-2 antibodies, this assay was modified. 
The tissue culture supernatants were tested in a concentrated form (ammonium sulfate
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precipitates). As expected, no tissue culture supernatant prevented the death of Neuro-2a 
cells; therefore, no anti-PbTx-2 antibodies were present (data not shown).
Since mouse anti-PbTx-2 IgG antibodies were detected in the serum of mouse 11, 
then it was just a matter of statistical probability. It is important to remember that more 
anti-KLH antibodies were present in the serum collected the day of the fusion when 
compared to antibodies against PbTx-2. This correlates with the number of B cells 
available for fusion. Figure 60 showed that a whole spectrum of antibodies was present 
in the serum; therefore, B cells to a wide group of compounds were available for fusion.
The next step was to perform a new fusion modifying the conditions used in fusion 
7 by changing the immunogen to BSA-PbTx-2.
Q  BSA-PbTx-2
1. Fusion 8
The general conditions of fusion 8 are summarized below:
• Myeloma cell line: Sp2/0-Agl4
• ELISA for screening: 100 pL volumes and TMB for color development
• OVA-PbTx-2 prepared as described in Materials and Methods, but duplicating the 
amount of PbTx-2 and reducing the concentration of OVA from 10 mg to 4 mg.
Mouse 12 was immunized with BSA-Brevetoxin-2. The immunization 
schedule is shown in Table 21. Figure 64 shows the response of mouse 12 after each 
injection with BSA-Brevetoxin-2.
Compared to the serum obtained after the first immunization, sera obtained after 
repeated boosts show that mouse 12 was responding to injections of BSA-PbTx-2 
producing anti-PbTx-2 antibodies. This assay detects IgG, IgM, and IgA antibodies.
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Table 21 immunization schedule for mouse 12 using BSA-Brevetoxin-2 (PbTx-2) for
preparation of anti-PbTx-2 antibodies.




1st immunization 100 pg ip + 100 ug sc FCAb 1 8
1st boost 100 pg ip FIAC 24 31
2nd boost 100 pg ip FIA 120 127
Final boost 100 pg ip None 156 159
a sc - subcutaneous; ip - intraperitoneal
b FCA - Freund’s complete adjuvant 
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Figure 64 Antibody production response of mouse 12 after each immunization with 
BSA-Brevetoxin-2 (PbTx-2). Plates were coated with OVA-PbTx-2 at 5 pg/mL. Each 
serum was diluted 1:1000. Goat anti-mouse IgG (H&L)-HRPO was diluted 1:5000. 
TMB was used for color development. Plotted points are the means of triplicate 
determinations. Variation from the mean was typically 5% or less.
Since it was important to determine the presence of mouse anti-PbTx-2 IgG 
antibodies (preferred isotype) and their relative concentration, the serum obtained the 
day of the fusion was serially diluted to determine its titer and a detection antibody 
specific for IgGs was used. OVA and OVA-PbTx-2 coated plates were used as controls
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using immune and pie-immune sera, respectively, and BSA coated plates detected the 
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Figure 65.Titer of serum collected the day of the fusion of mouse 12 immunized with 
BSA-Brevetoxin-2 (PbTx-2). Plates were coated with OVA-PbTx-2, OVA, and BSA at 
5 pg/mL. Goat anti-mouse IgG (y)-HRPO was diluted 1:5000. TMB was used for color 
development Plotted points are the means of triplicate determinations. Variation from
the mean was typically 5% or less.
The titer of anti-PbTx-2 IgG antibodies in the serum the day of the fusion was 
1:204,800. This clearly indicates that mouse anti-PbTx-2 IgGs were present in the serum 
collected the day of the fusion, which is a desired event since these antibodies indirectly 
show that B cells specific for PbTx-2 were present in the spleen. The secondary labeled 
antibody used for detection of murine antibodies was specific for IgG antibodies; 
therefore, the titer reflects the relative concentration of IgG antibodies only.
Since immune sera in OVA coated plates gave absorbance readings of less than 
0.1, the response observed was due to antibodies reacting to some portion of the PbTx-2
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molecule only. Also, the use of pre-immune serum with OVA-PbTx-2 coated plates 
gave absorbance readings of less than 0.1; therefore, the response observed was not due 
to compounds present in the mouse before immunizations. BSA coated plates detected 
the presence of a high concentration of anti-BSA IgG antibodies.
The ultimate proof that the response observed was due to mouse anti-PbTx-2 IgG 
antibodies was obtained by using competition studies. Serially diluted PbTx-2 was 
added to diluted serum (1:2000) to test if competition occurred (Figure 66).
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Figure 66.Computer-generated best fit competition curve for serum collected the day of 
the fusion of mouse 12 (immunized with BSA-Brevetoxin-2 [PbTx-2]). Plates were 
coated with OVA-PbTx-2 at 5 pg/mL. Goat anti-mouse IgG (y)-HRPO was diluted 
1:5000. TMB was used for color development Plotted points are the means of duplicate 
determinations. Variation from the mean was typically 5% or less.
Figure 66 shows that the addition of increasing concentrations of PbTx-2 decreased 
the response (A/Ao). This was an effect produced by competition of anti-PbTx-2 IgG 
antibodies in the serum. The IC50 was 0.17 pg/mL.
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Mouse anti-PbTx-2 IgG antibodies were detected in the serum collected the day of 
the fusion; however, to determine the specific IgG isotype(s) and if other isotypes 
specific for PbTx-2 were present, the serum was isotyped using an antigen-specific 
ELISA (Appendix B). Isotypes of BSA antibodies in the same serum were also 
determined, together with all isotypes present in the whole serum using a capture 
isotyping ELISA (Appendix B). The results of these isotyping experiments are 
























Figure 67. Antigen-specific and capture isotyping for serum collected the day of the 
fusion of mouse 12 (immunized with BSA-Brevetoxin-2 [PbTx-2]). Serum was diluted
1:1000 for testing.
Figure 67 shows that IgGl antibodies specific for PbTx-2 were present in the 
serum collected the day of the fusion. In the case of BSA coated plates, mainly IgGl, 
IgG2b, and IgM antibodies were detected. As expected, the capture isotyping ELISA 
detected all isotypes in the whole serum.
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The fusion was performed three days after the final boost. Sp2/0-Agl4 myeloma 
cells were used for fusion. The splenocytes cell suspension had a total of 1.2 x 10s cells. 
A 1:5 fusion ratio was selected; therefore, 2.4 x 107 myeloma cells were used. The 
mixed cells were suspended in 70 mL of conditioned media-HT to obtain a cell density 
of 2.1 x 106 cells/mL. Since 100 jiL were plated per well, the cell density was 2.1 x 105 
cells/well. A total of 7 plates was used. The feeding schedule was followed as described 
in Materials and Methods.
After screening of the wells showing hybridoma growth (430 wells), 22 
supernatants were initially scored as positive. After expansion and rescreening, just 9 
supernatants showed an absorbance at least twice the background. Therefore, the fusion 
efficiency was 2.1 %. Table 22 lists those fusion wells considered positive, the 
absorbance they showed when rescreened after the initial expansion, and their isotype.
Table 22.Wells derived from fusion 8 (mouse 12 immunized with BSA-Brevetoxin-2) 
selected for further testing. The ELISA for screening was performed using 100 (iL 
volumes, goat anti-mouse IgG (H&L)-HRPO at 1:1000 and TMB for color 
development. Isotyping was performed using a commercial kit.
Fusion well 
number
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Since the first seven fusions showed that no hybridomas of the desired specificity 
were selected after cloning, for the rest of the fusions the approach was different 
Supernatants were tested in an ELISA using different coating proteins, and if a 
potential hybridoma was detected, it would be cloned. It was unnecessary to keep 
cloning hybridomas producing antibodies to carrier proteins and/or unknown 
compounds.
As part of the controls used for this ELISA, plates were coated not only with OVA- 
PbTx-2, but also with irrelevant proteins such as OVA, LPH, BSA, and KLH. Figure 68 
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Figure 68.Tissue culture supernatants obtained from fusion 8 (mouse 12 immunized 
with BSA-Brevetoxin-2). Goat anti-mouse IgG (H&L)-HRPO was diluted 1:1000. TMB
was used for color development.
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Wells 117 and 275 contain IgG antibodies recognizing BSA, the carrier protein 
used for the preparation of the immunogen. They showed a high background because 
the supernatants were not diluted, but this non-specific responses should decrease as the 
supernatants are diluted. These antibodies recognize BSA and BSA-PbTx-2 coated 
plates. It is certain that they are not recognizing the PbTx-2 molecule in the BSA-PbTx- 
2 coated plates because the response observed in OVA and OVA-PbTX-2 coated plates 
was similar.
Wells 87, 334, and 391 contain IgM antibodies. They showed a high background, 
but an appreciable higher response to wells coated with BSA and BSA-PbTx-2 was 
observed. Wells 31, 71, 143, and 403 contain IgM antibodies of unknown specificity. 
They bind to the plates even when they are uncoated.
At this point, it was important to determine if the serum was reacting as the 
hybridoma supernatants. To test this, the same coating proteins were used (Figure 69).
As shown in Figure 69, the serum was reacting to the components of the 
immunogen, that is BSA and PbTx-2. However, no reaction was observed with foreign 
proteins such as unconjugated OVA, KLH or LPH.
To assure that no potential antibodies have been missed, the supernatants collected 
just before freezing the positive fusion wells were tested in a competitive assay using 20 
pg/mL of PbTx-2 as a competitor (Figure 70).
As expected, no competition was observed in the supernatants containing IgG 
antibodies to BSA. For the rest of die IgM antibodies, this ELISA showed no 
competition or evidence of anti-PbTx-2 antibodies.
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Figure 69.Response of serum collected the day of the fusion of mouse 12 (immunized 
with BSA-Brevetoxin-2 [PbTx-2]) with different coating proteins at 5 pg/mL. Serum 
was diluted 1:1000 for testing. Goat anti-mouse IgG (H&L)-HRPO was diluted 1:5000.
TMB was used for color development
□  PbTx-2 
■  No PbTx-2
Fusion well number
Figure 70.Competition assay using tissue culture supernatants from fusion 8 (mouse 12 
immunized with BSA-Brevetoxin-2 [PbTx-2]) and PbTx-2 at 20 pg/mL. Plates were 
coated with OVA-PbTx-2 at 5 pg/mL. Goat anti-mouse IgG (H&L)-HRPO was diluted 
1:5000. TMB was used for color development
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To further reassure that no potential antibodies were discarded, a highly sensitive 
cytotoxicity assay was used. The effect of PbTx-2 on Neuro-2 a cells was previously 
reported (Figure 21). A modification of this assay (Materials and Methods) was 
performed to try to detect any anti-PbTx-2 antibodies in the tissue culture supernatants. 
However, no cell death was prevented by addition of these supernatants (data not 
shown). This was expected since PbTx-2 has a very high affinity for the sodium channel 
and antibodies in the supernatants would need to have an extremely high affinity to 
compete. If a high affinity antibody towards PbTx-2 would have been present in the first 
place, it would have been detected with the ELISA analyses conducted earlier.
Mouse anti-PbTx-2 IgG antibodies were present in the serum collected the day of 
the fusion. However, no specific hybridomas were selected. This may have been due to 
overgrowth of hybridomas by non-producer cells present in the same wells, by 
overgrowth by fibroblasts, or by the loss of chromosomes involved in antibody 
production. Moreover, the presence of a high concentration of B cells specific for BSA 
and other compounds decreased the probability of fusing desired B cells. The next step 
was to perform a new fusion using the same conditions of fusion 8.
2. Fusion 9
The general conditions of fusion 9 are summarized below:
• Myeloma cell line: Sp2/0-Agl4
• ELISA for screening: 100 pL volumes and TMB for color development
• OVA-PbTx-2 prepared as described in Materials and Methods, but duplicating the 
amount of PbTx-2 and reducing the concentration of OVA from 10 mg to 4 mg.
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Mouse 13 was immunized with BSA-Brevetoxin-2. The immunization schedule is 
shown in Table 23.
Table 23 .Immunization schedule for mouse 13 using BSA-Brevetoxin-2 (PbTx-2) for
preparation of anti-PbTx-2 antibodies.




1st immunization 100 pg ip + 100 pg sc FCAb 1 8
1st boost 100 pg ip FIAC 24 31
2nd boost 100 pg ip FIA 120 127
Final boost 100 pg ip None 156 159
8 sc - subcutaneous; ip - intraperitoneal 
b FCA - Freund’s complete adjuvant 
c FIA - Freund’s incomplete adjuvant
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Figure 71. Antibody production response of mouse 13 after each immunization with 
BSA-Brevetoxin-2 (PbTx-2). Plates were coated with OVA-PbTx-2 at 5 pg/mL. Each 
serum was diluted 1:1000. Goat anti-mouse IgG (H&L)-HRPO was diluted 1:5000.
TMB was used for color development
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It is clear that the mouse was responding to repeated injections of the BSA-PbTx-2 
conjugate. The specific isotype(s) of these antibodies is uncertain because the secondary 
labeled antibody used for detection of murine antibodies was specific for both the heavy 
and light chains of IgG antibodies; therefore, it can cross-re act with IgM and IgA 
antibodies.
Since it was important to determine the presence of mouse anti-PbTx-2 IgG 
antibodies (preferred antibody isotype for use in an ELISA), the serum obtained the day 
of the fusion was serially diluted to determine its titer and murine antibodies were 
detected using a secondary labeled antibody specific for the constant y chain of murine 
antibodies. OVA and OVA-PbTx-2 coated plates were used as controls using immune 
and pre-immune sera, respectively. BSA coated plates were used to determine the 
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Figure 72.Titer of serum collected the day of the fusion of mouse 13 immunized with 
BSA-Brevetoxin-2 (PbTx-2). Plates were coated with OVA-PbTx-2, OVA, and BSA at 
5 pg/mL. Goat anti-mouse IgG (y)-HRPO was diluted 1:5000. TMB was used for color 
development. Plotted points are the means of triplicate determinations. Variation from
the mean was typically 5% or less.
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The titer of PbTx-2 IgG antibodies in the serum collected the day of the fusion was 
1:102,400. This indicates that mouse anti-PbTx-2 IgGs were present, which correlates 
with the presence of activated B cells secreting antibodies of the desired isotype and 
specificity. Since immune sera in OVA coated plates gave absorbance readings of less 
than 0.1, the response observed was due to antibodies reacting to some portion of the 
PbTx-2 molecule only. In addition, the use of pre-immune serum in OVA-PbTx-2 
coated plates gave absorbance readings of less than 0.1; therefore, the response observed 
was not due to compounds present in the mouse before the first immunization. Even 
though the titer of anti-PbTx-2 antibodies was high, it may be considered low when 
compared with the concentration of antibodies against BSA, which after a 1:409,600 
dilution still showed a high absorbance. This could be a problem in the fusion process 
because the final boost activated not only B cells specific for PbTx-2, but also those 
specific for BSA. As shown in previous fusions, this may reduce the probability of 
fusing desired B cells.
To further assure that the response observed was due to mouse anti-PbTx-2 IgG 
antibodies, a competitive assay was performed in the serum obtained the day of the 
fusion. Serial dilutions of PbTx-2 were incubated with diluted serum (1:2000). The 
absorbance reading obtained when no PbTx-2 was added, was designated Ao (Figure 
73). Mouse anti-PbTx-2 IgG antibodies were present in the serum collected the day of 
the fusion. The I C 5 0  was 0.23 pg/mL. This competition assay determined the presence of 
mouse anti-PbTx-2 IgG antibodies only; however, to determine the specific IgG 
isotype(s) and if other isotypes specific for PbTx-2 were present, the serum obtained the 
day of the fusion was isotyped using an antigen-specific ELISA (Appendix B).
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Figure 73 .Computer-generated best fit competition curve for serum collected the day of 
the fusion of mouse 13 (immunized with BSA-Brevetoxin-2 [PbTx-2]). Plates were 
coated with OVA-PbTx-2 at 5 pg/mL. Goat anti-mouse IgG (y)-HRPO was diluted 
1:5000. TMB was used for color development Plotted points are the means of duplicate 
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Figure 74.Antigen-specific and capture isotyping serum collected the day of the fusion 
of mouse 13 (immunized with BSA-Brevetoxin-2 [PbTx-2]). Serum was diluted 1:1000
for testing.
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Isotypes of BSA antibodies in the same serum were also determined. In addition, a 
capture isotyping ELISA (Appendix B) was performed in this same serum to show that 
at the time of the fusion a high number of antibodies were present, which correlates with 
the presence of B cells specific for molecules other than BSA and PbTx-2. The results 
of these isotyping experiments are summarized in Figure 74.
Figure 74 shows that mainly IgGl antibodies specific for PbTx-2 were present the 
day of the fusion. In the case of BSA coated plates, IgGl, IgG2a and IgM antibodies 
were present. The capture isotyping ELISA is capable of detecting all antibodies 
present in the serum, with no preference for their specificity. As expected, all isotypes 
were detected.
The fusion was performed three days after the last immunization. Sp2/0-Agl4 
myeloma cells were used for fusion. The splenocytes cell suspension had a total of 1.2 x 
10® cells. A 1:5 fusion ratio was selected; therefore, 2.4 x 107 myeloma cells were used. 
The mixed cells were suspended in 70 mL of conditioned media-HT to obtain a cell 
density of 2.1 x 106 cells/mL. Since 100 pL were plated per well, the cell density was
2.1 x 105 cells/well. A total of 7 plates was used. The feeding schedule after day 0 was 
followed as described in Materials and Methods.
The wells in the fusion plates showing growth were consecutively numbered 
among the plates and screened. After screening of the wells showing hybridoma growth 
(607 wells), 45 were initially scored as positive. After expansion and rescreening, just 8 
wells showed an absorbance at least twice the background. Therefore, the fusion 
efficiency was 1.32 %. Table 24 lists those fusion wells considered positive, their 
absorbance after rescreening, and their isotype.
165
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Table 24.Wells derived from fusion 9 (mouse 13 immunized with BSA-Brevetoxin-2) 
selected for further testing. The ELISA for screening was performed using 100 pL 
volumes, goat anti-mouse IgG (H&L)-HRPO at 1:1000 and TMB for color
development.
Fusion well Absorbance of fusion well the Isotype of









As in fusion 8, positive fusion wells were expanded and tested in an ELISA using 
different coating proteins. As part of the controls used for this ELISA, plates were 
coated not only with OVA-PbTx-2, but also with irrelevant proteins such as BSA, LPH, 
OVA, and KLH. At this point, unexpected results were found since the positive 
response obtained for OVA-PbTx-2 was not specific. Figure 75 shows the results of 
this ELISA using tissue culture supernatants of fusion wells before freezing.
Figure 75 shows that wells 98, 257, 327, and 571 are specific for the protein used 
to conjugate PbTx-2 for immunizations (BSA); therefore, the absorbance readings 
obtained through the screening process were due to non-specific binding of anti-BSA 
IgG antibodies in the supernatant.
The rest of the fusion wells were IgMs. Wells 104, 118, 250, and 481 gave almost 
the same absorbance with irrelevant proteins and even uncoated plates. It is tfren 
unlikely that the antibodies were recognizing some region of all these proteins The
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problem here was the nature of IgM antibodies (high avidity). Figure 74 already showed 
that in fact anti-BSA IgM antibodies were present in the serum the day of the fusion. It 
is likely that these antibodies were shown to be positive because of their high avidity.
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Figure 75.Tissue culture supernatants obtained from fusion 9 (mouse 13 immunized 
with BSA-Brevetoxin-2). Goat anti-mouse IgG (H&L)-HRPO was diluted 1:1000. TMB
was used for color development.
The next step was to determine if the serum was reacting as the hybridoma 
supernatants (binding to different proteins). When the titer of the serum was performed 
(Figure 72), it was determined that no antibodies against OVA were present the day of 
the fusion but, as expected, antibodies against BSA were present However, it was 
important to incorporate the other irrelevant proteins used in Figure 75. Figure 76 shows 
the results of this experiment
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Figure 76.Response of serum collected the day of the fusion of mouse 13 (immunized 
with BSA-Brevetoxin-2 [PbTx-2]) with different coating proteins at 5 pg/mL. Serum 
was diluted 1:1000 for testing. Goat anti-mouse IgG (H&L)-HRPO was diluted 1:5000.
TMB was used for color development
As shown in Figure 76, the serum was reacting to the components of the 
immunogen, that is BSA and PbTx-2. However, no specificity was observed to foreign 
antigens such as unconjugated OVA, KLH, or LPH.
To assure that no potential antibodies have been missed, the original supernatants 
collected just before freezing the cells were tested in a competitive assay using 20 
pg/mL of PbTx-2 as a competitor (Figure 77).
As expected, no competition was observed in the supernatants containing 
antibodies to BSA. For the rest of the IgM antibodies, this ELISA showed no 
competition or evidence of anti-PbTx-2 antibodies; therefore, this explains why no anti- 
PbTx-2 antibodies were obtained. To further reassure that no potential antibodies were 
discarded, a highly sensitive cytotoxicity assay was used. A standard curve with PbTx-2
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was prepared to test the effect of the toxin on Neuro-2a cells (Figure 21). It was found 
that no cell death occurred non-specifically due the tissue culture supernatants by 
themselves. For the specific cytotoxicity assay, it was found that none of the antibodies 
tested neutralized the activity of PbTx-2 (data not shown).
98 104 118 250 257 327 481 571
Fusion well number
Figure 77.Competition assay using tissue culture supernatants from fusion 9 (mouse 13 
immunized with BSA-Brevetoxin-2 [PbTx-2]) and PbTx-2 at 20 pg/mL. Plates were 
coated with OVA-PbTx-2 at 5 pg/mL. Goat anti-mouse IgG (H&L)-HRPO was diluted 
1:5000. TMB was used for color development.
Since mouse anti-PbTx-2 IgG antibodies were present in the serum of this mouse, 
then it was just a matter of statistical probability or loss of specific hybridomas. The 
next step was to perform a new fusion using now a new method called in vitro 
stimulation.
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3. Fusion 10
The general conditions of fusion 10 are summarized below:
• Myeloma cell line: Sp2/0-Agl4
• ELISA for screening: 100 pL volumes and TMB for color development
• OVA-PbTx-2 prepared as described in Materials and Methods but duplicating the 
amount of PbTx-2 and reducing the concentration of OVA from 10 mg to 4 mg.
Mouse 14 was immunized with BSA-PbTx-2. The immunization schedule is shown 
in Table 25.
Table 25 .Immunization schedule for mouse 14 using BSA-Brevetoxin-2 (PbTx-2) for
preparation of anti-PbTx-2 antibodies.
Immunization number Dose/Injection site* Adjuvant Injection Bleeding
day
1st immunization_____ 100 pg ip + 1QQ pg sc FCAb_____1________ 8________
1st boost____________ 100 pg ip_____________FIAC_____ 24_______ 31_______
Final boost (in vitro) 1 pg/mL medium None 158______ 158______
8 sc - subcutaneous; ip - intraperitoneal 
b FCA - Freund’s complete adjuvant 
c FIA - Freund’s incomplete adjuvant
Figure 78 shows the response of mouse 14 after each injection with BSA- 
Brevetoxin-2, except for the last bleed which was taken just before dissecting the spleen 
and performing the in vitro stimulation. It is clear that mouse 14 was responding to 
repeated injections of the BSA-PbTx-2 conjugate. Even after approximately 32 weeks 
without receiving booster injections, the concentration of anti-PbTx-2 antibodies 
remained high. Figure 78 shows the presence o f IgG, IgM, and/or IgA.
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Figure 78 Antibody production response of mouse 14 after each immunization with 
BSA-Brevetoxin-2 (PbTx-2) and before the in vitro stimulation. Plates were coated with
OVA-PbTx-2 at 5 pg/mL. Each serum was diluted 1:1000. Goat anti-mouse IgG 
(H&L)-HRPO was diluted 1:5000. TMB was used for color development Plotted points 
are the means of triplicate determinations. Variation from the mean was typically 5% or
less.
Since it was important to determine the presence of mouse anti-PbTx-2 IgG 
antibodies (preferred antibody isotype for use in an ELISA), the serum obtained the day 
of the fusion was serially diluted to determine its titer and murine antibodies were 
detected using a secondary labeled antibody specific for y constant chains. OVA and 
OVA-PbTx-2 coated plates were used as controls using immune and pre-immune sera, 
respectively. BSA coated plates were used to determine the response induced by the 
carrier protein (Figure 79).
The titer of PbTx-2 IgG antibodies present in the serum collected just before the in 
vitro immunization was 1:25,600. This suggests that mouse anti-PbTx-2 IgGs were 
present, and so it was expected that the B cells producing anti-PbTx-2 antibodies could 
be stimulated in vitro. Since pre-immune and immune sera in OVA-PbTx-2 and OVA
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coated plates, respectively, gave absorbance readings of less than 0.1, the response 
observed was due to antibodies reacting to some portion of the PbTx-2 molecule only 
and to antibodies produced only after immunizations with BSA-PbTx-2. Even though 
the titer of anti-PbTx-2 IgG antibodies was high, it was qualitatively lower to that of 
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Figure 79.Titer of serum collected before the in vitro stimulation of mouse 14 
immunized with BSA-Brevetoxin-2 (PbTx-2). Plates were coated with OVA-PbTx-2, 
OVA, and BSA at 5 pg/mL. Goat anti-mouse IgG (y)-HRPO was diluted 1:5000. TMB 
was used for color development. Plotted points are the means of triplicate 
determinations. Variation from the mean was typically 5% or less.
To reassure that the response observed was due to mouse anti-PbTx-2 IgG 
antibodies, a competitive assay was performed in the serum obtained just before 
performing the in vitro stimulation. Serial dilutions of PbTx-2 were incubated with 
diluted serum (1:1000) (Figure 80).
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Figure 80.Computer-generated best fit competition curve for serum collected before the 
in vitro stimulation of mouse 14 (immunized and stimulated with BSA-Brevetoxin-2 
[PbTx-2]). Plates were coated with OVA-PbTx-2 at 5 pg/mL. Goat anti-mouse IgG (y)- 
HRPO was diluted 1:5000. TMB was used for color development Plotted points are the 
means of duplicate determinations. Variation from the mean was typically 5% or less.
As shown in Figure 80, mouse anti-PbTx-2 IgG antibodies were present in the 
serum collected the day of the in vitro stimulation. The IC50 was 0.47 pg/mL.
To determine the specific IgG isotype(s) and if other isotypes specific for PbTx-2 
were present the serum was isotyped using an antigen-specific ELISA (Appendix B). 
Isotypes of BSA antibodies were also determined. In addition, a capture isotyping 
ELISA was performed to detect all isotypes present in the whole serum (Appendix B). 
The results of these isotyping experiments are summarized in Figure 81.
Figure 81 shows that IgGl, IgG2a, and IgM antibodies specific for PbTx-2 were 
present in the serum after 2 injections. In the case of BSA coated plates, IgGl, IgG2a, 
IgG2b, and IgM antibodies were present in the serum. The capture isotyping ELISA 
detected all isotypes in the serum collected just before the in vitro stimulation.
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Figure 81 .Antigen-specific and capture isotyping for serum collected before the in vitro 
stimulation o f mouse 14 (immunized and stimulated with BSA-Brevetoxin-2 [PbTx-2]).
Serum was diluted 1:1000 for testing.
The splenocytes cell suspension had a total of 1.7 x 10s. These cells were plated at 
a density of 6.8 x 106 cells/mL in 25 mL of in vitro stimulation media with 1 pg of 
BSA-PbTx-2 per mL of medium. After the in vitro stimulation, just 5.1 x 107 cells were 
recovered (30 %). This agreed with the literature review of other in vitro immunizations. 
The fusion was performed after five days of the in vitro stimulation of splenocytes with 
BSA-PbTx-2. A 1:5 fusion ratio was selected. Sp2/0-Agl4 myeloma cells were used 
for fusion; therefore, 1 x 107 myeloma cells were needed. The mixed cells were 
suspended in 30 mL of conditioned media-HT to obtain a cell density of 2 x 106 
cells/mL. Since 100 pL were plated per well, the cell density was 2 x 105 cells/well. A 
total of 3 plates was used. The feeding schedule after day 0 was followed as described in 
Materials and Methods.
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In this fusion the entire plates showed growth; therefore, numbers assigned to these 
wells were the number of the plate (B1-B3) and the corresponding column and row (A 
to H-l to 12). After screening of the wells showing hybridoma growth (384 wells), 40 
supernatants were originally scored as positive. After expansion and rescreening, just 9 
wells showed an absorbance at least twice the background. Therefore, the fusion 
efficiency was 2.3 %. Table 26 lists those fusion wells considered positive, the 
absorbance they showed when rescreened, and their isotype.
Table 26.Wells derived from fusion 10 (mouse 14 immunized  and stimulated with BSA- 
Brevetoxin-2) selected for further testing. The ELISA for screening was performed 
using 100 pL volumes, goat anti-mouse IgG (H&L)-HRPO at 1:1000 and TMB for 
color development Isotyping was performed using a commercial kit.
Fusion well 
number













Since the first seven fusions showed that no hybridomas of the desired specificity 
were selected after cloning, starting on fusion 8 the approach was different 
Supernatants were tested in an ELISA using different coating proteins, and if a 
potential hybridoma was detected, it would be cloned. It was unnecessary to keep 
cloning hybridomas producing antibodies to carrier proteins or unknown compounds.
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As part of the controls used for this ELISA, plates were coated with OVA-PbTx-2, 
but also with irrelevant proteins such as OVA, LPH, BSA, and KLH. Figure 82 shows 
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Figure 82.Tissue culture supernatants obtained from fusion 10 (mouse 14 immunized 
and stimulated with BSA-PbTx-2). Goat anti-mouse IgG (H&L)-HRPO was diluted 
1:1000. TMB was used for color development.
To explain the presence of anti-BSA antibodies after the fusion, a justification can 
be given: MDP was used in the in vitro stimulation, and since this is a polyclonal 
activator, it stimulated whatever B cells it encountered, without regard for their 
specificity. Since memory B cells against BSA remained in mice 14, these were 
activated. Since none of these hybridomas secreted the antibody of interest, they were
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not cloned. To assure that the serum was reacting only to specific proteins, it was tested 
in a new ELISA using more coating proteins (Figure 83).
*-
f  ' \ : ■>>. 
P . I -.
• t 1 -  S
BSA BSA-PbTx-2 OVA OVA-PbTx-2 KLH LPH
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Figure 83 .Response of serum collected before the in vitro stimulation of mouse 14 
(immunized and stimulated with B SA-Brevetoxin-2 [PbTx-2]) with different coating 
antigens at 5 pg/mL. Serum was diluted 1:1000 for testing. Goat anti-mouse IgG 
(H&L)-HRPO was diluted 1:5000. TMB was used for color development
As observed in Figure 83, the serum was reacting only to the components of the 
immunogen, that is BSA and PbTx-2. However, no specificity was observed to foreign 
antigens such as unconjugated OVA or KLH and LPH.
To assure that no potential antibodies have been missed, the supernatants collected 
just before freezing the cells were tested in a competitive assay using 20 pg/mL of 
PbTx-2 as a competitor (Figure 84).
As expected, no competition was observed in the supernatants already proven to 
contain antibodies to BSA. For the rest of the IgM antibodies, this ELISA showed no
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competition or evidence of anti-PbTx-2 antibodies; therefore, this explains why no anti- 
PbTx-2 antibodies were obtained. To further reassure that no potential antibodies were 
discarded, a highly sensitive cytotoxicity assay was used. A standard curve with PbTx-2 
was prepared to test the effect of the toxin on Neuro-2a cells (Figure 21). To assure that 
the concentrated supernatants were not toxic to the cells in a non-specific form, the 
absorbance readings were compared to those of cells receiving no toxin (just regular 
medium). It was found that no cell death occurred non-specifically. For the specific 
cytotoxicity assay, the tissue culture supernatants were used together with PbTx-2 and 
ouabain/veratridine. It was found that none of the antibodies tested neutralized the 
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Figure 84.Competition assay using tissue culture supernatants from fusion 10 (mouse 14 
immunized and stimulated with BSA-Brevetoxin-2 [PbTx-2]) and PbTx-2 at 20 pg/mL. 
Plates were coated with OVA-PbTx-2 at 5 pg/mL. Goat anti-mouse IgG (H&L)-HRPO 
was diluted 1:5000. TMB was used for color development
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Since mouse anti-PbTx-2 IgG antibodies were present in the serum of this mouse, 
then it was a matter o f statistical probability or loss of specific hybridomas. The next 
step was to perform a new fusion following the same conditions of fusion 14, but using 
PbTx-2 alone for the in vitro stimulation.
4. Fusion 11
The general conditions of fusion 11 are summarized below:
• Myeloma cell line: Sp2/0-Agl4
• ELISA for screening: 100 pL volumes and TMB for color development
• OVA-PbTx-2 prepared as described in Materials and Methods but duplicating the 
amount of PbTx-2 and reducing the concentration of OVA from 10 mg to 4 mg.
Mouse IS was im m unized with BSA-PbTx-2. The immunization schedule is shown 
Table 27.
Table 27.Tmmunization schedule for mouse 15 using BSA-Brevetoxin-2 (PbTx-2) for
preparation of anti-PbTx-2 antibodies.
Immunization number Dose/Injection site* Adjuvant Injection Bleeding
day day
1st immunization______100 pg ip + 100 pg sc FCA_____ 1________ 8_______
1st boost____________ 100 pg ip____________ FIAC______24_______ 31______
Final boost (in vitro) 1 pgd/mL medium None 158 158
a sc - subcutaneous; ip - intraperitoneal 
b FCA - Freund’s complete adjuvant 
c FIA - Freund’s incomplete adjuvant 
d In vitro stimulation with Brevetoxin-2
Figure 85 shows the response of mouse 15 after each injection with BSA- 
Brevetoxin-2, except for the last serum which was taken just before performing the in 
vitro stimulation.
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Figure 85.Antibody production response of mouse 15 after each immunization with 
BSA-Brevetoxin-2 (PbTx-2) and before the in vitro stimulation. Plates were coated with 
OVA-PbTx-2 at 5 pg/mL. Each serum was diluted 1:1000. Goat anti-mouse IgG 
(H&L)-HRPO was diluted 1:5000. TMB was used for color development Plotted point 
are the means of triplicate determinations. Variation from the mean was typically 5% or
less.
It was clear that mouse 15 was responding to repeated injections of the BSA-PbTx- 
2 conjugate. Even after approximately 32 weeks after the last boost the serum still 
showed a high concentration of anti-PbTx-2 antibodies. To know if some of these 
antibodies were of the IgG isotype, it was necessary to use a secondary labeled antibody 
specific for the y chain of murine antibodies. The serum obtained before the in vitro 
stimulation was serially diluted to determine its titer and if mouse anti-PbTx-2 IgG 
antibodies were present OVA and OVA-PbTx-2 coated plates were used as controls 
using immune and pre-immune serum, respectively. BSA coated plates were used to 
determine the response induced by the carrier protein (Figure 86).
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Figure 86.Titer of serum collected before the in vitro stimulation of mouse 15 
immunized with BSA-Brevetoxin-2 (PbTx-2). Plates were coated with OVA-PbTx-2, 
OVA, and BSA at 5 jig/mL. Goat anti-mouse IgG (y)-HRPO was diluted 1:5000. TMB 
was used for color development. Plotted points are the means of triplicate 
determinations. Variation from the mean was typically 5% or less.
The titer of PbTx-2 IgG antibodies in the serum collected before the in vitro 
stimulation was 1:51,200. This suggests that mouse anti-PbTx-2 IgGs were present in 
the serum. Since immune sera in OVA coated plates gave absorbance readings of less 
than 0.1, the response observed was due to antibodies reacting to some portion of the 
PbTx-2 molecule only. Also, the use of pre-immune serum with OVA-PbTx-2 coated 
plates gave absorbance readings of less than 0.1; therefore, the response observed was 
not due to compounds present in the mouse before the first immunization. As expected, 
the concentration of anti-BSA IgG antibodies was high.
To further assure that the response observed was due to mouse anti-PbTx-2 IgG 
antibodies, a competitive assay was performed using the serum of this mouse. Serial 
dilutions of PbTx-2 were incubated with diluted serum (1:800) (Figure 87).
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Figure 87.Computer-generated best fit competition curve for serum collected before the 
in vitro stimulation of mouse 15 (immunized with BSA-Brevetoxin-2 [PbTx-2] and 
stimulated with PbTx-2). Plates were coated with OVA-PbTx-2 at 5 pg/mL. Goat anti­
mouse IgG (y)-HRPO was diluted 1:5000. TMB was used for color development. 
Plotted points are the means of duplicate determinations. Variation from the mean was
typically 5% or less.
Figure 87 shows that competition of anti-PbTx-2 IgG antibodies for PbTx-2 in free 
form was possible. This was important because sometimes when the conjugated toxin is 
used for immunization, antibodies predominantly detect the toxin in that way; in other 
words, they cannot recognize the toxin in free form due to conformational changes. The 
IC50 was 1.17 pg/mL.
To determine the specific IgG isotype(s) and if other isotypes specific for PbTx-2 
were present, the serum obtained the day of the fusion was isotyped using an antigen- 
specific ELISA (Appendix B). Isotypes of BSA antibodies were also determined. In 
addition, a capture isotyping ELISA was performed to show that at the time of the 
fusion a high number of antibodies of unknown specificity were present (Appendix B). 
The results of these isotyping experiments are summarized in Figure 88.
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Figure 88 Antigen-specific and capture isotyping for serum collected before the in vitro 
stimulation of mouse 15 (immunized with BSA-Brevetoxin [PbTx-2] and stimulated 
with PbTx-2). Serum was diluted 1:1000 for testing.
Figure 88 shows that IgGl and IgM antibodies specific for PbTx-2 were present in 
the serum; a qualitative comparison of these isotypes shows the predominance of IgGl 
antibodies. In the case of BSA coated plates, IgGl, IgG2b, and IgM antibodies were 
present The capture isotyping ELISA detects all antibodies present in the serum, with 
no preference for their specificity. As expected, all isotypes were detected.
A total of 1.8 x 10® cells splenocytes was obtained from mouse 15. These cells 
were plated at a cell density of 6 x 106 cells/mL in 30 mL of in vitro stimulation media 
with 1 pg of PbTx-2 per mL of medium. The fusion was performed five days after the in 
vitro stimulation. Just 35% of the original splenocytes survived the stimulation (6.3 x 
107 cells). Sp2/0-Agl4 myeloma cells were used for fusion. A 1:5 fusion ratio was 
selected; therefore, 1.3 x 107 myeloma cells were used. The mixed cells were suspended 
in 40 mL of conditioned media-HT to obtain a cell density of 1.9 x 106 cells/mL. Since
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100 \lL  were plated per well, the cell density was 1.9 x 105 cells/well. A total of 4 plates 
was used. The feeding schedule after day 0 was followed as described in Materials and 
Methods.
All wells in the fusion plates showed growth; therefore, the numbering system was 
followed using guidelines provided in fusion 10. After screening of the wells showing 
hybridoma growth (384 wells), 40 wells were originally scored as positive. After 
expansion and rescreening, just 11 wells showed an absorbance at least twice the 
background. Therefore, the fusion efficiency was 2.86 %. Table 28 lists those fusion 
wells considered positive, their absorbance after rescreening, and their isotype.
Table 28.Wells derived from fusion 11 (mouse 15 immunized with BSA-Brevetoxin-2 
and stimulated with brevetoxin-2) selected for further testing. The ELISA for screening 
was performed using 100 pL volumes, goat anti-mouse IgG (H&L)-HRPO at 1:1000 
and TMB for color development Isotyping was performed using a commercial kit
Fusion well Absorbance of fusion well the Isotype of












Since the first seven fusions showed that no hybridomas of the desired specificity 
were selected after cloning, the same approach of fusion 10 was used. Supernatants
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were tested in an ELISA using different coating proteins, and only if  a potential 
hybridoma was detected, then it would be cloned. As part of the controls used for this 
ELISA, plates were coated with OVA-PbTx-2 but also with irrelevant proteins such as 
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Figure 89.Tissue culture supernatants obtained from fusion 11 (mouse IS immunized 
with BSA-Brevetoxin-2 [PbTx-2] and stimulated with PbTx-2). Goat anti-mouse IgG 
(H&L)-HRPO was diluted 1:1000. TMB was used for color development.
PbTx-2 specific B cells were not activated, this can be due to the lack of 
recognition of PbTx-2 by the immune system. Even though B cells may recognize this 
molecule, the T cells were not likely to interact with the antigen-MHC II complex;
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therefore, activation of B cells did not occur, and so there was no clonal expansion. The 
selected hybridomas are of no use; therefore, they were not cloned.
To confirm that the serum was reacting properly, a new ELISA was used 
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Figure 90.Response of serum collected before the in vitro stimulation of mouse 15 
(immunized with BSA-Brevetoxin-2 [PbTx-2] and stimulated with PbTx-2) with 
different coating antigens at 5 pg/mL. Serum was diluted 1:1000 for testing. Goat anti­
mouse IgG (H&L)-HRPO was diluted 1:5000. TMB was used for color development.
As observed in Figure 90, the serum was reacting only to the components of the 
immunogen, that is BSA and PbTx-2. However, no specificity was observed to foreign 
antigens such as unconjugated OVA or KLH and LPH.
To assure that no potential antibodies have been missed, the original supernatants 
(before cloning) collected just before freezing the cells were tested in a competitive 
assay using 20 pg/mL of PbTx-2 as a competitor (Figure 91).
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Fusion well number
Figure 91 .Competition assay using tissue culture supernatants from fusion 11 (mouse 15 
immunized with BSA-Brevetoxin-2 [PbTx-2] and stimulated with PbTx-2) and PbTx-2 
at 20 (xg/mL. Plates were coated with OVA-PbTx-2 at 5 |xg/mL. Goat anti-mouse IgG 
(H&L)-HRPO was diluted 1:5000. TMB was used for color development.
As expected, no competition was observed in the supernatants containing 
antibodies to BSA. For the rest of the IgM antibodies, this ELISA showed no 
competition or evidence of anti-PbTx-2 antibodies; therefore, this explains why no anti- 
PbTx-2 antibodies were obtained. To further reassure that no potential antibodies were 
discarded, a highly sensitive cytotoxicity assay was used. A standard curve with PbTx-2 
was prepared to test the effect of PbTx-2 on Neuro-2a cells (Figure 21).
To assure that the concentrated supernatants were not toxic to the cells in a non­
specific form, the absorbance readings were compared to those of cells receiving no 
toxin O'ust regular medium). It was found that no cell death occurred non-specifically.
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For the specific cytotoxicity assay, it was found that none of the antibodies tested 
neutralized the activity of PbTx-2 (data not shown). This was expected since PbTx-2 
has a very high affinity for the sodium channel and antibodies in the supernatants would 
need to have an extremely high affinity to compete. If a high affinity antibody towards 
PbTx-2 would have been present in the first place, it would have been detected with the 
ELISA analyses conducted earlier. Even tough the antibodies were tested in a 
concentrated form to possibly compensate for the low affinity, no effect was observed. It 
can be concluded that these IgM antibodies do not recognize PbTx-2.
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DISCUSSION OF RESULTS
A) PREPARATION OF MONOCLONAL ANTIBODIES
An immunized animal generally produces a random number of antibody molecules 
to yield a polyclonal antiserum. An estimated 10-40 x 106 distinct antibody molecules 
can theoretically be generated by a BALB/C mouse that contains about 2 x 10* B cells. 
About 1 out of every 10,000 antibody molecules appears to recognize a given epitope 
with varying degrees of affinity. Thus, for any given epitope, several different 
monoclonal antibodies could be produced by an animal. In practice, however, only a 
random few (up to 10) B cell clones are activated and only a few distinct antibodies are 
generated out of this repertoire of randomly formed specificities. Therefore, it is 
practically impossible to make reproducible antibodies against a given epitope 
(Deshpande, 1996). This explains why more than one mouse should be immunized with 
a new immunogen.
Antibody specificity may vary widely between individual animals with respect to 
the dominant antigenic episodes recognized on a given protein antigen (Coligan et al.,
1991). This would explain why 3 mice did not respond to the injection of the KLH- 
PbTx-2 conjugate, while others responded to the same or different immunogenic 
conjugates. The specificity of a polyclonal antiserum depends on the collective 
properties of the entire population of antibodies, which are determined by the structures 
of the various antibody binding sites. Polyclonal antiserum reacts with several 
immunodominant determinants on the antigen and includes antibodies with the capacity 
to make high and low affinity contacts. The antibodies themselves will be of various 
classes and subclasses and will include a substantial amount of the IgM class (Coligan
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et al., 1991; Campbell, 1996). Each new challenge with an antigen generates a new low- 
affinity IgM response (Campbell, 1996). This was observed in this study where the 
isotyping experiments performed in the serum collected the day of the fusion revealed 
the presence of IgMs against the carrier protein and PbTx-2, even after several 
injections of the immunogenic conjugates.
The specificity of an antibody or antiserum is defined by its ability to discriminate 
between the antigen against which it was made and any other antigen that might occur in 
the test specimens. In practice, one cannot test the whole universe of antigens, but only 
selected antigens. Cross-reactivity is defined as the ability to react with related antigens 
other than the immunogen. In most cases, cross-reactive ligands have lower affinity than 
the immunogen for a particular antibody (Berzofsky et al., 1993). In this study, 
antibodies o f unknown specificity were selected in all fusions. As mentioned above, it is 
impossible to test against a whole spectrum of antigens to determine the exact 
specificity of antibodies. However, it is certain that these selected antibodies are not 
specific for brevetoxin-2. Their exact specificity, therefore, is not of interest.
Since Pbx-2 is a small hydrophobic molecule, conjugation to carrier proteins was 
necessary to elicit an immune response. The coupling of haptens to proteins not only 
allows T cells to help anti-PbTx-2 antibody-producing B cells, but also improves the 
immunogenicity of the hapten by increasing the size of the antigen. In previous 
experiments, it has been reported that for hydrophobic haptens, the highest immune 
response against conjugates (measured as serum titer, fusion efficiency, and number of 
conjugate-specific antibody-secreting clones) was induced by KLH, followed by BSA 
and gelatin. They did not test the effect of LPH. Carrier proteins can modulate both the
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mean affinity  constant of serum and the affinity constant of the monoclonal antibodies 
obtained. The mean affinity constants value of antibodies directed against small haptens 
seems to depend mainly on the carrier molecule (Fasciglione et al., 1996).
The most popular carrier is the highly immunogenic KLH. It is an extremely large 
protein which contains an abundance of functional groups available for conjugation with 
hapten molecules (Hermanson, 1996). LPH and BSA were also tested in this study to 
determine if  they could increase the probability of obtaining anti-PbTx-2 antibodies. 
However, there was no trend observed among titers, IC50S, or fusion efficiency. 
Therefore, the selection of different proteins for conjugation of PbTx-2 made no 
significant difference. High and low titers with high and low IC50S were obtained. In 
practice, the preparation of the LPH conjugate was difficult because of its low 
solubility. Therefore, for future experiments, the use of KLH conjugates would be 
recommended for immunizations and BSA conjugates to coat the plates.
For B cells to produce antibody molecules, it is necessary to obtain help from T 
cells. However, T cells cannot recognize immunogens by themselves; they need to be 
presented via the major histocompatibility complex class II (MHC II). This presentation 
is performed via antigen presenting cells (APC) such as B cells themselves, 
macrophages or dendritic cells. A given clone of B cells recognizes one determinant on 
the antigen via the immunoglobulin (Ig) receptor, whereas the T cell usually recognizes 
another determinant (usually in the carrier) expressed on the processed antigen by MHC 
H (Coligan et al., 1991).
Mechanisms for internalization of the immunogen are different for B cells from the 
other antigen presenting cells. Different B cells bearing specific surface
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immunoglobulins for PbTx-2 would preferentially process PbTx-2 differently to put 
more of some potential fragments than others on their surface, in contrast to non­
specific presenting cells that would process the antigen indifferently (Berzofsky and 
Berkower, 1993).
Freund's adjuvants have been used extensively in the preparation of antigens for 
immunization because they induce a high, long-lasting antibody titer that is often still 
measurable 25 weeks or more after boosting (Coligan et al., 1991). This phenomenon 
was observed in the current study when titering the serum of mice 14 and 15 which had 
not been immunized over approximately 32 weeks prior to the in vitro boosting. This 
would also explain why some mice showed a decreased titer in their serum after some 
injections; high antibody concentrations may have been present in the serum, and so the 
amount of immunogen left for activating new B cells was lower.
The first immunization usually elicits a primary response, perhaps below the limits 
of measurement, because the cells do not contain the number of specific precursors 
necessary for a measurable response (Coligan et al., 1991). This was shown in all 
immunizations made in this study, where responses were detected only after the first 
boost. The mouse used for fusion 6 required four injections. The immunization response 
over time experiments gave useful information with respect to the relative concentration 
and development of anti-PbTx-2 antibodies. These experiments were used as a guide to 
choose the mouse that would be used for the next fusion.
To confirm than an immune response was being elicited by the immunogen, the 
titer of the serum was measured after each injection. The titer of an antibody preparation 
is a measure o f its concentration under a defined set of conditions. It can be defined in
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several ways: (1) the lowest dilution of the antibody(ies) to bind significantly to a 
specific antigen or (2) the dilution of antibody(ies) that gives half-maximal binding to 
antigen (Liddell and Cryer, 1991). For the purpose of this study, this parameter was 
HefinpH as that dilution giving absorbance readings at least twice the background (pre- 
immnne serum). These experiments allowed for the determination of IgG antibodies 
specific for PbTx-2 present in the sera collected the day of each fusion. This was an 
important parameter because this indirectly correlates with the number of PbTx-2 
specific B cells that had been activated in the final boost
The four parameter logistic equation was used to analyze the competition curves 
performed in the serum obtained the day of the fusion (Christopoulos and Diamandis, 
1996). This assay was used to test if antibodies in serum could compete for PbTx-2 in 
free form versus conjugated PbTx-2 bound to the plates. The less PbTx-2 required to 
lower the response (A/Ao) by 50% (IC50), the more sensitive the antibody would be. 
Sensitivity is the property of an assay that defines the smallest amount of analyte that 
can be detected under the conditions of the assay (Deshpande, 1996). The assurance that 
anti-PbTx-2 IgG antibodies could compete for free PbTx-2 confirmed their potential for 
future use in immunological-based detection methods. All tested mice sera in this study 
showed to contain antibodies capable of recognizing free PbTx-2.
In this study, the myeloma cell line Sp2/0-Agl4 was selected for 10 fusions of 
spleen cells. This cell line has the advantage of slightly adhering to the plates making 
feedings and counting of colonies after cloning easier. At some point in the study, it was 
uncertain if this cell line had lost its ability to secrete immunoglobulins as a whole, not 
just specific immunoglobulins. To test this, one of the screenings of fusion 3 included
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coating the plates with the carrier protein used for immunization (LPH). If myeloma 
cells worked they should produce hybridomas secreting anti-LPH antibodies. This 
experiment showed that indeed an extensive number of wells showed this activity (data 
not shown). Even though there was certain assurance of the efficiency of this cell line, a 
new myeloma cell line was used in the next fusion. NS-1 was selected because it was 
proved to be successful in the production of monoclonal antibodies against a small 
hydrophobic compound (Eun Sun Park, personal communication). Changing the 
myeloma line made no difference in the success of the fusion; therefore, the original 
myeloma cell line was used for the rest of the fusions. Moreover, NS-1 cells have a 
disadvantage. They reduce the proportion of hybrids which will potentially secrete 
wholly lymphocyte-derived antibodies. This is because they secrete kappa light chains 
of immunoglobulin which are only secreted along with lymphocyte immunoglobulins 
following hybridization (Liddell and Cryer, 1991).
The plating cell density after the fusion was at around 10s cells per well. This 
theoretically should produce about one single clone per well (Campbell, 1996). 
However, sometimes more than one clone was observed in some of the wells, though no 
more than 3 clones/well were observed. Mouse clones are initially unstable and cells 
tend to lose their ability to secrete antibody. Cells that lose this ability usually grow 
faster and outgrow other cells in the same well that are still secreting antibody 
(Campbell, 1996). This problem of overgrowth of non-producers is a possible 
explanation in the lack of success in isolating the desired clone.
About one third of spleen cells are supporting tissues (fibroblasts, endothelial cells, 
etc.) (Campbell, 1996). In this study, the presence of fibroblasts in the fusion plates was
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a problem. If they were present, the hybridoma cells should be transferred as soon as 
possible to avoid fibroblast overgrowth in the well. However, it was impossible to 
transfer the cells too soon because this may cause them not to expand. This also may 
have caused the loss of some potential clones. Coligan et al. (1991) recommended that 
when cells were expanded from a fusion well with fibroblasts, extra care was taken not 
to scrape the bottom of the well (which will loosen the fibroblasts).
Throughout each fusion, a high number of wells showed to be positive for anti- 
PbTx-2 antibodies after the first screening. However, after expansion of the wells with 
potential clones, most of the clones would scored negative when rescreened and only 
those scoring positive after expansion have been reported in this document What 
happened to wells initially testing positive and then negative after rescreening may be 
due to fibroblast overgrowth, non-producers overgrowth, or loss of chromosomes. It is 
possible that the antibodies detected in the first screening came from antibody producers 
which could not be saved.
In a typical fusion, only about 1% of the starting cells fuse, and only 0.001% form 
stable hybrids (Mayforth, 1993). Depending on the purity of the antigen used, and the 
immunization protocol, more than 50% of the master wells will contain hybridomas, 
and of those, less than 1-5% will contain the desired hybridoma (Coligan et al., 1991). 
Therefore, if we consider that the average number of plates obtained per fusion was 6, 
we would have 576 wells, from which around 288 (50%) would contain hybridomas and 
about 3 to 14 (1-5%) would have the hybridoma of desired specificity. If those specific 
wells contained non-producers or fibroblasts in the same well, the lack of success in 
obtaining anti-PbTx-2 antibodies could be explained.
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B cells are non-specifically activated by interleukins, mitogens, or other growth 
factors and then a broad spectrum of different blastoid B cells are fused (Uthoff and 
Boldicke, 1993). This explains why hybridomas secreting antibodies of unknown 
specificity were present in the fusion plates. In fact, the isotyping experiments showed 
that a whole spectrum of antibodies was present in the serum collected on the day of 
each fusion.
Supernatants frequently contain 1-10 pg/mL of monoclonal antibodies, so they are 
normally assayed without dilution (Coligan et cd., 1991; Liddell and Cryer, 1991). Even 
though a positive well can be defined differently by each researcher, for the purpose of 
this study, a positive well was defined as that showing at least double absorbance 
readings over the response for the negative control wells (fresh medium). Wells that had 
been scored negative at least twice were excluded from further screening. It is important 
to remember that a positive test by ELISA only shows that antibodies against a 
component of the mixture bound to the solid support are present These antibodies may 
also cause non-specific binding. This could explain the screening of unrelated 
antibodies of high avidity (IgM) or antibodies towards the carrier protein due to their 
high concentration in the supernatants.
For screening, plates were coated with 10 pg/mL of the appropriate conjugate. 
Since more than 10 pg/mL to coat the plate would be wasteful (protein capacity of 
polystyrene plates is 300 ng/cm2 (Deshpande, 1996)) and results in the formation of 
multiple layers which causes unstable binding during washing procedures (Liddell and 
Cryer, 1991), no more than 10 pg/mL were used to coat the plates. In an effort to 
increase the amount of PbTx-2 present on the plate, new PbTx-2 conjugates were
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prepared following a modification of the original procedure (Levine and Shimizu,
1992). This did not result in increased success in selection of hybridomas producing 
PbTx-2 antibodies. To further increase the sensitivity of the assay, TMB was used in 
later fusions (6 to 11) because it gives higher absorbance values than ABTS 
(Deshpande, 1996). The former is by far the most popular chromogenic substrate 
because of its excellent sensitivity as well as its long-term stability and availability. To 
further increase the sensitivity of the screening assay, the working volumes were 
increased to 100 pL.
The sensitivity of the screening assay may also be improved using at least one of 
the three heterologous combinations (Deshpande, 1996):
• hapten heterology, where different but related haptens are attached at the same site 
using the same linkage
• bridge heterology, where a different cross-linker is used for coupling the hapten to 
carrier proteins
• site heterology, where the same linking group is attached to different sites.
Three factors are critical for production of specific immunogenic conjugates: hapten 
conjugation, choice of carrier, and amount of neodeterminants. Conjugation methods 
should yield 100% conjugate of well-defined chemical structure, produce a stable link, 
and be practical (economic) and simple. None of the known conjugation procedures 
fully meets these requirements (Fasciglione et al., 1996). One disadvantage of the PbTx- 
2 molecule is the lack of several reactive groups to attach the carrier proteins. This 
limits the number of reactions that may be used. The only available group for relatively 
easy reactions is the aldehyde in the side chain (Figure 9). More complex reactions
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cannot be excluded; however, the price and availability of PbTx-2 limit this approach. 
The use of different linkers has been reported (Baden et al., 1984; Poli et al., 1990; 
Levine and Shimizu, 1992). For this study, a Schiff base reaction was selected. Efforts 
to buy PbTx-2 bound to BSA by carbodiimide to increase the sensitivity of the assay 
were conducted. The cost to coat just one plate exceeded $100, and it has been shown 
that a fusion may yield an average of 6 plates, and not just one screening would be 
necessary, as well as screening after expansion and cloning. The high cost made this 
approach financially limited. The use of a similar compound to use the concept of 
hapten heterology was not possible either. PbTx-2 is a type 2 brevetoxin. PbTx type 1 
molecules have not been successful in the production of conjugates because they are 
unstable (Mark Poli, personal communication).
In the screening assays, at least one well per plate contained fresh culture medium 
as negative control. A positive control, such as polyclonal antibodies, was necessary to 
ensure the effectiveness of the test (Liddell and Cryer, 1991).
It is possible, especially in the early stages of development, that a new hybridoma 
cell may discard excess chromosomes. Not only cells coding for specific antibody are at 
risk, but also those necessary for vital functions (Liddell and Cryer, 1991). Although 
cloning can be performed by the soft agar technique, clones derived by this technique 
must be adapted to liquid culture before the supernatants can be tested. Since cloning by 
limiting dilution allows direct testing of the supernatants, this method was considered 
much more advantageous and used for this study (Coligan et al., 1991).
Cloning is important to reduce the risk of overgrowth by non-producing cells and 
to ensure that the antibodies are truly monoclonal. Subjectively at least, some of the
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wells may be considered to contain monoclonal growth. Positive wells which are likely 
to be of monoclonal origin are expanded and then recloned at least three times, after 
which the final plate should display positive antibody production in virtually all seeded 
wells (Liddell and Cryer, 1991). Since clones obtained in this study were not found to 
be of the desired specificity, they were not cloned again. Since B lymphocytes require 
lymphokines produced by other cells and do not readily grow alone, the hybridomas 
were given conditioned medium for cloning (Campbell, 1996).
Small quantities of the monoclonal antibody can be used in preliminary 
experiments to determine if the monoclonal antibody has the desired property before 
expending the extra effort required to produced purified monoclonal antibodies (Coligan 
et al., 1991). For this study, 10 mL of tissue culture supernatants were collected. For 
expansion of hybridomas, clones were cultured for five days. The monoclonal antibody 
is not metabolized by the cells, therefore, it accumulates in the culture supernatant and 
can be purified (Coligan et al., 1991). In addition, cells make the most antibody when 
they are dying (Campbell, 1996). Ammonium sulfate precipitation can be used to purify 
all subclasses of mouse antibodies (50% saturation, 291 g/L) (Coligan et al., 1991; 
Goers, 1993). Stirring was necessary to avoid localized high concentrations of 
ammonium sulfate that could cause precipitation of non-immunoglobulins.
Monoclonal antibodies cross-react, and when they do, the cross-reaction is not 
minor and cannot be removed by absorption. In polyclonal sera, each different antibody 
has a distinct range of reactivity. The serum as a whole may show only low-titered 
cross-reaction that can be removed by absorption. Therefore, a polyclonal serum may be 
more specific than any one of its clonal parts (Berzofsky et al., 1993).
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IgM antibodies generally express germline determined variable regions that have 
not yet been modified by somatic mutation. That is why they tend to bind to antigens 
with low affinity. Antibodies of the IgG, IgA, and IgE isotypes are made later than IgM 
antibodies during a primary response, but account for most of the antibody that is 
produced during a memory response. Although isotype switching and affinity 
maturation are independent processes, they usually occur simultaneously (Snapper and 
Finkelman, 1993). IgM antibodies have a low affinity, they show multireactivity with 
different antigens in immunoassays such as ELISA procedures, and purification is much 
more difficult than with IgG antibodies (Uthoff and Boldicke, 1993). Therefore, IgM 
antibodies are seldom useful as a reagent in an ELISA.
In this study, hybridomas secreting IgM antibodies were selected. The secondary 
labeled antibody used to detect murine antibodies was raised against the IgG class; 
therefore, it can detect a large number of IgM and IgA antibodies. The antibodies are 
able to cross-react by reaction with the constant region determinants of the X or k light 
chains. While these seem to be a small section of an antibody, the fact that IgMs bind 
more readily and have 10 of such chains to offer to the second antibody, means that one 
detects as many positive IgMs as IgGs using an antibody directed to the whole IgG 
molecule. A second antibody which is IgG specific should be produced by 
immunization of the constant region o f purified mouse y-chain (Campbell, 1991). The 
use of a labeled antibody recognizing both IgM and IgG allowed for the selection of 
IgM antibodies that at the end were found to be of unknown specificity. However, the 
use of an antibody specific for IgG for initial screening may not be adequate, because 
potential IgM antibodies would also be discarded.
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New immunodominant epitopes (neodeterminants) are introduced by most coupling 
agents. Therefore, the conjugation method should be selected carefully to decrease the 
immune response against neodeterminants and to increase antibody specificity against 
the hapten. A study performed by Fasciglione and co-workers (1996) determined that 
for all of the hydrophobic haptens tested (heme, theophyline, pyrrol-equinoline quinone, 
or an oligopentapeptide [Leu-Trp-Gly-Phe-Ala]) most of the immune response was 
directed against either the neodeterminants (the e-lysine aminic bond) or those regions 
of the haptens involved in the coupling reaction. None of the monoclonal antibodies 
obtained was specific for the free haptens. However, the researchers found that 
hydrophilic haptens induced specific antibodies and only a few clones were directed 
against neodeterminants. The explanation was that hydrophobic haptens bound to 
carriers hide inside the carrier itself by interactions with hydrophobic domains. This 
causes the lack/reduction of productive interaction/stimulation with specific B cells.
It has been previously found that the affinity constant of an antibody is of key 
importance in defining the detection limit of an immunoassay. In the case of haptenic 
antigens, the haptens are conjugated to a protein to bind it to a plate. This procedure 
may give lowered affinity constants possibly because of the problem of distinguishing 
between unliganded antibody and singly liganded antibody bound to antigens on solid- 
phase. I C 5 0  values are dependent on many factors, such as antibody concentrations, 
structure, quality and quantity of enzyme tracers, enzyme substrates and their 
concentrations, and the length and time of incubations (Chu et al. 1995).
Antisera induced by hapten-protein conjugates contain antibodies specific to the 
carrier, the hapten, and to the bridge structure between hapten and protein and/or
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adjacent regions of the protein. Therefore, one of the major problems in monoclonal 
antibody production is the selection of antibodies capable of binding only the hapten 
(Danilova, 1994). It has been proposed that for haptens, the screening should be 
conducted with a conjugate differing from the immunogen with regard to both carrier 
protein and the chemical linkage between hapten and protein. In addition, hapten- 
protein coupling should be performed via different amino acid residues (Danilova, 
1994). As previously discussed, the chemical structure of PbTx-2 unfortunately limits 
this approach.
For the selection of suitable monoclonal antibodies, two major problems can arise. 
The affinity of monoclonal antibodies can be low (often lower than polyclonal 
antibodies) and lead to an insufficient detection limit, or low specificity of monoclonal 
antibodies to small haptens resulting in cross-reactivity with hapten analogues (often 
broader than that of polyclonal antibodies) (Chappey et al., 1992). In this study, none of 
the fusions gave potential hybridomas secreting anti-PbTx-2 antibodies after expansion. 
As previously mentioned, the loss of potential hybridomas may have been due to 
overgrowth of other cells present in the same well or to the loss of chromosomes. 
However, as explained above, the sensitivity of the assay might be a problem, and even 
though the sensitivity of the screening assay was improved, the success in selecting 
potential hybridomas did not increase. In addition, many parameters can influence the 
binding of monoclonal antibodies to haptens; this may not be that critical with 
polyclonal antibodies. For example, monoclonal antibodies are more sensitive to 
changes in pH, ionic strength, and the addition of additives such as Tween 20 and 
blocking proteins used in incubation steps. The screening assay was optimized using
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polyclonal antibodies. However, a possibility exists that these conditions may have not 
been optimal for monoclonal antibodies. It was impossible to optimize the assay 
conditions for each tissue culture supernatant tested. This is usually performed at later 
stages in the characterization of specific monoclonal antibodies.
As monoclonal antibodies are issued from a unique B lymphocyte clone, it is often 
assumed that all monoclonal antibodies are immunologically specific. In reality, many 
monoclonal antibodies to haptens are polyspecific, i.e., controlled polyspecificity 
represented by the cross-reactivity toward compounds with the same chemical skeleton 
with varying functional groups (this type of polyspecificity is easily verified by 
standardized cross-reactivity studies), and uncontrolled polyspecificity which involves 
cross-reactivity of monoclonal antibodies with compounds different from the native 
compound (these compounds are not always identified and often do not present strong 
structural or chemical analogies with the hapten, thus precluding cross-reactivity 
studies) (Chappey et al., 1992). These interacting compounds can bind to the paratope 
of the monoclonal antibody at sites other than those interacting with the original hapten. 
Uncontrolled polyspecificity is often discovered at a late stage during the development 
of the immunoassay (Chappey et al., 1992). This type of polyspecificity has been found 
for compounds such as 2,4-dinitrophenyl-aminoalkyl (Imnan and Bamett, 1989), 
metamphetamine (Kelly, 1990), and digoxin (Graves, 1986). A high affinity for an 
analyte does not exclude interference by unknown compounds (Chappey et al., 1992).
Normal animal serum contains a wide range of autoantibodies. They are usually of 
the IgM isotype. Extensive cross-reactivity (polyreactivity) is apparent even with 
bacterial antigens and organic chemical haptens. However, polyreactivity is not an
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exclusive property of natural autoantibodies, it can also be an attribute of antibodies 
against bacterial antigens, chemical haptens, and foreign properties. There is convincing 
evidence that unmutated germ-line gene segments encode the heavy and light-chain 
variable regions of natural antibodies. In mice, there is no selectivity for particular 
variable heavy or light genes. B cells with the capacity to produce autoantibodies are 
numerous in the normal immune repertoire. They may be a mechanism to eliminate 
degraded autoantigens and senescent cells. They may serve as precursors of antibodies 
to exogenous antigens - their cross-reactions with foreign antigens give the systems an 
advantageous "head start" (Schwartz, 1993).
Polyclonal antibodies against brevetoxins have been produced (Baden et al., 1984; 
Poli et al., 1990; Trainer and Baden, 1991; Levine and Shimizu, 1992; Poli and 
Hewetson, 1992; Poli et al., 1995). The apparent affinity constant obtained for rabbit 
anti-PbTx-2 antibodies in two different studies was 8 pM (Levine and Shimizu, 1992) 
and 26 pM (Poli et al., 1995); for goat anti-PbTx-3 lower affinity constants obtained by 
two groups were 0.75 nM (Poli and Hewetson, 1992) and 1.32 nM (Trainer and Baden, 
1991). The group of Naar (1997) presented studies on the preparation of monoclonal 
antibodies against brevetoxins. However, no further information has been available, 
questioning the success of their attempt.
It is important to remember that PbTx-2 is so small that it needs to be conjugated 
to a protein to be able to build an immune response. Therefore, most of the antibodies 
produced for this conjugate will be directed towards the carrier protein. In this study, it 
has been demonstrated that anti-PbTxs IgGs antibodies were present in the serum of the 
mice; however, at the moment of the fusion, the statistical probability of obtaining these
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antibodies was decreased by the high number of antibodies directed towards the carrier 
protein and non-specific compounds. Therefore, it can be concluded that the inability to 
establish a hybridoma cell line for brevetoxin was not lack of recognition of PbTx-2 by 
the mice or the fusion procedure, but a low statistical probability.
Even tough a conjugate with more PbTx-2 was prepared to coat the plates, no 
antibodies specific for PbTx-2 were detected. The screening assay has been exhaustively 
evaluated and is known to perform correctly. The screening assay was verified by 
measuring the response before and after immunizations, by titering the serum with the 
conjugate and the carrier protein alone, and by competition assays. However, 
polyclonal antibodies may behave very different from monoclonal antibodies. For 
instance, they consist of a sum of antibodies produced each containing different affinity 
for the toxin. Therefore, a polyclonal antibody assay may be more sensitive. It may be 
possible that the assay was not sensitive enough to detect antibodies recognizing a 
single epitope in PbTx-2. This problem could be overcome by the use of a sandwich 
ELISA, which is known to be more sensitive; however, PbTx-2 is so small that it is not 
likely that two antibodies could recognize the toxin at different sites due to steric 
hindrance.
If IgGs were present in the supernatants of the hybridoma cells, some explanations 
could be given for their absence at the end of the screening period. First of all, even 
though the cells are plated to statistically achieve just one hybridoma per well, this can 
hardly be controlled at this stage. Probably hybridoma cells producing IgGs against 
brevetoxin-2 were present in the supernatants when tested initially. However, if non­
secreting hybridomas were present in the same well, the non-secreting hybridomas
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would likely overgrew the brevetoxin antibody producing colony. If cloning is 
performed soon enough, the producing clones could be saved. However, for the present 
study, even after cloning it was impossible to isolate desired cells. This can be due to 
the chromosomal adjustment that the fused cells underwent This is a procedure that 
could not be controlled either.
B) IN  VITRO STIMULATION
The mixed lymphocyte culture (MLC) of MHC-disparate mouse thymocytes from 
BALB/C and C57BL/6 mice contains interleukin-2 (IL-2), IL-4, IL-5, and allogeneic 
helper factors (AHF). It also contains factors with isotype regulatory effects, e.g., B cell 
differentiation factor p. (BCDFp) which induces IgM secretion and B cell differentiation 
factor p (BCDFP) which significantly increases the secretion of IgGl from stimulated 
murine B cells.
To obtain cytokines produced by T cells, phorbol-12-myristate acetate (PMA) was 
used to stimulate the EL-4 cell line. PMA induces a variety of biologic and biochemical 
responses in vitro. In lymphocytes cultures, it is either mitogenic or co-mitogenic for T 
cells. The mechanism by which PMA stimulates IL-2 production by the EL-4 cells is 
unknown; however, it is suspected that it may delay the entry of EL-4 cells into S-phase, 
leading to an accumulation in G1 phase of the cell cycle (Farrar et al., 1980). Other 
researchers have found that PMA may actually inhibit the binding of IL-2 into the 
corresponding EL-4 receptors (Hilfiker, unpublished results).
EL-4 cells stimulated with PMA should be cultured under practically serum-free 
conditions. This would significantly reduced the protein contamination of the culture 
supernatant (Farrar et al., 1980). It is important to keep a low level of serum during
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stimulation of EL-4 cells since higher levels of serum proteins might interfere with the 
cellular effects of PMA, thereby reducing the production of B cell growth factors/B cell 
differentiation factors (BCGF/BCDF) (Borrebaeck, 1986). Therefore, the recommended 
serum concentration (1%) was used for this study. The 48 hrs period for culturing was 
selected because it has been found that this incubation period induces the highest 
production of hybridomas. Other periods tested by different researchers included 24, 72, 
and 96 hrs (Borrebaeck and Moller, 1986).
To determine the synergistic effect of different concentrations o f MLC and EL-4 
derived factors, Borrebaeck and Moller (1986) stimulated in vitro murine splenocytes 
with 12.5, 25, and 37.5% of EL-4 derived lymphokines combined with 0 to 50% of 
MLC supernatant A maximum of 33% of MLC supernatant with 25% of EL-4 derived 
lymphokines resulted in the optimal combination. Therefore, these recommended 
concentrations of MLC and EL-4 supernatants were used for the preparation of the in 
vitro stimulation medium.
The kinetics o f an antigen-specific in vitro immunization has been investigated by 
Borrebaeck and Moller (1986) by determining the number of antigen-specific B cells on 
days 4, 5, 6, and 7. The 5-day stimulation period revealed a twofold increase in the 
number of antigen-specific B cells. Therefore, the 5-day stimulation period was selected 
for this phase of the study.
A range of concentrations from 10 ng to 10 pg/mL has been tested to determine the 
difference in the number of stimulated antigen-specific B cells (Borrebaeck and Moller, 
1986). The results showed that the in vitro immunisation had a sigmoidal dose- 
dependent relationship that started to level off above 10 pg/mL. It has been reported that
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concentrations as low as 50 finoles o f antigen/mL medium can still produce antigen- 
specific hybridomas (Moller and Borrebaeck, 1988). A concentration of 1 pg/mL was 
selected for the in vitro stimulations performed in this study.
In successful immunizations, numerous large blast cells are observed after 5 days 
(Reading, 1982). This differentiation is supported by lymphokines in the MLC 
supernatant (Moller and Borrebaeck, 1988). Blasts were observed in the tissue culture 
flasks containing the stimulated B cells; however, this only meant that stimulation was 
achieved, but did not say anything about their specificity.
The use of rabbit serum reduces the problems of batch to batch variation of fetal 
bovine serum (FBS). It also reduces the effect of serum proteins on B-cell activation, 
when compared to using 15-20% FBS (Moller and Borrebaeck, 1998). Therefore, rabbit 
serum was used for the production of the in vitro stimulation medium.
The IgM antibodies isolated from in vivo or in vitro immunizations usually show 
variable specificity. In a study performed by Ossendorp et al. (1988), IgM antibodies 
from in vivo and in vitro immunized splenocytes with thyroglobulin showed this 
problem. Most of them were cross-reactive with other antigens. About 50% of the 
antibodies were cross-reactive with all antigens tested and also showed a reaction with 
uncoated wells. About 40% were unreactive with uncoated wells but showed reactivity 
with several unrelated antigens. Just 10% showed specificity to thyroglobulin. In the 
present study, most of the selected hybridomas were found to secrete antibodies of 
unknown specificity.
Along with antigen-specific B cell activation, in vitro immunization may also 
activate and drive a variety of non-antigen specific B cells to antibody production
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(Borrebaeck and Moller, 1986). In addition, polyclonal B cell activators are directly 
mitogenic for murine B cells, irrespective of antigen specificity, and also induce 
polyclonal antibody production. Many of these compounds are components of bacterial 
cell walls (DeFranco, 1993), such as muramyl dipeptide (MDP), which was used in the 
in vitro stimulation protocol as described by Boss (1984) and Borrebaeck (1986). As 
shown in fusion 10, MDP activated B cells specific for BSA. It has been reported that 
background B cells were enhanced in the presence of MDP. The enhancement was 
about 3 times greater than in cultures without MDP. The latter functioned as a 
polyclonal activator (Specter et al., 1978).
In fusion 11, the addition of PbTx-2 alone did not elicit antibodies specific for this 
molecule. This is because the molecule is small and unlikely to receive help from T 
cells. It may be recognized by B cells, but being a T-dependent antigen, it needs T cells 
to elicit B cell activation and differentiation into antibody-secreting cells.
Q  CYTOTOXICITY ASSAY
The cytotoxicity assay has been used to differentiate fractions containing sodium 
channel enhancing toxins in the presence of ouabain and veratridine (specific 
cytotoxicity) from other compounds in the absence of ouabain and veratridine (non­
specific cytotoxicity) (Manger et al., 1994,1995a, 1995b).
This is a simple spectrophotometric assay using 3-[4,5-dimethylthiazol-2-yI]- 
diphenyl-tetrazolium (MTT) to determine cell viability in the Neuro-2a cell line. 
Tetrazolium salts accept electrons from oxidized substrates or appropriate coenzymes, 
which result in their reduction to a colored formazan product (Vistica et al., 1991). 
MTT labeled cells are lysed using DMSO, and the plate is read in an ELISA plate
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reader. The dissolved formazan solution has been previously proved to be unstable at 
room temperature. It is recommended to standardize the time for reading the plates in 
the spectrophotometer (Wan et al., 1994). To prevent changes in absorbance readings, 
plates were read immediately after addition of DMSO, but being careful to wait for 
solubilization of all the formazan product
The assay is contingen t, in large part on the physical removal of 
ouabain/veratridine treated cells due to their diminished adherence to the culture wells, 
and the ability of sodium channel enhancing toxins to increase this effect in a dose 
dependent fashion (Manger et al., 1995b). This was achieved by flicking the plate to 
remove the medium before addition of MTT. The physical removal of the overlaying 
medium aids in the removal of both dead cells and test samples. However, removal of 
cells is not strictly necessary, since MTT can differentiate between dead and live cells. 
Previous results showed that only live cells actively cleaved MTT, while dead cells were 
almost completely negative (Mosmann, 1983).
This cytotoxicity assay was modified in an attempt to detect potential hybridomas 
containing anti-PbTx-2 antibodies. The concentrated supernatants were added together 
with a fixed amount of PbTx-2 in order to determine if the effect of the latter could be 
neutralized by anti-PbTx-2 antibodies. None of the supernatants tested caused a 
neutralization effect. This was somehow expected because high affinity antibodies 
would be necessary in the first place. This is because PbTx-2 has a high affinity for the 
sodium channel. Therefore, a compound with an even higher affinity would be 
necessary to compete for free PbTx-2. If a high affinity antibody would have been 
present, it would have been detected with the ELISA experiments performed during
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screening. These assay results confirm earlier findings that the selected hybridoma cell 
lines tested did not contain anti-brevetoxin- 2  monoclonal antibodies.
An important control in this cytotoxicity assay was measured by adding PbTx-2 to 
Neuro-2a cells without ouabain and veratridine. If cell death occurred it was due to 
compounds lacking sodium channel enhanced activity (non-specific cytotoxicity). This 
is the basis to differentiate between specific cytotoxicity (due to sodium channel 
enhancing toxins) and non-specific cytotoxicity. No cell death was found to be due to 
compounds present in the supernatants without activation by ouabain and veratridine.
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SUMMARY
Table 29 and Figures 92, 93, and 94, show a summary of the fusions performed in 
this study, identified by mouse number, protein used for preparation of immunogenic 
conjugates, the titer of PbTx-2 IgG antibodies in the serum obtained the day of the 
fusion and the IC$o. The clones selected as well as their isotype and presumed specificity 
are presented.
Table 29.Summary of fusions performed in an attempt to produce monoclonal 
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Mouse Protein Titer on ICso Fusion well Iso type Specificity
conjugate day of (pg/mL)* (Cloning
used fusion* well)




























12 BSA-PbTx-2 1:204,80 0.17 31 IgM Unknown
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Moose Protein Titer on IC50 Fusion well Isotype Specificity
conjugate day of (pgfrnL)* (Cloning
used fusion* well)








14 BSA-PbTx-2 1:25,600 0.47 B1C2 IgM BSA
(in vitro B1E4 IgGl BSA
stimulation B1E9 IgGl BSA
with BSA- B1E11 IgGl BSA





15 BSA-PbTx-2 1:51,200 1.17 1A1 IgM BSA
(in vitro 1B1 IgGl BSA
stimulation 1C9 IgGl BSA








♦Except mice 14 and 15, which is the titer of serum obtained before the in vitro 
stimulation.
IC50 -  concentration of brevetoxin- 2  necessary to reduce the response (A/Ao) by 50% 
LPH - Limulus polyphemus hemocyanin 
KLH - Keyhole limpet hemocyanin 
BSA - Bovine serum albumin
Table 29 and Figures 92, 93, and 94 show that the carrier protein used for 
conjugation of PbTx-2 for immunization made no real difference. Different titers and 
IC50S were found within each group, and no trend was observed.
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Figure 92.Summary of immunization responses over time for mice immunized with 
different protein-brevetoxin-2 (PbTx-2) conjugates.
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Figure 93 .Summary of serum titers for mice immunized with different protein-
brevetoxin-2 (PbTx-2) conjugates.
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Figure 94.Summary of competition curves for mice immunized with different protein-
brevetoxin-2 (PbTx-2) conjugates.
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Some mice had a low titer but showed to have higher affinity for the free toxin, as 
demonstrated by the lower ICso> Antiserum of high affinity may have either a high titer 
or low titer (Deshpande, 1996). For future selection of carriers, it was found that LPH 
was difficult to handle because of its low solubility. Therefore, the use of KLH is 
recommended since, in general, it is more immunogenic than BSA. A KLH-PbTx-3 
conjugate was previously shown to be more immunogenic than BSA-PbTx-3 (Trainer 
and Baden, 1991).
No monoclonal antibodies against PbTx-2 were selected after each fusion process. 
It is still uncertain what variable accounts for this result Several experiments have 
already proved that mouse anti-PbTx-2 IgG antibodies were present in all the mice the 
day of their fusion. This means that the spleen had produced antibody-secreting cells, 
the target of the fusion process. Problems after the fusion that could account for the lack 
of specific hybridomas cloud include loss of chromosomes producing antibodies, 
overgrowth by non-producers, and overgrowth o f hybridoma cells by fibroblasts.
The use of a different myeloma cell line for the fusion process did not show 
significant differences in the yield of desired hybridomas. Therefore, Sp2/0-Agl4 was 
used in the remainder of the fusions. The Sp2/0-Agl4 cell line has advantages over NS- 
1, in that its slight adherence to the plates facilitates feeding and counting of clones. 
Also, its lack of secretion of light chains which can get incorporated into the newly 
synthesized antibodies is helpful.
The in vitro stimulation technique allows for a closer control of conditions before 
fusion. Since previously immunized mice were used, the correct term is in vitro 
stimulation. In this study, the use of a polyclonal activator (MDP) was intended to
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increase the number of PbTx-2 specific B cells in a non-specific manner; however, at 
the same time it activated other B cells, hi the case of stimulation with BSA-PbTx-2, 
only antibodies specific for BSA were detected. These activation of B cells specific for 
BSA comes from the immunogen stimulation (BSA-PbTx-2) and from the action of 
MDP. For PbTx-2 stimulated splenocytes, it was found that no PbTx-2-specific 
antibodies were activated. This may be the result of the lack of T cell help due to the 
size of the PbTx-2 molecule. The polyclonal activator, however, did activate clones 
specific for BSA.
The cytotoxicity assay was previously developed to screen samples with suspected 
sodium channel activity. In an attempt to detect supernatants containing anti-PbTx-2, 
this assay was modified. However, no potential neutralizing activity was detected.
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CONCLUSIONS AND RECOMMENDATIONS
For further studies involving the production of monoclonal antibodies against 
ciguatoxin-like compounds using protein-brevetoxin-2 (PbTx-2) conjugates, the 
following recommendations are made:
• Use intrasplenlc immunization.
This method was introduced by Nilsson and Larsson (1990). It is an extremely 
useful procedure, especially when using low amounts of antigen. In addition, it is easier 
to obtain an antibody response using minute amounts of immunogen by the intrasplenic 
route than by the intraperitoneal or intravenous routes (Larsson and Nilsson, 1988). The 
immunogen should be deposited in the mouse through a small incision in the splenic 
capsule (Grohman et al., 1991). Since this major surgical procedure is required in a 
small mouse, this is not an easy procedure; therefore, mortality and morbidity cannot be 
underestimated (Cardillo et al., 1995). In theory, intrasplenic immunization may allow 
for a higher titer for PbTx-2 antibodies which will ultimately yield a higher number of 
hybridomas producing antibodies of the desired specificity.
• Perform more in vitro immunizations.
This method allows for a greater control of the final stimulation conditions. In 
addition, the effect of antibodies in the serum that may decrease the amount of 
immunogen given, does not apply. For this study, only 1 dose (1 pg/mL) was selected. It 
would be advantageous to use higher doses to test the effect of this technique towards 
this particular immunogen.
It has been found that sometimes in vitro immunizations without the addition of 
specific T helper (Th) cells fail. The spleen suspension presumably contains these cells.
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Perhaps the antigen-specific Th cells could not be activated under the in vitro culture 
conditions chosen or the number of activated Th was insufficient to react with the 
corresponding specific B cell (Uthoffi and Boldicke, 1993).
It has been reported that higher yields of antigen-specific B cells can be obtained by 
using Th cells that have been primed with the carrier molecule. These cells would be 
incubated together with the splenocytes and the conjugate (carrier-toxin). Direct T cell 
help is provided to the antigen-specific B cells. This model ensures B cell-T cell 
interaction since the carrier-specific Th cells recognize the processed antigen (carrier) 
together with the major histocompatibility complex II (MHC class II) presented by the B 
cell. On activation, the Th cells produce interleukin-2, a cytokine which plays a role in 
driving normal B cells to IgG production under antigen-driven MHC-restricted 
circumstances. This model differs to the procedure used for this study in which only 
cytokines derived from T cells were present, but there was no cell-cell interaction 
(Schilizzi et al., 1992; Uthoff and Boldicke, 1993).
• Use the Fox NY myeloma cell line and Robertsonian 5-Bnr mice.
This new myeloma cell line was isolated from NS-1. It is resistant to the toxic 
effects of adenine and hypoxanthine and is double enzyme deficient (adenosine 
phosphoribosyltransferase [APRT"] and hypoxanthine phosphoribosyltransferase 
[HPRT ]). In the Robertsonian 5-Bnr mouse, the active heavy chain Ig locus on 
chromosome 12 and the enzyme APRT on chromosome 8 are genetically linked. When 
the cell fusion mixture is exposed to a selection medium requiring the APRT activity, it 
will eliminate both APRT-deficient myeloma cells and non-antibody-producing APRT- 
deficient cells. This property allows for the selection of fused cells producing
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antibodies. This increases the yield of antibody-producing clones by eliminating non­
secreting clones which could overgrow potential hybridomas (Taggart and SamlofF, 
1983; Wong et al., 1996).
This research has confirmed previous reports showing that polyclonal antibodies 
against PbTx-2 are possible to raise. Animals tested have included rabbits, goats, and 
mice. Mice have the disadvantage of producing low serum yields. Therefore, for the 
production of polyclonal antibodies it is recommended to use larger anim als.
In this study, no hybridoma cell lines producing anti-PTx-2 antibodies were 
obtained. Potential clones may have been lost due to overgrowth by either non­
producing cells or fibroblasts present in the same well. They may have also lost their 
ability to secrete immunoglobulins by the loss of specific chromosomes. The use of the 
in vitro immunization technique failed to activate specific B cells in culture. However, 
this method could be modified to increase the probability of obtaining hybridomas of 
the desired specificity.
Although the production of monoclonal anti-PbTx-2 antibodies was not 
accomplished in this study, further studies should proceed, including the use of the in 
vitro immunization and intrasplenic immunization techniques, and the Fox NY  
myeloma cell line and Robertsonian 5-Bnr mice.
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APPENDIX A: FORMULATIONS
Phosphate buffered saline (PBS) (pH 7.4,1 L)*■ .........  '  * ■»
Compound Amount
Potassium chloride (KC1) 0 . 2  g
Sodium chloride (NaCl) 8 . 0  g
Sodium phosphate dibasic (NasHPO^ 1 -2  g
Potassium phosphate (K H 2PO4)__________ 0 .2  g
PBS-Tween 20 (PBST) (pH 7.4,1 L)
Compound Amount
Potassium chloride (KC1) 0 . 2  g
Sodium chloride (NaCl) 8 . 0  g
Sodium phosphate dibasic (Na2HP0 4 ) 1 -2  g
Potassium phosphate (K H 2PO4) 0 . 2  g
Tween 20 500 uL
1% BSA-PBST (pH 7.4,1 L)
Compound Amount
Potassium chloride (KC1) 0 . 2  g
Sodium chloride (NaCl) 8 . 0  g
Sodium phosphate dibasic (Na2HPC>4) 1 .2  g
Potassium phosphate (KH2PO4) 0 . 2  g
Tween 20 500 pL
BSA 1 0  mg
Medium for Myeloma cells (1 L)
Compound Concentration
DMEM high glucose 4.5 g glucose
NaHCOs To get pH of * 7.2
HEPES 15 mM
FBS 1 0 %
L-glutamine 2 mM
Sodium pyruvate 1 mM
Gentamicin 50 mg
Nystatin 1 0 0 , 0 0 0  units
Washing medium (1 L)
Compound Concentration
DMEM high glucose 4.5 g glucose/L
NaHCCb To get pH o f» 7.2
HEPES 15 mM
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Complete/HT medium (1 L)
Compound Concentration
DMEM high glucose 4.5 g glucose






Sodium pyruvate 1 mM
Non-essential amino acids 0.01 mM
Gentamicin 50 mg
Nystatin 100,000 units
J774A.1 cells medium (1 L)
Compound Concentration
DMEM high glucose 4.5 g glucose




Sodium pyruvate 1 mM
Non-essential amino acids 0.01 mM
Gentamicin 50 mg
Nystatin 100,000 units
Conditioned medium/HT (1 L)
Compound Concentration
DMEM high glucose 4.5 g glucose
NaHCCb To get pH o f« 7.2
HEPES 15 mM
FBS 20%





Sodium pyruvate 1 mM
Gentamicin 50 mg
Non-essential amino acids 0.01 mM
Nystatin 100,000 units
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Conditioned medium/HAT (1 L)
Compound Concentration
DMEM high glucose
NaHCOj To get pH o f * 7.2
HEPES 15 mM
FBS 20%







Non-essential amino acids 0.01 mM
Gentamicin 50 mg
Nystatin 100,000 units
Media for Mixed Lymphocyte Culture (1 L)
Compound Concentration
DMEM high glucose 4.5 g glucose






Non-essential amino acids 0.01 mM
2-Mercaptoethanol 50 pM
Rabbit serum 2%
Media for Propagation of EL-4 cells (1 L)
Compound Concentration
RPMI-1640






Non-essential amino acids 0.01 mM
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Media for Stimulation of EL-4 cells (1 L)
Compound Concentration
RPMI-1640






Phorbol myristate acetate 10 ng/mL medium
Non-essential amino acids 0.01 mM
Media for in vitro stimulation (1 L)
Compound Concentration
DMEM high glucose 4.5 g glucose










Muramyl dipeptide 10 pg/mL
Media for Neuro-2a cells (1 L)
Compound Concentration
RPMI-1640
NaHCCh To get pH o f« 7.2
HEPES 15 mM




Sodium pyruvate 1 mM
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•  0 * Wash
• • • • • • • • • •
Coat with BSA-PbTx-2 
or OVA-PbTx-2
LJ- • < > *
Add 
^ pun or 
supernatant
Block with 
1% BSA or 
^  1% gelatin
Goat anti-mouse IgG-HRPO
•rcw




Incubate Serum or Supernatant with Free Brevetoxin-2
I
high 
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Antigen-specific Isotyping ELISA
Incubate








Coat with BSA-PbTx-2 
or OVA-PbTx-2
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APPENDIX C: RAW DATA
Immunization response over time



























Pre-immune serum absorbance average: 0.064








































Final boost 1.822 1.805 0.0153 0.85
1.792
1.801
Pre-immnne serum absorbance average: 0.066



































Pre-immune serum absorbance average: 0.071
Mouse 4 immunizet with LPH-Brevetoxin-2
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Pre-immune serum absorbance average: 0.069































Pre-immune serum absorbance average: 0.085
Mouse 8 immunized with KLH-Brevetoxin-2



























Pre-immune serum absorbance average: 0.093































Pre-immune serum absorbance average: 0.073
Mouse 11 immunized with KLH-Brevetoxin-2



































Pre-immune serum absorbance average: 0.073























Pre-immune serum absorbance average: 0.063
Mouse 13 immunized with BSA-Brevetoxin-2
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Pre-immune serum absorbance average: 0.072



















Pre-immune serum absorbance average: 0.072



















Pre-immune serum absorbance average: 0.075
Seram titer using BSA-PbTx-2 or OVA-PbTx-2 coated plates












1/100 1.858 1.843 1.855 1.852 0.0079 1.79
1/200 1.735 1.723 1.717 1.725 0.0092 1.66
1/400 1.474 1.495 1.489 1.486 0.0108 1.42
1/800 1.188 1.197 1.226 1.203 0.0199 1.14
(table continued)
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Dilution Absorbance Absorbance Absorbance Absorbance Standard CV
1 2 3 average Deviation
1/1600 0.925 0.946 0.955 0.942 0.0154 0.88
1/3200 0.651 0.653 0.678 0.661 0.0150 0.60
1/6400 0.432 0.468 0.458 0.453 0.0185 4.11
1/12800 0.297 0.291 0301 0396 0.0050 1.69
1/25600 0.204 0.203 0.209 0.205 0.0032 1.57
1/51200 0.163 0.157 0.152 0.157 0.0055 3.50
1/102400 0.135 0.133 0.126 0.131 0.0047 3.60
1/204800 0.115 0.117 0.113 0.115 0.0020 1.74
1/409600 0.073 0.074 0.075 0.074 0.0010 135
Immune serum in BSA coated plates average: 0.065
Pre-immune serum in BSA-PbTx-2 coated plates average: 0.059
Mouse 2 - BSA-PbTx-2
Dilution Absorbance Absorbance Absorbance Absorbance Standard CV
1 2 3 average Deviation
1/100 1.934 1.924 1.942 1.933 0.0090 0.47
1/200 1.794 1.765 1.783 1.781 0.0146 0.82
1/400 1.506 1.505 1.511 1.507 0.0032 031
1/800 1.188 1.166 1.172 1.175 0.0114 0.97
1/1600 0.896 0.883 0.892 0.890 0.0066 0.75
1/3200 0.604 0.600 0.611 0.605 0.0055 0.92
1/6400 0.400 0.415 0.403 0.406 0.0079 1.95
1/12800 0.266 0.270 0.281 0.272 0.0078 2.85
1/25600 0.185 0.187 0.174 0.182 0.0070 3.85
1/51200 0.142 0.143 0.152 0.146 0.0055 3.78
1/102400 0.129 0.122 0.133 0.128 0.0550 4.34
1/204800 0.108 0.112 0.105 0.108 0.0035 3.24
1/409600 0.079 0.073 0.074 0.075 0.0032 4.27
Immune serum in BSA coated plates average: 0.069
Pre-immune serum in BSA-PbTx-2 coated plates average: 0.063
Mouse 3 - BSA-PbTx-2
Dilution Absorbance Absorbance Absorbance Absorbance Standard CV
1 2 3 average Deviation
1/100 1.841 1.834 1.849 1.841 0.0075 0.41
1/200 1.554 1.583 1.576 1.571 0.0151 0.96
1/400 1.164 1.151 1.168 1.161 0.0088 0.77
1/800 0.799 0.790 0.803 0.797 0.0066 0.84
1/1600 0.548 0.539 0.541 0.543 0.0047 0.87
1/3200 0.349 0346 0.347 0.347 0.0015 0.44
1/6400 0.236 0.236 0.242 0338 0.0035 1.46
1/12800 0.168 0.172 0.179 0.173 0.0056 3.22
1/25600 0.132 0.136 0.130 0.133 0.0031 230
(table continued)
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Dilution Absorbance Absorbance Absorbance Absorbance Standard CV
1 2 3 average Deviation
1/51200 0.117 0.118 0.121 0.119 0.0021 1.75
1/102400 0.105 0.108 0.112 0.108 0.0035 329
1/204800 0.106 0.101 0.111 0.106 0.0050 4.72
1/409600 0.075 0.072 0.079 0.075 0.0035 4.66
Immune serum in BSA coated plates average: 0.062
Pre-immune serum in BSA-PbTx-2 coated plates average: 0.055
Mouse 4 - BSA-PbTx-2
Dilution Absorbance Absorbance Absorbance Absorbance Standard CV
I 2 3 average Deviation
1/100 1.429 1381 1.415 1.408 0.0247 1.75
1/200 1.033 0.968 0.987 0.996 0.0334 3 36
1/400 0.650 0.598 0.613 0.620 0.0268 4.31
1/800 0.417 0388 0.408 0.404 0.0148 3.67
1/1600 0.291 0.265 0.286 0281 0.0138 4.92
1/3200 0.202 0.186 0.197 0.195 0.0082 4.19
1/6400 0.154 0.142 0.147 0.148 0.0060 4.08
1/12800 0.128 0.119 0.120 0.122 0.0049 4.03
1/25600 0.109 0.108 0.103 0.107 0.0032 3.01
1/51200 0.106 0.098 0.097 0.100 0.0049 4.92
1/102400 0.099 0.095 0.093 0.096 0.0031 3.19
1/204800 0.098 0.100 0.092 0.097 0.0042 431
1/409600 0.073 0.070 0.075 0.073 0.0025 3.46
Immune serum in BSA coated plates average: 0.077
Pre-immune serum in BSA-PbTx-2 coated plates average: 0.062
Mouse 7 - BSA-PbTx-2
Dilution Absorbance Absorbance Absorbance Absorbance Standard CV
1 2 3 average Deviation
1/100 1.826 1.780 1.813 1.806 0.0237 131
1/200 1.584 1.596 1.579 1.586 0.0087 0.55
1/400 1.204 1.194 1.211 1.203 0.0085 0.71
1/800 0.860 0.874 0.867 0.867 0.0070 0.81
1/1600 0.588 0.607 0.593 0.596 0.0098 1.65
1/3200 0.403 0391 0397 0397 0.0060 1.51
1/6400 0.253 0.255 0.248 0.252 0.0036 1.43
1/12800 0.177 0.177 0.172 0.175 0.0029 1.65
1/25600 0.146 0.143 0.147 0.145 0.0021 1.43
1/51200 0.115 0.119 0.114 0.116 0.0026 228
1/102400 0.102 0.105 0.101 0.103 0.0021 2.03
1/204800 0.104 0.100 0.099 0.101 0.0026 2.62
1/409600 0.076 0.073 0.072 0.074 0.0021 2.83
Immune serum in BSA coated plates average: 0.063 
Pre-immune serum in BSA-PbTx-2 coated plates average: 0.067
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Mouse 8 - BSA-PbTx-2
Dilution Absorbance Absorbance Absorbance Absorbance Standard CV
1 2 3 average Deviation
1/100 1.684 1.630 1.657 1.657 0.0270 1.63
1/200 1.492 1.484 1.490 1.489 0.0042 038
1/400 1.166 1.143 1.147 1.152 0.0123 1.07
1/800 0.839 0.808 0.814 0.820 0.0164 2.00
1/1600 0.580 0.563 0.569 0.571 0.0086 1.51
1/3200 0.377 0.371 0382 0377 0.0055 1.46
1/6400 0.258 0.247 0353 0353 0.0055 2.18
1/12800 0.187 0.180 0.183 0.183 0.0035 1.92
1/25600 0.146 0.142 0.143 0.144 0.0021 1.45
1/51200 0.126 0.135 0.129 0.130 0.0046 3.52
1/102400 0.114 0.107 0.110 0.110 0.0035 3.18
1/204800 0.108 0.109 0.102 0.106 0.0038 3.56
1/409600 0.075 0.072 0.073 0.073 0.0015 2.08
Immune serum in BSA coated plates average: 0.065
Pre-immune serum in BSA-PbTx-2 coated plates average: 0.071
Mouse 10 - BSA-PbTx-2
Dilution Absorbance Absorbance Absorbance Absorbance Standard CV
1 2 3 average Deviation
1/100 0.821 0.837 0.806 0.821 0.0155 1.88
1/200 0.532 0.557 0.547 0.545 0.0125 231
1/400 0350 0360 0353 0.354 0.0051 1.45
1/800 0.213 0.221 0319 0.218 0.0041 1.91
1/1600 0.134 0.141 0.137 0.137 0.0035 2.56
1/3200 0.102 0.100 0.100 0.100 0.0012 1.48
1/6400 0.088 0.088 0.085 0.087 0.0017 1.99
1/12800 0.083 0.089 0.081 0.084 0.0041 4.94
1/25600 0.076 0.080 0.079 0.078 0.0021 2.66
1/51200 0.075 0.072 0.073 0.073 0.0015 2.08
1/102400 0.073 0.076 0.074 0.074 0.0015 2.05
1/204800 0.075 0.076 0.074 0.075 0.0010 1.33
1/409600 0.07 0.071 0.069 0.070 0.0010 1.43
Immune serum in BSA coated plates average: 0.068
Pre-immune serum in BSA-PbTx-2 coated plates average: 0.064












1/100 1.750 1.736 1.742 1.743 0.0070 0.41
1/200 1.607 0.676 1.634 1.639 0.0347 2.12
1/400 1.353 1357 1361 1.357 0.0040 039
1/800 1.031 1.015 1.028 1.025 0.0085 0.83
(table continued)
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Dilution Absorbance Absorbance Absorbance Absorbance Standard CV
1 2 3 average Deviation
1/1600 0.663 0.665 0.659 0.662 0.0030 0.46
1/3200 0.430 0.469 0.445 0.448 0.0197 3.49
1/6400 0372 0.293 0.289 0.285 0.0111 3.91
1/12800 0.174 0.183 0.179 0.179 0.0045 2.52
1/25600 0.129 0.137 0.125 0.130 0.0061 4.69
1/51200 0.107 0.105 0.103 0.105 0.0020 1.90
1/102400 0.088 0.087 0.082 0.086 0.0032 3.75
1/204800 0.076 0.075 0.075 0.075 0.0006 0.77
1/409600 0.074 0.073 0.070 0.072 0.0021 2.88
Immune serum in BSA coated plates average: 0.071
Pre-immune serum in BSA-PbTx-2 coated plates average: 0.074
Mouse 12 - OVA-PbTx-2
Dilution Absorbance Absorbance Absorbance Absorbance Standard CV
I 2 3 average Deviation
1/100 1.168 1.170 1.159 1.165 0.0059 0.50
1/200 1.158 1.161 1.166 1.162 0.0040 035
1/400 1.149 1.155 1.154 1.153 0.0032 038
1/800 1.117 1.120 1.119 1.119 0.0015 0.14
1/1600 1.072 1.077 1.078 1.076 0.0032 0.30
1/3200 1.010 1.011 1.007 1.009 0.0020 031
1/6400 0.894 0.896 0.892 0.894 0.0020 032
1/12800 0.650 0.647 0.655 0.651 0.0040 0.62
1/25600 0.472 0.480 0.472 0.475 0.0046 0.97
1/51200 0.319 0.321 0312 0.317 0.0047 1.49
1/102400 0.202 0.199 0.201 0.201 0.0015 0.76
1/204800 0.158 0.145 0.155 0.152 0.0068 4.48
1/409600 0.090 0.089 0.096 0.091 0.0038 4.16
Immune serum in BSA coated plates average: 0.083
Pre-immune serum in BSA-PbTx-2 coated plates average: 0.070
Mouse 13 - OVA-PbTx-2
Dilution Absorbance Absorbance Absorbance Absorbance Standard CV
1 2 3 average Deviation
1/100 1.190 1.199 1.194 1.194 0.0045 038
1/200 1.168 1.175 1.169 1.171 0.0038 0.32
1/400 1.168 1.174 1.161 1.167 0.0065 0.56
1/800 1.159 1.147 1.152 1.153 0.0060 0.52
1/1600 1.079 1.089 1.067 1.078 0.0110 1.02
1/3200 0.978 1.002 1.011 0.997 0.0170 1.71
1/6400 0.750 0.795 0.810 0.785 0.0312 3.98
1/12800 0.619 0.607 0.611 0.612 0.0061 0.99
1/25600 0.509 0.498 0.500 0.502 0.0059 1.17
(table continued)
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Dilution Absorbance Absorbance Absorbance Absorbance Standard CV
1 2 3 average Deviation
1/51200 0.403 0392 0394 0396 0.0059 1.48
1/102400 0.238 0.229 0330 0332 0.0049 2.13
1/204800 0.118 0.122 0.111 0.117 0.0056 4.76
1/409600 0.093 0.101 0.094 0.095 0.0044 4.59
Immune serum in BSA coated plates average: 0.091
Pre-immune serum in BSA-PbTx-2 coated plates average: 0.086
Mouse 14 - OVA-PbTx-2
Dilution Absorbance Absorbance Absorbance Absorbance Standard CV
1 2 3 average Deviation
1/100 1.107 1.125 1.117 1.117 0.0090 0.81
1/200 1.104 1.096 1.103 1.101 0.0043 039
1/400 0.991 0.995 0.997 0.994 0.0030 031
1/800 0.815 0.823 0.821 0.819 0.0042 0.51
1/1600 0.691 0.742 0.723 0.719 0.0257 2.59
1/3200 0.607 0.611 0.601 0.606 0.0050 0.83
1/6400 0.439 0.451 0.448 0.446 0.0062 1.40
1/12800 0.259 0.244 0356 0.253 0.0079 3.14
1/25600 0.122 0.133 0.128 0.128 0.0055 4.31
1/51200 0.103 0.101 0.104 0.103 0.0015 1.49
1/102400 0.080 0.085 0.079 0.081 0.0032 3.95
1/204800 0.076 0.083 0.079 0.079 0.0035 4.43
1/409600 0.065 0.069 0.069 0.068 0.0072 0.05
Immune serum in BSA coated plates average: 0.069
Pre-immune serum in BSA-PbTx-2 coated plates average: 0.059
Mouse 15 - OVA-PbTx-2
Dilution Absorbance Absorbance Absorbance Absorbance Standard CV
I 2 3 average Deviation
1/100 1.374 1366 1353 1370 0.0461 3.43
1/200 1.354 1.332 1342 1.344 0.0106 0.78
1/400 1.109 1.122 1.115 1.115 0.0065 0.58
1/800 0.988 0.992 0.976 0.985 0.0083 0.84
1/1600 0.796 0.803 0.812 0.803 0.0080 0.99
1/3200 0.639 0.645 0.602 0.629 0.0233 3.70
1/6400 0.498 0.511 0.505 0.505 0.0065 1.29
1/12800 0383 0.398 0387 0.389 0.0078 1.99
1/25600 0.247 0359 0.253 0.253 0.0060 237
1/51200 0.123 0.135 0.127 0.128 0.0061 4.76
1/102400 0.106 0.115 0.109 0.110 0.0045 4.17
1/204800 0.092 0.089 0.093 0.091 0.0020 238
1/409600 0.068 0.072 0.073 0.071 0.0026 3.73
Immune serum in BSA coated plates average: 0.059 
Pre-immune serum in BSA-PbTx-2 coated plates average: 0.068
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Seram titer using LPH, KLH, or BSA coated plates
Mouse 1 - LPH
Dilution Absorbance Absorbance Absorbance Absorbance Standard CV
1 2 3 average Deviation
1/100 1.873 1.852 1.823 1.849 0.0251 1.36
1/200 1.821 1.827 1.826 1.825 0.0032 0.18
1/400 1.807 1.815 1.813 1.812 0.0042 0.23
1/800 1.811 1.807 1.823 1.814 0.0083 0.46
1/1600 1.815 1.818 1.818 1.815 0.0025 0.14
1/3200 1.772 1.832 1.842 1.815 0.0379 1.09
1/6400 1.807 1.817 1.814 1.813 0.0051 0.28
1/12800 1.762 1.745 1.769 1.759 0.0123 0.70
1/25600 1.660 1.705 1.640 1.669 0.0333 1.99
1/51200 1.532 1.544 1.533 1.536 0.0067 0.43
1/102400 1.425 1.439 1.440 1.435 0.0084 0.58
1/204800 1.221 1.242 1.235 1.233 0.0110 0.86
1/409600 0.961 0.932 0.880 0.924 0.0410 4.44
Mouse 2 - LPH
Dilution Absorbance Absorbance Absorbance Absorbance Standard ”cv
1 2 3 average Deviation
1/100 1.918 1.932 1.927 1.926 0.0071 037
1/200 1.918 1.927 1.924 1.923 0.0046 0.24
1/400 1.910 1.913 1.953 1.925 0.0240 1.25
1/800 1.907 1.922 1.939 1.923 0.0160 0.83
1/1600 1.901 1.932 1.904 1.912 0.0171 0.89
1/3200 1.872 1.903 1.907 1.894 0.0192 1.01
1/6400 1.865 1.879 1.874 1.873 0.0071 0.38
1/12800 1.825 1.815 1.832 1.824 0.0085 0.47
1/25600 1.736 1.722 1.768 1.742 0.0235 1.35
1/51200 1.560 1.650 1.670 1.627 0.0586 3.60
1/102400 1.432 1.459 1.464 1.452 0.0172 1.19
1/204800 1.219 1.241 1.232 1.231 0.0111 0.90
1/409600 1.023 1.072 1.072 1.056 0.0283 1.68
Mouse 3 - LPH
Dilution Absorbance Absorbance Absorbance Absorbance Standard CV
1 2 3 average Deviation
1/100 1.832 1.862 1.864 1.853 0.0179 0.97
1/200 1.814 1.832 1.825 1.824 0.0090 0.50
1/400 1.814 1.826 1.800 1.813 0.0130 0.72
1/800 1.800 1.816 1.807 1.080 0.0080 0.44
1/1600 1.791 1.762 1.797 1.783 0.0187 1.05
1/3200 1.762 1.792 1.798 1.784 0.0193 1.08
(table continued)
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1/6400 1.723 1.782 1.728 1.744 0327 1.88
1/12800 1.591 1.720 1.662 1.658 0.0646 3.90
1/25600 1.589 1.528 1.536 1.551 0.0332 2.14
1/51200 1.458 1.432 1.442 1.444 0.0131 0.91
1/102400 1.219 1.263 1.271 1.251 0.0280 234
1/204800 1.021 1.069 1.038 1.043 0.0243 2.33
1/409600 0.891 0.905 0.895 0.897 0.0072 0.80











1/100 1.794 1.838 1.852 1.828 0.0303 1.66
1/200 1.872 1.800 1.813 1.828 0.0384 2.09
1/400 1.800 1.796 1.835 1.810 0.0214 1.19
1/800 1.772 1.825 1.808 1.802 0.0271 1.50
1/1600 1.756 1.796 1.774 1.775 0.0200 1.13
1/3200 1.752 1.779 1.761 1.764 0.0137 0.78
1/6400 1.729 1.766 1.747 1.747 0.0185 1.06
1/12800 1.654 1.694 1.677 1.675 0.0200 130
1/25600 1.592 1.597 1.613 1.601 0.0197 0.69
1/51200 1.480 1.496 1.472 1.483 0.0122 0.82
1/102400 1358 1.296 1.311 1.288 0.0273 2.12
1/204800 1.091 1.117 1.101 1.103 0.0131 1.19
1/409600 0.925 0.950 0.920 0.935 0.0150 1.60












1/100 1.852 1.834 1.841 1.842 0.0091 0.49
1/200 1.823 1.837 1.842 1.834 0.0098 0.54
1/400 1.808 1.837 1.817 1.821 0.0148 0.82
1/800 1.795 1.799 1.802 1.798 0.0035 0.19
1/1600 1.792 1.816 1.833 1.814 0.0206 1.14
1/3200 1.761 1.786 1.802 1.783 0.0207 1.16
1/6400 1.768 1.737 1.817 1.774 0.0403 237
1/12800 1.709 1.766 1.724 1.733 0.0295 1.70
1/25600 1.687 1.715 1.723 1.708 0.0189 1.11
1/51200 1.629 1.638 1.667 1.645 0.0198 131
1/102400 1.528 1.503 1.537 1.523 0.0176 1.16
1/204800 1.379 1.403 1.352 1.378 0.0255 1.85
1/409600 1.152 1.178 1.164 1.164 0.0130 1.12
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Mouse 8 - KLH
Dilution Absorbance Absorbance Absorbance Absorbance Standard CV
1 2 3 average Deviation
1/100 1.781 1.804 1.812 1.799 0.0I6I 0.89
1/200 1.762 1.792 1.778 1.777 0.0150 0.84
1/400 1.752 1.779 1.766 1.766 0.0135 0.77
1/800 1.723 1.745 1.741 1.736 0.0117 0.67
1/1600 1.671 1.682 1.821 1.725 0.0836 4.85
1/3200 1.620 1.702 1.543 1.622 0.0795 4.90
1/6400 1.525 1.533 1.562 1.540 0.0195 1.26
1/12800 1.332 1372 1.445 1.383 0.0573 4.14
1/25600 1.117 1.125 1.119 1.120 0.0042 037
1/51200 1.030 1.027 1.019 1.025 0.0057 0.55
1/102400 0.867 0.879 0.858 0.868 0.0105 131
1/204800 0.747 0.788 0.802 0.770 0.0286 3.67
1/409600 0.739 0.755 0.746 0.747 0.0080 1.07
Mouse 10 - KLH
Dilution Absorbance Absorbance Absorbance Absorbance Standard CV
1 2 3 average Deviation
1/100 1.768 1.782 1.803 1.784 0.0176 0.98
1/200 1.714 1.795 1.802 1.770 0.0489 2.76
1/400 1.763 1.778 1.754 1.765 0.0121 0.69
1/800 1.752 1.757 1.769 1.759 0.0087 0.49
1/1600 1.743 1.767 1.764 1.758 0.0131 0.74
1/3200 1.752 1.748 1.757 1.752 0.0045 036
1/6400 1.682 1.747 1.793 1.741 0.0558 330
1/12800 1.719 1.735 1.727 1.727 0.0080 0.46
1/25600 1.629 1.637 1.635 1.636 0.0042 035
1/51200 1.426 1.451 1.449 1.442 0.0139 0.96
1/102400 1.219 1.242 1326 1.229 0.0118 0.96
1/204800 1.066 1.102 1.093 1.087 0.0187 1.72
1/409600 0.921 0.947 0.932 0.933 0.0131 1.40
Mouse 11- KLH
Dilution Absorbance Absorbance Absorbance Absorbance Standard CV
1 2 3 average Deviation
1/100 1.831 1.845 1.827 1.834 0.0095 0.52
1/200 1.852 1.825 1.832 1.836 0.0140 0.76
1/400 1.819 1.837 1.832 1.829 0.0093 0.51
1/800 1.823 1.829 1.827 1.826 0.0031 0.17
1/1600 1.796 1.831 1.804 1.810 0.0183 1.01
1/3200 1.791 1.803 1.796 1.797 0.0060 034
1/6400 1.722 1.783 1.765 1.757 0.0313 1.78
(table continued)
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1/12800 1.742 1.763 1.759 1.755 0.0111 0.64
1/25600 1.743 1.750 1.761 1.751 0.0090 0.52
1/51200 1.518 1.602 1.579 1.566 0.0434 2.77
1/102400 1.491 1.452 1.475 1.473 0.0196 133
1/204800 1303 1335 1346 1328 0.0223 1.68
1/409600 0.918 0.946 0.937 0.934 0.0143 1.53












1/100 1.902 1.935 1.923 1.920 0.0167 0.087
1/200 1.955 1.931 1.948 1.945 0.0123 0.063
1/400 1.917 1.931 1.923 1.924 0.0070 0.036
1/800 1.908 1.922 1.918 1.916 0.0072 038
1/1600 1.912 1.916 1.890 1.906 0.0140 0.73
1/3200 1.887 1.912 1.904 1.901 0.0128 0.67
1/6400 1.883 1.899 1.917 1.899 0.0170 0.90
1/12800 1.863 1.895 1.892 1.883 0.0176 0.94
1/25600 1.816 1.893 1.927 1.879 0.0568 3.02
1/51200 1.842 1.855 1.879 1.859 0.0188 1.01
1/102400 1.777 1.798 1.793 1.789 0.0110 0.61
1/204800 1.664 1.702 1.682 1.683 0.0190 1.13












1/100 1.881 1.905 1.912 1.899 0.0163 0.86
1/200 1.887 1.889 1.903 1.893 0.0087 0.46
1/400 1.892 1.907 1.899 1.899 0.0075 0.39
1/800 1.856 1.892 1.907 1.885 0.0262 1.39
1/1600 1.825 1.873 1.857 1.852 0.0244 1.32
1/3200 1.812 1.863 1.839 1.838 0.0255 1.39
1/6400 1.807 1.833 1.842 1.827 0.0181 0.99
1/12800 1.792 1.826 1.805 1.808 0.0171 0.95
1/25600 1.782 1.758 1.845 1.795 0.0449 2.50
1/51200 1.756 1.738 1.772 1.755 0.0170 0.97
1/102400 1.721 1.725 1.746 1.731 0.0134 0.78
1/204800 1.625 1.772 1.643 1.680 0.0802 4.77
1/409600 1.623 1.649 1.642 1.638 0.0134 0.82
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Mouse 14 - BSA
Dilution Absorbance Absorbance Absorbance Absorbance Standard CV
1 2 3 average Deviation
1/100 1.892 1.883 1.911 1.895 0.0143 0.75
1/200 1.897 1.882 1.903 1.894 0.0108 0.57
1/400 1.902 1.883 1.889 1.891 0.0097 0.51
1/800 1.887 1.889 1.892 1.889 0.0025 0.13
1/1600 1.866 1.897 1.874 1.879 0.0161 0.86
1/3200 1.853 1.877 1.838 1.856 0.0197 1.06
1/6400 1.813 1.862 1.844 1.839 0.0248 135
1/12800 1.772 1.768 1.814 1.784 0.0255 1.43
1/25600 1.768 1.622 1.754 1.714 0.0806 4.70
1/51200 1.522 1.497 1.563 1.527 0.0333 2.18
1/102400 1.267 1.389 1.366 1341 0.0648 4.83
1/204800 1.097 1.116 1.112 1.108 0.0100 0.90
1/409600 0.976 1.003 0.992 0.099 0.0136 137
Mouse 15 - BSA
Dilution Absorbance Absorbance Absorbance Absorbance Standard CV
1 2 3 average Deviation
1/100 1.903 1.927 1.916 1.914 0.0120 0.63
1/200 1.890 1.897 1.918 1.904 0.0146 0.77
1/400 1.892 1.899 1.894 1.895 0.0036 0.19
1/800 1.869 1.883 1.897 1.879 0.0140 0.74
1/1600 1.843 1.872 1.855 1.858 0.0146 0.78
1/3200 1.869 1.826 1.802 1.823 0.0339 1.85
1/6400 1.726 1.705 1.733 1.723 0.0145 0.85
1/12800 1.652 1.683 1.689 1.678 0.0198 1.19
1/25600 1.562 1.571 1.580 1.571 0.0090 0.57
1/51200 1.443 1.449 1.468 1.458 0.0131 0.89
1/102400 1.198 1.273 1.245 1.239 0.0530 439
1/204800 1.109 1.104 1.092 1.104 0.0087 0.79




a= 0.985 r*= 0.994
























0.00240 0.99626 0.98419 0.00015 0.05838 0.05269
0.00480 0.99751 0.98355 0.00019 0.05898 0.05239
0.00970 1.00000 0.98242 0.00031 0.06020 0.05188
0.01950 0.96636 0.98047 0.00020 0.04482 0.05100
0.03900 0.98255 0.97715 0.00003 0.05194 0.04951
0.07810 0.97445 0.97144 0.00001 0.04831 0.04700
0.15620 0.95763 0.96173 0.00002 0.04120 0.04288
031250 0.91713 0.94534 0.00080 0.02640 0.03636
0.62500 0.88972 0.91818 0.00081 0.01824 0.02674
135000 0.85483 0.87434 0.00038 0.01004 0.01433
2.50000 0.80125 0.80668 0.00003 0.00217 0.00271
5.00000 0.72087 0.70903 0.00014 0.00114 0.00208
10.00000 0.62679 0.58098 0.00210 0.01635 0.03016
20.00000 0.44237 0.43263 0.00009 0.09752 0.10370
40.00000 0.25500 028354 0.00081 024965 022194
80.00000 0.10300 0.15365 0.00257 0.42465 0.36120
160.00000 0.09800 0.05384 0.00195 0.43119 0.49113




b= 1.066 r= 0.999
c= 2.903
d= 0.052
[PbTx2] Experim. Calculated (Exp A/Ao- (Exp A/Ao- (Calc A/Ao-
(jjg/mL) A/Ao A/Ao Calc A/Ao)2 Avg)2 Avg)2
0.00120 0.99499 0.98993 0.00003 0.11095 0.10761
0.00240 0.99928 0.98968 0.00009 0.11383 0.10744
0.00480 0.99570 0.98914 0.00004 0.11143 0.10709
0.00970 0.99210 0.98801 0.00002 0.10904 0.10635
0.01950 0.98000 0.98564 0.00003 0.10119 0.10482
0.03900 0.98000 0.98076 0.00000 0.10119 0.10167
0.07810 0.97000 0.97066 0.00000 0.09493 0.09534
(table continued)
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a= 0.983 r2= 0.994





















0.00240 0.99768 0.98247 0.00023 0.08316 0.07462
0.00480 0.99768 0.98210 0.00024 0.08316 0.07442
0.00970 0.99675 0.98137 0.00024 0.08263 0.07403
0.01950 0.98561 0.97993 0.00003 0.07635 0.07324
0.03900 0.99582 0.97711 0.00035 0.08210 0.07172
0.07810 0.96984 0.97155 0.00000 0.06788 0.06877
0.15620 0.92436 0.96073 0.00132 0.04625 0.06322
0.31250 0.90000 0.94000 0.00160 0.03637 0.05322
0.62500 0.86000 0.90149 0.00172 0.02271 0.03694
135000 0.83000 0.83390 0.00002 0.01457 0.01553
2.50000 0.75267 0.72621 0.00070 0.00188 0.00029
5.00000 0.61439 0.57860 0.00128 0.00901 0.01708
10.00000 0.40000 0.41313 0.00017 0.09566 0.08772
20.00000 037000 0.26468 0.00003 0.19298 0.19769
40.00000 0.10000 0.15586 0.00312 0.37124 0.30629
(table continued)
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80.00000 0.08900 0.08734 0.00000 038477 038683
160.00000 0.08400 0.04823 0.00128 039100 0.43701

























0.00240 0.99100 0.98349 0.00006 038883 038082
0.00480 0.97000 0.95478 0.00023 036670 025121
0.00970 0.94000 0.90977 0.00091 033662 0.20812
0.01950 0.81000 0.84397 0.00115 0.12704 0.15241
0.03900 0.73000 0.75453 0.00060 0.07641 0.09058
0.07810 0.61702 0.64294 0.00067 0.02672 0.03586
0.15620 0.55319 0.51941 0.00114 0.00992 0.00433
0.31250 0.44000 039876 0.00170 0.00018 0.00300
0.62500 0.30000 0.29484 0.00003 0.02358 0.02520
135000 0.20000 0.21447 0.00021 0.06430 0.05717
2.50000 0.12000 0.15736 0.00140 0.11127 0.08774
5.00000 0.09500 0.11918 0.000S8 0.12857 0.11181
10.00000 0.09000 0.09469 0.00002 0.13218 0.12879
20.00000 0.08000 0.07939 0.00000 0.13955 0.14001
40.00000 0.08000 0.06999 0.00010 0.13955 0.14713
80.00000 0.08000 0.06427 0.00025 0.13955 0.15155
160.00000 0.07800 0.06082 0.00030 0.14105 0.15425






























0.00240 0.99600 0.98006 0.00025 032536 030743
0.00480 0.96900 0.95360 0.00024 029529 027879
0.00970 0.87200 0.90539 0.00112 0.19928 023021
0.01950 0.80000 0.82511 0.00063 0.14018 0.15961
0.03900 0.71600 0.70608 0.00010 0.08434 0.07867
0.07810 0.59400 0.55489 0.00153 0.02836 0.01672
0.15620 0.37900 039856 0.00038 0.00217 0.00073
031250 0.26600 026701 0.00000 0.02547 0.02515
0.62500 0.16300 0.17445 0.00013 0.06896 0.06307
125000 0.11900 0.11714 0.00000 0.09400 0.09514
2.50000 0.08100 0.08443 0.00001 0.11875 0.11639
5.00000 0.06010 0.06663 0.00004 0.13359 0.12886
10.00000 0.05500 0.05718 0.00000 0.13734 0.13573
20.00000 0.05900 0.05224 0.00005 0.13439 0.13939
40.00000 0.05500 0.04968 0.00003 0.13734 0.14131
80.00000 0.05500 0.04835 0.00004 0.13734 0.14231
160.00000 0.05500 0.04767 0.00005 0.13734 0.14283

























0.00240 1.00110 0.99609 0.00003 0.05888 0.05647
0.00480 0.99750 0.99609 0.00000 0.05714 0.05647
0.00970 1.00230 0.99609 0.00004 0.05946 0.05647
(table continued)
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0.01950 0.99820 0.99608 0.00000 0.05748 0.05647
0.03900 0.99370 0.99605 0.00001 0.05534 0.05645
0.07810 1.00870 0.99594 0.00016 0.06263 0.05640
0.15620 0.98990 0.99555 0.00003 0.05357 0.05622
031250 0.98750 0.99414 0.00004 0.05246 0.05555
0.62500 0.99050 0.98903 0.00000 0.05385 0.05317
135000 0.95700 0.97093 0.00019 0.03942 0.04515
2.50000 0.90500 0.91090 0.00003 0.02148 0.02324
5.00000 0.73000 0.74821 0.00033 0.00081 0.00010
10.00000 0.51900 0.47391 0.00203 0.05734 0.08096
20.00000 0.19600 0.24540 0.00244 0.31635 036322
40.00000 0.14500 0.14267 0.00001 037632 0.37918
80.00000 0.12700 0.10929 0.00031 039873 0.42141
160.00000 0.10100 0.09964 0.00000 0.43224 0.43403




b= 1.1222 r2= 0.999
c= 3.7672 r= 0.999
d= 0.0703
[PbTx2] Experim. Calculated (Exp A/Ao- (Exp A/Ao- (Calc A/Ao-
(jxg/mL) A/Ao A/Ao Calc A/Ao)2 Avg)2 Avg)2
0.00120 1.02000 0.99746 0.00051 0.10722 0.09296
0.00240 1.00000 0.99733 0.00001 0.09452 0.09288
0.00480 1.00100 0.99704 0.00002 0.09514 0.09271
0.00970 0.99900 0.99642 0.00001 0.09391 0.09233
0.01950 0.99900 0.99505 0.00002 0.09391 0.09150
0.03900 0.99000 0.99211 0.00000 0.08847 0.08973
0.07810 0.97000 0.98575 0.00025 0.07698 0.08596
0.15620 0.95000 0.97222 0.00049 0.06628 0.07821
031250 0.93000 0.94410 0.00020 0.05638 0.06328
0.62500 0.90000 0.88858 0.00013 0.04303 0.03842
1.25000 0.80000 0.78914 0.00012 0.01154 0.00933
(table continued)
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r=  0.999 
r= 0.999
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0.00240 0.99800 0.99269 0.00003 038025 0.27466
0.00480 0.97400 0.97440 0.00000 0.25542 0.25582
0.00970 0.95000 0.94236 0.00006 033174 032444
0.01950 0.90000 0.88965 0.00011 0.18610 0.17728
0.03900 0.79000 0.80892 0.00036 0.10329 0.11581
0.07810 0.67000 0.69635 0.00069 0.04056 0.05186
0.15620 0.57000 0.56027 0.00009 0.01028 0.00840
031250 0.45000 0.42065 0.00086 0.00035 0.00230
0.62500 0.32000 0.29990 0.00040 0.02209 0.02846
1.25000 0.19000 0.20983 0.00039 0.07762 0.06697
2.50000 0.12000 0.14982 0.00089 0.12153 0.10162
5.00000 0.09500 0.11279 0.00032 0.13959 0.12661
10.00000 0.09000 0.09101 0.00000 0.14335 0.14258
20.00000 0.08000 0.07856 0.00000 0.15102 0.15214
40.00000 0.08000 0.07155 0.00007 0.15102 0.15765
80.00000 0.08000 0.06765 0.00015 0.15102 0.16077
160.00000 0.07800 0.06549 0.00016 0.15258 0.16251




b= 0.972 r^  0.999


































































































































b= 1.1375 r*= 1.000
c= 0.4675 r= 1.000
d= 0.0688
[PbTx-2] Experim. Calculated (Exp A/Ao- (Exp A/Ao- (Calc A/Ao-
(pg/mL) A/Ao A/Ao Calc A/Ao)2 Avg)2 Avg)2
0.00120 1.00500 1.00166 0.00001 0.21624 031314
0.00240 1.00000 1.00040 0.00000 0.21161 0.21198
0.00480 0.99980 0.99763 0.00000 0.21143 030944
0.00970 0.98500 0.99148 0.00004 0.19803 030384
0.01950 0.98000 0.97821 0.00000 0.19361 0.19203
0.03900 0.96000 0.95044 0.00009 0.17641 0.16847
0.07810 0.88000 0.89482 0.00022 0.11561 0.12590
0.15620 0.79000 0.79425 0.00002 0.06251 0.06465
0.31250 0.66000 0.64090 0.00036 0.01440 0.01018
(table continued)
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1̂ = 0.999 
r= 1.000
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Isotyping of serum obtained die day of fusion or before in vitro stimulation for 
mice 14 and 15
Controls:
1% BSA-PBST in capture isotyping antibodies plates: 0.053 
Pre-immune serum in BSA-PbTx-2 or OVA-PbTx-2 coated plates: 0.061 
Pre-immune serum in LPH, KLH, or BSA coated plates: 0.058
Mouse 1
Whole serum PbTx-2 specific LPH specific
IgGl 1.351 0.791 1.173
IgG2a 1.357 0.075 0.101
IgG2b 1.436 0.066 0.107
IgG3 1.319 0.103 0.121
IgM 1.428 0.224 0.758
IgA 0.984 0.064 0.061
Mouse 2
Whole serum PbTx-2 specific LPH specific
IgGl 1.332 0.667 1.159
IgG2a 1.350 0.074 0.263
IgG2b 1.379 0.059 0.148
IgG3 1.327 0.101 0.128
IgM 1.394 0.201 0.563
IgA 1.109 0.084 0.067
Mouse 3
Whole serum PbTx-2 specific LPH specific
IgGl 1.299 0.450 1.121
IgG2a 1.317 0.086 0.125
IgG2b 1.381 0.076 0.129
IgG3 1.259 0.087 0.097
IgM 1.385 0.093 0.25
IgA 0.985 0.073 0.064
Mouse 4
Whole serum PbTx-2 specific LPH specific
IgGl 1.313 0.387 1.109
IgG2a 1.306 0.069 0.132
IgG2b 1.379 0.104 0.119
IgG3 1.217 0.151 0.121
IgM 1.357 0.095 0.347
IgA 0.881 0.128 0.061
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Mouse 7
Whole serum PbTx-2 specific KLH specific
IgGl 1.331 0.694 1.153
IgG2a 1.372 0.123 0.428
IgG2b 1.387 0.127 0.270
IgG3 1.308 0.210 0.219
IgM 1.370 0.192 0.618
IgA 1.046 0.091 0.085
Mouse 8
Whole serum PbTx-2 specific KLH specific
IgGl 1.338 0.544 0.752
IgG2a 1.367 0.096 0.126
IgG2b 1.397 0.113 0.089
IgG3 1.265 0.147 0.093
IgM 1.372 0.258 0.175
IgA 1.066 0.201 0.075
Mouse 10
Whole serum PbTx-2 specific KLH specific
IgGl 1.327 0.286 1.141
IgG2a 1.359 0.161 0.340
IgG2b 1.397 0.081 0.209
IgG3 1.313 0.232 0.275
IgM 1.379 0.225 0.547
IgA 1.120 0.169 0.129
Mouse 11
Whole serum PbTx-2 specific KLH specific
IgGl 1.304 0.394 1.189
IgG2a 1.415 0.140 0.492
IgG2b 1.420 0.082 0.361
IgG3 1.325 0.135 0.226
IgM 1.403 0.147 0.840
IgA 0.993 0.162 0.094
Mouse 12
Whole serum PbTx-2 specific BSA specific
IgGl 1.287 0.426 1.001
IgG2a 1.279 0.061 0.160
IgG2b 1.229 0.047 0.218
IgG3 1.225 0.056 0.187
IgM 1.342 0.079 0.496
IgA 0.911 0.050 0.054
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Mouse 13
Whole serum PbTx-2 specific BSA specific
IgGl 1.309 0.381 1.087
IgG2a 1.292 0.172 0.203
IgG2b 1.253 0.068 0.159
IgG3 1.256 0.121 0.100
IgM 1.345 0.172 0.484
IgA 0.927 0.102 0.128
Mouse 14
Whole serum PbTx-2 specific BSA specific
IgGl 1.146 0.258 1.123
IgG2a 0.769 0.204 0.512
IgG2b 1.120 0.063 0.254
IgG3 1.030 0.105 0.110
IgM 1.223 0.184 0.577
IgA 0.385 0.117 0.120
Mouse 15
Whole serum PbTx-2 specific BSA specific
IgGl 1.175 0.312 1.106
IgG2a 0.893 0.104 0.137
IgG2b 1.133 0.068 0.216
IgG3 1.008 0.116 0.104
IgM 1.258 0.206 0.352
IgA 0.519 0.131 0.100
Ammonium sulfate precipitates after cloning
Mouse 1 - 1:100
BSA-PbTx2 BSA KLH
7(333) 0.435 0.423 0.458
88(10) 0.177 0.196 0.206
119(530) 0.222 0.211 0.247
151(391) 0.580 0.522 0.540
287(604) 1.308 1.253 1.358
295(634) 0.590 0.575 0.595
Mouse 1- 1:1000
BSA-PbTx2 BSA KLH
7(333) 0.090 0.083 0.085
88(10) 0.177 0.196 0.206
119(530) 0.271 0.236 0.292
LPH OVA OVA-PbTx2 None
1.654 0.502 0.487 0.493
0.175 0.185 0.191 0.186
0.417 0.207 0.209 0.212
1.060 0.58 0.596 0.585
1.444 1.344 1.412 1.378
1.081 0.550 0.564 0.535
LPH OVA OVA-PbTx2 None
0.952 0.089 0.092 0.083
0.175 0.185 0.191 0.189
0.343 0.245 0.264 0.253
(table continued)
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151(391) 0.222 0311 0347 0.417 0307 0309 0.199
287(604) 0.364 0345 0357 0369 0349 0366 0352
295(634) 0.193 0.176 0.184 0.474 0.170 0.169 0.175
Mice 3 and 4 -  1:100
BSA-PbTx2 BSA KLH LPH OVA OVA-PbTx2 None
126(83) 0.624 0.635 0.647 0.651 0.639 0.647 0.623
167(68) 0397 0.402 0398 0391 0376 0382 0354
282(34) 0.593 0.602 0.615 0.607 0.618 0.607 0.599
286(53) 1.200 1315 1330 1.195 1320 1.270 1350
321(32) 0.890 0.930 0.870 0.992 0.890 0.912 0.900
451(78) 0.467 0.480 0.475 0.463 0.435 0.456 0.448
476(163) 0.420 0.418 0.432 0.441 0.425 0.418 0.413
Mice 3 and 4 - 1:1000 
BSA-PbTx2 BSA KLH LPH OVA OVA-PbTx2 None
126(183) 0325 0320 0312 0.311 0301 0395 0312
167(68) 0.193 0.176 0.184 0.174 0.170 0.169 0.182
282(34) 0353 0367 0.387 0.402 0.373 0365 0373
286(53) 0.703 0.714 0.721 0.757 0.732 0.725 0.732
321(32) 0.422 0.413 0.403 0.413 0.412 0.410 0.413
451(78) 0360 0.380 0.385 0384 0.380 0.369 0.359
476(163) 0.179 0.185 0.197 0.183 0.192 0.199 0303
Mouse 7 - 1:100
BSA-PbTx2 BSA KLH LPH OVA OVA-PbTx2 None
21(40) 0.623 0.625 0.635 1340 0.643 0.623 0.642
83(29) 0.578 0.582 0.590 0.587 0.582 0.576 0.57
91(47) 0.727 0.742 0.735 1.120 0.748 0.723 0.732
196(70) 0.612 0.623 0.627 0.632 0.617 0.621 0.63
328(115) 0.612 0.634 0.642 0.923 0.624 0.635 0.64
343(124) 0.812 0.834 0.823 1.750 0.835 0.825 0.825
Mouse 7 - 1:1000
BSA-PbTx2 BSA KLH LPH OVA OVA-PbTx2 None
21(40) 0.321 0.315 0.367 0.834 0.334 0.345 0333
83(29) 0315 0.307 0.309 0.317 0.307 0.312 0306
91(47) 0.557 0.574 0.623 0.734 0.564 0.576 0.559
196(70) 0.489 0.475 0.512 0.530 0.476 0.465 0.469
328(115) 0.438 0.450 0.532 0.689 0.478 0.489 0.481
343(124) 0.470 0.460 0.475 0.932 0.493 0.473 0.480
Mouse 8 - 1:100
BSA-PbTx2 BSA KLH LPH OVA OVA-PbTx2 None
19(24) 0.435 0.453 0.723 0.423 0.428 0.435 0.439
117(17) 0.592 0.602 0.591 0.582 0.590 0.596 0.583
129(10) 0.617 0.623 0.613 0.635 0.629 0.639 0.613
205(15) 0.534 0.543 0.562 0.532 0.545 0.539 0.542
(table continued)
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212(15) 0.923 0.934 0.920 0.928 0.935 0.942 0.919
259(15) 0323 0342 1.940 0329 0333 0340 0329
532(12) 0.605 0.613 0.632 0.634 0.648 0.626 0.639
Mouse 8 - 1:1000
BSA-PbTx2 BSA KLH LPH OVA OVA-PbTx2 None
19(24) 0.189 0.185 0.425 0.191 0.182 0.192 0.189
117(17) 0.492 0.502 0.498 0.532 0.519 0.596 0.583
129(10) 0.484 0.508 0.503 0.500 0.439 0.404 0.423
205(15) 0361 0.372 0385 0393 0352 0.368 0.401
212(15) 0.612 0.623 0.620 0.624 0.656 0.645 0.632
259(15) 0.173 0.159 1.620 0.151 0.144 0.137 0.139
532(12) 0.423 0.439 0.435 0.457 0.472 0.462 0.482
Mouse 10 - 1:100 
BSA-PbTx2 BSA KLH LPH OVA OVA-PbTx2 None
19(4) 0.425 0.428 0.435 0.422 0.429 0.415 0.429
21(15) 0.453 0.443 0.445 0.448 0.453 0.429 0.406
49(5) 0.513 0.521 0.507 0.526 0.524 0.526 0.522
86(7) 0379 0.382 0.826 0369 0363 0.389 0376
225(2) 0.426 0.435 1.157 0.417 0.428 0.436 0.429
240(3) 0.429 0.425 0.435 0.429 0.431 0.426 0.428
270(15) 0.334 0.329 0.957 0.323 0.321 0.335 0.327
Mouse 10 - 1:1000 
BSA-PbTx2 BSA KLH LPH OVA OVA-PbTx2 None
19(4) 0323 0245 0240 0.229 0.231 0.245 0.251
21(15) 0.298 0285 0356 0.275 0288 0295 0.281
49(5) 0332 0327 0324 0.321 0.325 0.307 0.312
86(7) 0301 0.198 0.517 0201 0.213 0.215 0.227
225(2) 0391 0.278 0.778 0.259 0266 0.272 0.282
240(3) 0.201 0.195 0.213 0201 0.215 0.217 0.206
270(15) 0.189 0.191 0.556 0.201 0207 0.203 0.195
Mouse 11 - 1:100 
BSA-PbTx2 BSA KLH LPH OVA OVA-PbTx2 None
1(12) 0.270 0.263 1.736 0.259 0.252 0.245 0.248
44(20) 0.375 0.389 1.872 0.382 0.362 0.377 0.358
45(17) 0.270 0275 1.523 0.269 0245 0.249 0354
72(9) 0.240 0.235 1.347 0.237 0248 0.243 0339
100 (16) 0.922 0.932 1.672 0.917 0.926 0.923 0.931
225 (3) 0.313 0.328 1213 0.329 0342 0.336 0329
261(18) 0.975 0.986 0.969 0.959 0.972 0.965 0.962
275 (7) 0313 0.327 0315 0317 0.328 0.319 0.323
Mouse 11 - 1:1000 
BSA-PbTx2 BSA KLH LPH OVA OVA-PbTx2 None
1(12) 0.123 0.125 1.304 0.132 0.119 0.117 0.128
(table continued)
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44(20) 0.236 0345 1.551
45(17) 0.179 0.182 1371
72(9) 0.113 0.109 1.166
100(16) 0.656 0.649 1322
225(3) 0.122 0.125 0.944
261(18) 0327 0319 0313
275(7) 0.173 0.179 0.175
0339 0346 0329 0334
0.183 0.176 0.189 0.185
0.112 0.107 0.115 0.112
0.642 0.647 0.629 0.635
0.132 0.129 0.134 0.126
0324 0327 0328 0336
0.182 0.185 0.177 0.174
Tissue culture supernatants with different proteins
Mouse 12
BSA-PbTx2 BSA KLH LPH OVA OVA-PbTx2 None
31 1321 1336 1341 1.343 1327 1332 1.327
71 0373 0333 0352 0349 0341 0367 0359
87 1376 1384 0.812 0.829 0.824 0.832 0.819
117 1315 1353 0347 0351 0349 0330 0337
143 0.513 0.526 0.518 0.530 0.524 0.511 0.527
275 1.827 1.839 0.723 0.741 0.731 0.715 0.729
334 0.508 0.513 0381 0387 0375 0382 0373
391 0.713 0.725 0350 0341 0337 0347 0352
403 0.502 0.511 0.521 0.517 0.519 0.513 0.520
Mouse 13
BSA-PbTx2 BSA KLH LPH OVA OVA-PbTx2 None
98 1.513 1.526 0.813 0.832 0.826 0.822 0.817
104 0.172 0.169 0.175 0.180 0.176 0.176 0.179
118 0.196 0303 0305 0.189 0.199 0.198 0.187
250 0.270 0.262 0373 0364 0380 0.273 0.268
257 1.126 1.134 0.513 0.529 0.517 0.514 0.521
327 1.023 1.056 0315 0322 0.331 0319 0.326
481 0.271 0.256 0364 0359 0362 0.270 0.264
571 1316 1.327 0.471 0.456 0.463 0.452 0.466
Mouse 14
BSA-PbTx2 BSA KLH LPH OVA OVA-PbTx2 None
B1C2 0.896 0.883 0.315 0323 0.307 0.313 0319
B1E4 1322 1.117 0.271 0356 0359 0370 0363
B1E9 1313 1.321 0.436 0.423 0.419 0.431 0.417
B1E11 0.913 0.926 0371 0.363 0359 0.365 0.356
B2A10 1.415 1.427 0.323 0.329 0317 0.315 0.328
B2D7 0.756 0.771 0.225 0.217 0.230 0.223 0.219
B2F3 1.011 1.028 0.212 0.195 0.199 0303 0307
B3EG 1.479 1.501 0.231 0317 0.229 0325 0.219
B3F1 1.276 1.291 0.413 0.407 0.415 0.422 0.417
Mouse 15
BSA-PbTx2 BSA KLH LPH OVA OVA-PbTx2 None
1A1 1.199 1.205 0.551 0.564 0.571 0.559 0.568
(table continued)
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1B1 0.761 0.782 0.167 0.159 0.171 0.153 0.166
1C9 1312 1307 0352 0.367 0363 0370 0358
1E4 1.489 1.497 0371 0358 0361 0373 0370
IG3 0.811 0.823 0.792 0.805 0.816 0.821 0.807
2A2 0.971 0.934 0.252 0347 0350 0344 0355
2D3 0.613 0.622 0.617 0.631 0.622 0.624 0.631
3B2 1.857 1.872 0.459 0.459 0.462 0.468 0.463
4A8 1.412 1.424 0375 0358 0357 0366 0.372
4E2 0.413 0.427 0.421 0.417 0.423 0.430 0.418
4E11 1389 1373 0364 0372 0.359 0366 0372
Coating with different proteins and using moose serum
Coating
antigen
Mouse 1 Mouse 2 Mouse 3 Mouse 4 Mouse 7 Mouse
BSA 0.085 0.075 0.058 0.064 0.069 0.065
BSA- 0.895 0.831 0.589 0332 0.618 0.421
PbTx-2
OVA 0.110 0.087 0.090 0.095 0.082 0.078
OVA- 0.639 0.555 0372 0.086 0.346 0.238
PbTx-2
KLH 0.102 0.095 0.095 1.277 1358 1.269
LPH 1.329 1.361 1.281 0.100 0.099
Coating
antigen
Mouse 10 Mouse 11 Mouse 12 Mouse 13 Mouse 14 Mouse
15
BSA 0.061 0.061 1.071 0.981 0.957 0.926
BSA- 0313 0371 1.017 0.969 0.938 0.903
PbTx-2
OVA 0.072 0.071 0.096 0.096 0.056 0.065
OVA- 0.196 0358 0.379 0.354 0.234 0.288
PbTx-2
KLH 1.276 1.298 0.123 0.103 0.103 0.096
LPH 0.095 0.099 0.096 0.096 0.096 0.085
Competition with supernatants
Mouse 1 ______________
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Mice 3 and 4
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Cytotoxicity assay standard curve
Brevetoxin-2 with ouabain/veratridine - 4 hrs
[PbTx-2] % control % control % control % control Standard CV
ng/well 1 2 3 average Deviation
0 9932 100.7 99.79 99.87 0.7550 0.76
035 1013 99.60 100.5 100.5 0.8553 0.85
0.5 89.85 95.70 96.57 94.04 3.6546 3.89
10 92.92 97.90 94.38 94.77 2.7279 2.88
2 80.59 8226 85.42 82.76 2.4530 2.96
4 67.43 66.40 6137 65.07 3.2426 4.98
6 55.82 60.90 5828 58.33 2.5404 4.35
8 52.36 5736 56.17 55.29 2.6119 427
10 43.78 44.61 4420 4420 0.4150 0.94
Brevetoxin-2 with ouabain/veratridine -20 hrs
[PbTx-2] % control % control % control % control Standard CV
ng/well 1 2 3 average Deviation
0 100.4 98.70 100.3 99.80 0.9539 0.96
0.25 7430 75.60 74.90 74.93 0.6506 0.87
0.5 69.80 70.30 72.10 70.73 1.2096 1.71
10 63.80 64.70 6330 6427 0.4509 0.70
2 51.90 52.80 52.20 52.3 0.4583 0.88
4 44.13 45.01 44.18 44.44 0.4943 1.11
6 36.11 36.32 35.99 36.14 0.1716 0.47
8 33.07 33.12 33.15 33.11 0.0404 0.12
10 31.60 32.70 33.10 32.47 0.7767 239














0 95.80 98.52 97.41 9724 13676 1.4064
0.25 93.18 9529 94.12 94.19 1.0571 1.1222
0.5 1002 9930 99.70 99.73 0.4509 0.4521
(table continued)
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10 9932 98.58 98.15 97.99 1.7701 1.8063
2 99.57 96.08 9834 98.68 0.5918 0.5997
4 91.72 94.26 94.18 9339 1.4439 1.5462
6 9432 98.23 9734 96.63 2.0494 2.1209
8 9734 98.25 9639 9739 0.9311 0.96
10 96.90 97.42 97.17 97.16 0.2600 037














0 100.1 99.82 100.1 100.0 0.1652 0.1652
035 9731 9839 9831 97.97 0.5786 0.5906
0.5 9738 99.12 96.17 97.52 1.4899 1.5278
10 99.57 100.1 99.87 00.86 0.2802 03806
2 9939 99.75 98.93 9932 0.4110 0.4138
4 95.4 96.21 97.18 9636 0.8911 0.9258
6 94.15 95.72 94.19 94.69 0.8951 0.9453
8 99.13 96.15 98.48 97.92 1.5669 1.6002
10 95.53 9837 97.16 96.99 13781 1.4210
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against cieuatoxin-related compounds.
To appear in  Ph. D. Dissertation. Department of Food Science. Louisiana State 
University
I would like to include the following material, which originally appeared as:
Figure Middle fimires in page 112
Author Taylor
Article Evolutions: The voltaee-pafced sodium channel
Journal Journal of NIH Research
Volume 6. No. II. 1994
Publisher Medical Economic^
Comments The figures have been adapted
It is my understanding that you have the rights to these materials. I therefore request your 
permission to reprint this selection. Your agreement should be indicated by signing this 
letter. We agree that foil credit will be given to the author and publisher.
If you do not control these rights in their entirety, please let me know with whom I should 
communicate. If permission of the author also is required, please kindly provide the 
author’s most recent address.
Consideration of this request at your earliest convenience will be most appreciated.
Sincerely, 
Sonia EdithPlease ri signed letter to: .an Perez
We ;-on«the terms of this letter.
Date
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L o u i s i a n a  S t a t e  U n i v e r s i t y ________
a a m m €•***•»
Ceporiment o f foorf Science
Perm ission Request Form
To: APS Permissions Office From: Sonia Edith Guanan-Perez
9650 Rockville Pike Louisiana Stale University
Bethesda, MD 20814 • Dept Food Science
Tel: (301)530-7070 111 Food Science Building
FAX: (301)571-1814 FAX:(504)388-5300
Dear Publisher: American Physiological Society Date: October 6,1998
In my Dissertation entitled Preparation of Monoclonal Antibodies Against Ciguatoxin- 
rclated Compounds
to appear in Ph. D. Dissertation. Department of Food Science. Louisiana State University
I would like to include the following material, which originally appeared as:
Figure No. 4. page S24.
Author: Catterall
Article: Cellular and Molecular Biology of volt?p^-g?ted sodium channels
Journal: Physiological Reviews
Volume: 72. pages SI5-S48
Publisher: .American Physiological Society
Comments: The figure has been adapted. Please end enclosed a copy of the
original figure and the adapted version as it will appear.
It is my understanding that you have the rights to this materiaL I therefore request your 
permission to reprint this selection- Your agreement should be indicated by signing the 
enclosed copy of this letter. We agree that full credit will be given to the author and 
publisher.
If you do not control these rights in their entirety, please let me know with whom I should
communicate. If permission of the author also is required, please kindly provide the
author's most recent address.
Consideration of this request at your earliest convenience will be most appreciated.
Sincerely 
Sor^6^
Please return signed letter to: Sonia fcaiih Guzman-Perez
^ e grant permission requested on the terms of this letter. i,v • rte AMcA'Cak rriYSOLOGICAL SOCtri
 saaaeefaae-ra -e   D aIe
~f—'-p-~ ~7—»-
iralsfial sp?cift*3 aoove p.-cv'ded tne 
oyblcalion is c ^ e d  as v»s source.
\c tm &
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L o u i s i a n a  S t a t e  U n i v e r s i t y
D eportm ent o f Food Science
October 21,1998
Ms. Julia Mulligan 
Marcel Dekker, Inc.
270 Madison Avenue 
New York, NY 10016 
FAX: (212)685-4540
Dear Ms. Mulligan:
I am writing you regarding our contribution of the chapter "Ciguatera toxins: 
chemistry an detection" that will be printed in the book Seafood toxicity: mode of action, 
pharmacology and physiology (Luis M. Botana, Editor). I would like to request your 
permission to include portions of this manuscript in my doctoral dissertation at Louisiana 
State University, Department of Food Science. In order to be able to do this, I need a 
letter of permission from your company which will be included in the fin a l document as 
an appendix.
I appreciate your help, and look forward to hearing from you soon.
Sincerely,
Sonia Edith Guzman Perez 
Ph. D. Candidate
PERMISSION GRANTED with the understandm* that 
prooer credit be pwsn to  Marcel O ek W  Inc.
Reterrnc* L**t should include
Aorno'-s (». TITLE Of BOOK OK jOu SHAL. 
  Numoec  lne * ¥
Year o* PuDbcabon
Eicn item lo be 'oonnted should carry the Hue*
ftepnntod trom R<.  **
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VITA
The author was bom on February 14, 1972, in Mexico City, being third child to 
Agustm Guzman Martinez and Ana Maria Perez de Guzman and sister to Agustin, 
Anita, and Francisco Gunman Perez. In 199S, she graduated with honors from 
Universidad La Salle in Mexico City, Mexico, earning the degree of Licenciada en 
Quimica de Alimentos. She spent one semester at the University of Arizona, 
Department of Nutritional Sciences, as part of an exchange program between both 
universities. Immediately after graduation she enrolled in Louisiana State University to 
pursue a doctoral degree in Food Science with the Interdepartamental Concentration in 
Toxicology. Her research interests focused on the development o f monoclonal 
antibodies against ciguatoxin-related compounds. During her doctoral program, the 
author was involved with the local Food Science Club and The Institute of Food 
Technologists, holding several leadership positions. Her studies were supported by El 
Consejo Nacional de Ciencia y Tecnologia, Louisiana State University Graduate School, 
and fellowship awards from The Institute of Food Technologists. In addition, she held a 
research assistant position in the Department of Food Science, Louisiana State 
University, throughout her stay. She is currently a candidate for the degree of Doctor of 
Philosophy, which will be conferred in May, 1999.
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DOCTORAL EXAMINATION AND DISSERTATION REPORT
Candidate: Sonia Edith Guzman Perez 
Major Field: Food Science
Title of Dissertation: In Vivo and in Vitro Stimulation of Murine
Splenocytes with Brevetoxin-2 immunogenic 
Conjugates for the Preparation of Monoclonal 






Novemher ? 0 r 1 QQ«-------
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Sr
IMAGE EVALUATION 
TEST TARGET (Q A -3)
/
✓




1653 East Main Street 
Rochester, NY 14609 USA 
Phone: 716/482-0300 
Fax: 716/288-5989
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